{
  "doc_id": "16",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "二甲双胍临床应用专家共识(2016年版)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍临床应用专家共识(2016年版)",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Expert consensus on the clinical application of metformin (2016 edition)"
        }
      ],
      "paragraph_en": "Expert consensus on the clinical application of metformin (2016 edition)"
    },
    {
      "paragraph_id": "1",
      "paragraph": "二甲双胍应用于临床已有50多年的历史，是目前全球应用最广泛的口服降糖药之一。近年来，虽然有多个新型降糖药物上市，但二甲双胍仍是全球使用量迅速增加的经典口服降糖药物。二甲双胍有良好的单药/联合治疗的疗效和安全性证据、良好的卫生经济学效益证据，以及心血管并发症预防等方面明确的临床证据。因此，该药已经成为全球控制糖尿病的核心药物。二甲双胍在我国已经有20多年的临床应用经验。1995年，美国食品药品监督管理局(FDA)正式批准二甲双胍用于治疗T2DM。2004年，欧盟正式批准二甲双胍用于治疗10岁及上T2DM患儿。国内外主要糖尿病指南均建议，无论对于超重还是体重正常的T2DM患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了该药在糖尿病治疗中的重要地位。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍应用于临床已有50多年的历史，是目前全球应用最广泛的口服降糖药之一。近年来，虽然有多个新型降糖药物上市，但二甲双胍仍是全球使用量迅速增加的经典口服降糖药物。二甲双胍有良好的单药/联合治疗的疗效和安全性证据、良好的卫生经济学效益证据，以及心血管并发症预防等方面明确的临床证据。因此，该药已经成为全球控制糖尿病的核心药物。二甲双胍在我国已经有20多年的临床应用经验。1995年，美国食品药品监督管理局(FDA)正式批准二甲双胍用于治疗T2DM。2004年，欧盟正式批准二甲双胍用于治疗10岁及上T2DM患儿。",
          "start_idx": 0,
          "end_idx": 256,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T2",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T3",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 82,
              "end_idx": 86,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T4",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 122,
              "end_idx": 125,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T5",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T6",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 215,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T7",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 236,
              "end_idx": 240,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T8",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 253,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T9",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 249,
              "end_idx": 251,
              "entity_en": "T2"
            },
            {
              "entity_id": "T10",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 223,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T11",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 219,
              "end_idx": 221,
              "entity_en": "T2"
            },
            {
              "entity_id": "T12",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "oral"
            },
            {
              "entity_id": "T13",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 157,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T21",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "oral"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T6",
              "tail_entity_id": "T10"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T7",
              "tail_entity_id": "T8"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T9",
              "tail_entity_id": "T8"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T11",
              "tail_entity_id": "T10"
            }
          ],
          "sentence_en": "Metformin has been used in clinical practice for more than 50 years and is currently one of the most widely used oral hypoglycemic drugs in the world. In recent years, although a number of new hypoglycemic drugs have been launched, metformin is still a classic oral hypoglycemic drug with rapidly increasing global usage. Metformin has good evidence of efficacy and safety of monotherapy/combination therapy, good evidence of health economic benefits, and clear clinical evidence in the prevention of cardiovascular complications. Therefore, this drug has become a core drug for controlling diabetes worldwide. Metformin has more than 20 years of clinical application experience in my country. In 1995, the U.S. Food and Drug Administration (FDA) officially approved metformin for the treatment of T2DM. In 2004, the European Union officially approved metformin for the treatment of children aged 10 years and older with T2DM."
        },
        {
          "sentence_id": "1",
          "sentence": "国内外主要糖尿病指南均建议，无论对于超重还是体重正常的T2DM患者，除非存在禁忌证或无法耐受，否则都应从一开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了该药在糖尿病治疗中的重要地位。",
          "start_idx": 256,
          "end_idx": 358,
          "entities": [
            {
              "entity_id": "T14",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T15",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T16",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "T2"
            },
            {
              "entity_id": "T17",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T18",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T19",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T20",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "overweight"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T16",
              "tail_entity_id": "T15"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R5",
              "head_entity_id": "T17",
              "tail_entity_id": "T15"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T18",
              "tail_entity_id": "T19"
            }
          ],
          "sentence_en": "Major diabetes guidelines at home and abroad recommend that, regardless of whether they are overweight or normal-weight T2DM patients, metformin should be used for treatment from the beginning unless there are contraindications or intolerance, and metformin should be included in combination treatment plans, which reflects the important position of this drug in diabetes treatment."
        }
      ],
      "paragraph_en": "Metformin has been used in clinical practice for more than 50 years and is currently one of the most widely used oral hypoglycemic drugs in the world. In recent years, although several new hypoglycemic drugs have been launched, metformin is still a classic oral hypoglycemic drug with rapidly increasing global usage. Metformin has good evidence of efficacy and safety of monotherapy/combination therapy, good evidence of health economic benefits, and clear clinical evidence in the prevention of cardiovascular complications. Therefore, this drug has become a core drug for global diabetes control. Metformin has more than 20 years of clinical application experience in my country. In 1995, the US Food and Drug Administration (FDA) officially approved metformin for the treatment of T2DM. In 2004, the European Union officially approved metformin for the treatment of children aged 10 years and above with T2DM. Major diabetes guidelines at home and abroad recommend that, regardless of whether T2DM patients are overweight or normal in weight, metformin should be used for treatment from the beginning, and metformin should be included in the combination therapy plan, which reflects the important position of this drug in diabetes treatment."
    },
    {
      "paragraph_id": "2",
      "paragraph": "自2014年版《二甲双胍临床应用专家共识》发布以来，该共识已成为临床医生正确认识、合理使用二甲双胍的重要学术参考文献。近两年，针对二甲双胍的研究涌现出了一些新的临床证据。为此，内分泌临床专家、药学专家对2014年版《二甲双胍临床应用专家共识》进行更新。推荐意见、循证医学据分级、常见缩略语见表1~3。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "自2014年版《二甲双胍临床应用专家共识》发布以来，该共识已成为临床医生正确认识、合理使用二甲双胍的重要学术参考文献。",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T23",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Since the release of the 2014 edition of \"Expert Consensus on the Clinical Application of Metformin\", this consensus has become an important academic reference for clinicians to correctly understand and rationally use metformin."
        },
        {
          "sentence_id": "1",
          "sentence": "近两年，针对二甲双胍的研究涌现出了一些新的临床证据。",
          "start_idx": 59,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T24",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "In the past two years, some new clinical evidence has emerged in the research on metformin."
        },
        {
          "sentence_id": "2",
          "sentence": "为此，内分泌临床专家、药学专家对2014年版《二甲双胍临床应用专家共识》进行更新。",
          "start_idx": 85,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T25",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "To this end, endocrine clinical experts and pharmaceutical experts updated the 2014 edition of \"Expert Consensus on the Clinical Application of Metformin\"."
        },
        {
          "sentence_id": "3",
          "sentence": "推荐意见、循证医学据分级、常见缩略语见表1~3。",
          "start_idx": 126,
          "end_idx": 150,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations, evidence-based medicine classification, and common abbreviations are shown in Tables 1 to 3."
        }
      ],
      "paragraph_en": "Since the release of the 2014 edition of the Expert Consensus on the Clinical Application of Metformin, it has become an important academic reference for clinicians to correctly understand and rationally use metformin. In the past two years, some new clinical evidence has emerged in the research on metformin. To this end, endocrine clinical experts and pharmacy experts have updated the 2014 edition of the Expert Consensus on the Clinical Application of Metformin. Recommendations, evidence-based medical classification, and common abbreviations are shown in Tables 1 to 3."
    },
    {
      "paragraph_id": "3",
      "paragraph": "一、临床地位与使用时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、临床地位与使用时机",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Clinical status and timing of use"
        }
      ],
      "paragraph_en": "1. Clinical status and timing of use"
    },
    {
      "paragraph_id": "4",
      "paragraph": "1.二甲双胍被推荐为治疗T2DM的一线首选和全程用药：二甲双胍有可靠的短期和长期降糖疗效，单独使用能有效降低T2DM患者的FPG、PPG，可使HbA1c下降1.0%~2.0%(去除安慰剂效应后)，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的二甲双胍的降糖疗效强于其他口服降糖药。数据分析显示，二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(I级)。与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，今后需调整治疗方案的可能性也最低。二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险。另外，二甲双胍具有心血管保护作用。二甲双胍的长期治疗与新诊断T2DM患者及已经发生心血管疾病的T2DM患者的心血管疾病发生风险下降相关(I级)。二甲双胍具有良好的安全性和耐受性，低血糖发生率低，其胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症或乳酸酸中毒风险。与其他降糖药物相比，二甲双胍具有良好的成本-效益比(I级)。如无禁忌证，二甲双胍是治疗T2DM的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍被推荐为治疗T2DM的一线首选和全程用药：二甲双胍有可靠的短期和长期降糖疗效，单独使用能有效降低T2DM患者的FPG、PPG，可使HbA1c下降1.0%~2.0%(去除安慰剂效应后)，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的二甲双胍的降糖疗效强于其他口服降糖药。数据分析显示，二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(I级)。与以其他口服降糖药物作为一线药物治疗的患者相比，以二甲双胍作为一线治疗的患者加用第二种口服降糖药或需要联合胰岛素治疗的时间最晚，今后需调整治疗方案的可能性也最低。二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险。另外，二甲双胍具有心血管保护作用。二甲双胍的长期治疗与新诊断T2DM患者及已经发生心血管疾病的T2DM患者的心血管疾病发生风险下降相关(I级)。二甲双胍具有良好的安全性和耐受性，低血糖发生率低，其胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症或乳酸酸中毒风险。",
          "start_idx": 0,
          "end_idx": 502,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T27",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T28",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "T2"
            },
            {
              "entity_id": "T29",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T30",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T31",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "T2"
            },
            {
              "entity_id": "T32",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T33",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T34",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 76,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T35",
              "entity": "下降1.0%~2.0%",
              "entity_type": "Test_Value",
              "start_idx": 76,
              "end_idx": 87,
              "entity_en": "Decrease by 1.0%~2.0%"
            },
            {
              "entity_id": "T36",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 109,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T37",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 105,
              "end_idx": 107,
              "entity_en": "T2"
            },
            {
              "entity_id": "T38",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 112,
              "end_idx": 117,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T39",
              "entity": "降低1.8%",
              "entity_type": "Test_Value",
              "start_idx": 117,
              "end_idx": 123,
              "entity_en": "1.8% reduction"
            },
            {
              "entity_id": "T40",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T41",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 164,
              "end_idx": 172,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T42",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 178,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T43",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 187,
              "end_idx": 189,
              "entity_en": "oral"
            },
            {
              "entity_id": "T44",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 200,
              "end_idx": 204,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T45",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 220,
              "end_idx": 222,
              "entity_en": "oral"
            },
            {
              "entity_id": "T46",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 236,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T47",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 247,
              "end_idx": 249,
              "entity_en": "oral"
            },
            {
              "entity_id": "T48",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 268,
              "end_idx": 272,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T49",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 286,
              "end_idx": 288,
              "entity_en": "oral"
            },
            {
              "entity_id": "T50",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 296,
              "end_idx": 299,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T51",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 324,
              "end_idx": 328,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T52",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 330,
              "end_idx": 333,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T53",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 339,
              "end_idx": 344,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T54",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 353,
              "end_idx": 357,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T55",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 358,
              "end_idx": 361,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T56",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 347,
              "end_idx": 350,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T57",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 367,
              "end_idx": 371,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T58",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 373,
              "end_idx": 376,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T59",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 381,
              "end_idx": 385,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T60",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 394,
              "end_idx": 398,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T61",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 394,
              "end_idx": 396,
              "entity_en": "T2"
            },
            {
              "entity_id": "T62",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 405,
              "end_idx": 410,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T63",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 405,
              "end_idx": 408,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T64",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 411,
              "end_idx": 415,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T65",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 411,
              "end_idx": 413,
              "entity_en": "T2"
            },
            {
              "entity_id": "T66",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 418,
              "end_idx": 423,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T67",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 418,
              "end_idx": 421,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T68",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 436,
              "end_idx": 440,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T69",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 453,
              "end_idx": 456,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T70",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 462,
              "end_idx": 467,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T71",
              "entity": "肾脏损害",
              "entity_type": "Disease",
              "start_idx": 476,
              "end_idx": 480,
              "entity_en": "Kidney damage"
            },
            {
              "entity_id": "T72",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 476,
              "end_idx": 478,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T73",
              "entity": "高乳酸血症",
              "entity_type": "Disease",
              "start_idx": 488,
              "end_idx": 493,
              "entity_en": "Hyperlactatemia"
            },
            {
              "entity_id": "T74",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 494,
              "end_idx": 499,
              "entity_en": "Lactic acidosis"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T26",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T28",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R9",
              "head_entity_id": "T29",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R10",
              "head_entity_id": "T32",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R11",
              "head_entity_id": "T33",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T34",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T31",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R14",
              "head_entity_id": "T37",
              "tail_entity_id": "T36"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T38",
              "tail_entity_id": "T36"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R16",
              "head_entity_id": "T41",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R17",
              "head_entity_id": "T54",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R18",
              "head_entity_id": "T55",
              "tail_entity_id": "T51"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R19",
              "head_entity_id": "T54",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R20",
              "head_entity_id": "T55",
              "tail_entity_id": "T52"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T59",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R22",
              "head_entity_id": "T61",
              "tail_entity_id": "T60"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R23",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R24",
              "head_entity_id": "T65",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R25",
              "head_entity_id": "T67",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R26",
              "head_entity_id": "T69",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R27",
              "head_entity_id": "T70",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R28",
              "head_entity_id": "T72",
              "tail_entity_id": "T71"
            }
          ],
          "sentence_en": "1. Metformin is recommended as the first-line first choice and full-course medication for the treatment of T2DM: Metformin has reliable short-term and long-term glucose-lowering effects. When used alone, it can effectively reduce FPG and PPG in patients with T2DM, reduce HbA1c by 1.0%~2.0% (after removing the placebo effect), and reduce HbA1c by 1.8% (possibly including the placebo effect) in newly diagnosed T2DM patients in China, and is not affected by body weight. Under similar baseline HbA1c conditions, the glucose-lowering effect of the best effective dose (2000 mg/d) of metformin is stronger than that of other oral hypoglycemic drugs. Data analysis shows that patients who have poor efficacy in metformin monotherapy can further obtain significant blood sugar improvement (grade I) in combination with other oral hypoglycemic drugs. Compared with patients who use other oral hypoglycemic drugs as first-line drugs, patients who use metformin as first-line treatment have the latest time to add a second oral hypoglycemic drug or need combined insulin treatment, and are also least likely to need to adjust their treatment plan in the future. Metformin combined with insulin can further reduce HbA1c, reduce insulin dosage, weight gain and the risk of hypoglycemia. In addition, metformin has a cardiovascular protective effect. Long-term treatment with metformin is associated with a reduced risk of cardiovascular disease in patients with newly diagnosed T2DM and T2DM patients who have already developed cardiovascular disease (Grade I). Metformin has good safety and tolerability, a low incidence of hypoglycemia, and its gastrointestinal reactions are mostly transient and do not cause kidney damage. Long-term use does not increase the risk of hyperlactatemia or lactic acidosis."
        },
        {
          "sentence_id": "1",
          "sentence": "与其他降糖药物相比，二甲双胍具有良好的成本-效益比(I级)。",
          "start_idx": 502,
          "end_idx": 532,
          "entities": [
            {
              "entity_id": "T75",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Compared with other glucose-lowering drugs, metformin has a favorable cost-effectiveness ratio (level I)."
        },
        {
          "sentence_id": "2",
          "sentence": "如无禁忌证，二甲双胍是治疗T2DM的首选药物和联合治疗方案中的基础治疗药物，且应一直保留在糖尿病治疗方案中。",
          "start_idx": 532,
          "end_idx": 586,
          "entities": [
            {
              "entity_id": "T76",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T77",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T78",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "T2"
            },
            {
              "entity_id": "T79",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R29",
              "head_entity_id": "T76",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R30",
              "head_entity_id": "T78",
              "tail_entity_id": "T77"
            }
          ],
          "sentence_en": "If there are no contraindications, metformin is the first choice drug for the treatment of T2DM and the basic treatment drug in combination therapy, and should always be retained in the diabetes treatment plan."
        }
      ],
      "paragraph_en": "1. Metformin is recommended as the first-line first choice and full-course medication for the treatment of T2DM: Metformin has reliable short-term and long-term glucose-lowering effects. When used alone, it can effectively reduce FPG and PPG in patients with T2DM, reduce HbA1c by 1.0%~2.0% (after removing the placebo effect), and reduce HbA1c by 1.8% (possibly including the placebo effect) in newly diagnosed T2DM patients in China, and is not affected by body weight. Under similar baseline HbA1c conditions, the glucose-lowering effect of the best effective dose (2000 mg/d) of metformin is stronger than that of other oral hypoglycemic drugs. Data analysis shows that patients who have poor efficacy in metformin monotherapy can further obtain significant blood sugar improvement (grade I) in combination with other oral hypoglycemic drugs. Compared with patients who use other oral hypoglycemic drugs as first-line drugs, patients who use metformin as first-line treatment have the latest time to add a second oral hypoglycemic drug or need combined insulin treatment, and are also least likely to need to adjust their treatment plan in the future. Metformin combined with insulin can further reduce HbA1c, reduce insulin dosage, weight gain and the risk of hypoglycemia. In addition, metformin has a cardiovascular protective effect. Long-term treatment with metformin is associated with a reduced risk of cardiovascular disease in patients with newly diagnosed T2DM and T2DM patients who have already developed cardiovascular disease (Grade I). Metformin has good safety and tolerability, a low incidence of hypoglycemia, and its gastrointestinal reactions are mostly transient and do not cause kidney damage. Long-term use does not increase the risk of hyperlactatemia or lactic acidosis. Compared with other hypoglycemic drugs, metformin has a good cost-effectiveness ratio (Grade I). If there are no contraindications, metformin is the first choice drug for the treatment of T2DM and the basic treatment drug in the combination therapy regimen, and should always be retained in the diabetes treatment regimen."
    },
    {
      "paragraph_id": "5",
      "paragraph": "2.二甲双胍是否只是超重/肥胖T2DM患者的首选用药：回顾性和前瞻性临床研究结果均显示，二甲双胍在正常体重/超重/肥胖T2DM患者中的疗效相当(I级)。因此，体重不是能否使用二甲双胍治疗的决定因素。无论对于超重/肥胖或体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍是否只是超重/肥胖T2DM患者的首选用药：回顾性和前瞻性临床研究结果均显示，二甲双胍在正常体重/超重/肥胖T2DM患者中的疗效相当(I级)。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T80",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T81",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T82",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T83",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T84",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "T2"
            },
            {
              "entity_id": "T85",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T86",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T87",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T88",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T89",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R31",
              "head_entity_id": "T80",
              "tail_entity_id": "T83"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R32",
              "head_entity_id": "T84",
              "tail_entity_id": "T83"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T85",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R34",
              "head_entity_id": "T89",
              "tail_entity_id": "T88"
            }
          ],
          "sentence_en": "2. Is metformin only the first choice for overweight/obese T2DM patients: The results of retrospective and prospective clinical studies have shown that metformin has comparable efficacy in normal weight/overweight/obese T2DM patients (Level I)."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，体重不是能否使用二甲双胍治疗的决定因素。",
          "start_idx": 76,
          "end_idx": 99,
          "entities": [
            {
              "entity_id": "T90",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, body weight is not a determining factor for the use of metformin treatment."
        },
        {
          "sentence_id": "2",
          "sentence": "无论对于超重/肥胖或体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。",
          "start_idx": 99,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T91",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T92",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T93",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T94",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T95",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T96",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T94",
              "tail_entity_id": "T95"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R36",
              "head_entity_id": "T96",
              "tail_entity_id": "T95"
            }
          ],
          "sentence_en": "Regardless of whether the patient is overweight/obese or has normal weight, major diabetes guidelines at home and abroad recommend metformin as the first choice for the treatment of T2DM."
        }
      ],
      "paragraph_en": "2. Is metformin only the first choice for overweight/obese T2DM patients: Retrospective and prospective clinical research results have shown that metformin has comparable efficacy in normal weight/overweight/obese T2DM patients (level I). Therefore, weight is not a determining factor for whether metformin can be used for treatment. Regardless of whether it is for overweight/obese or normal weight patients, major diabetes guidelines at home and abroad recommend metformin as the first choice for the treatment of T2DM."
    },
    {
      "paragraph_id": "6",
      "paragraph": "3.二甲双胍能否预防糖尿病：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。但在我国预防糖尿病尚不是二甲双胍的适应证。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.二甲双胍能否预防糖尿病：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。",
          "start_idx": 0,
          "end_idx": 83,
          "entities": [
            {
              "entity_id": "T97",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T99",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T100",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T101",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T102",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 54,
              "entity_en": "Prediabetes"
            },
            {
              "entity_id": "T103",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T104",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R37",
              "head_entity_id": "T97",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R38",
              "head_entity_id": "T99",
              "tail_entity_id": "T100"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R39",
              "head_entity_id": "T99",
              "tail_entity_id": "T101"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R40",
              "head_entity_id": "T104",
              "tail_entity_id": "T103"
            }
          ],
          "sentence_en": "3. Can metformin prevent diabetes? Metformin is the first drug proven to prevent or delay the onset of diabetes. It can effectively reduce the risk of T2DM in people with prediabetes and has good tolerance and long-term effectiveness."
        },
        {
          "sentence_id": "1",
          "sentence": "但在我国预防糖尿病尚不是二甲双胍的适应证。",
          "start_idx": 83,
          "end_idx": 104,
          "entities": [
            {
              "entity_id": "T105",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T106",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "However, the prevention of diabetes is not yet an indication for metformin in our country."
        }
      ],
      "paragraph_en": "3. Can metformin prevent diabetes? Metformin is the first drug proven to prevent or delay the onset of diabetes. It can effectively reduce the risk of T2DM in people with prediabetes, and has good tolerance and long-term effectiveness. However, in my country, the prevention of diabetes is not yet an indication for metformin."
    },
    {
      "paragraph_id": "7",
      "paragraph": "DPP是一项糖尿病预防计划的随机对照研究，该研究结果显示，强化生活方式干预和二甲双胍(850mg，2次/d)治疗，3年内T2DM的发生率分别降低58%和31%(I级)。DPP随访研究显示，以安慰剂为对照，二甲双胍可降低IGT人群糖尿病发生率约13%(I级)。DPP/DPPOS结果显示，与强化生活方式干预相比，二甲双胍能减少糖尿病前期发展为糖尿病的发生率，减少患者体重增加，且10年内花费更低(I级)。印度IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低糖尿病的发生风险，分别为26.4%和28.2%(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好起始生活方式干预；对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病。接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP是一项糖尿病预防计划的随机对照研究，该研究结果显示，强化生活方式干预和二甲双胍(850mg，2次/d)治疗，3年内T2DM的发生率分别降低58%和31%(I级)。DPP随访研究显示，以安慰剂为对照，二甲双胍可降低IGT人群糖尿病发生率约13%(I级)。DPP/DPPOS结果显示，与强化生活方式干预相比，二甲双胍能减少糖尿病前期发展为糖尿病的发生率，减少患者体重增加，且10年内花费更低(I级)。印度IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低糖尿病的发生风险，分别为26.4%和28.2%(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好起始生活方式干预；对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。建议糖尿病前期人群应起始生活方式干预，对生活方式不能有效控制血糖的患者，给予二甲双胍可有效预防糖尿病。接受二甲双胍干预的患者应限于有预防糖尿病意愿、有很好的治疗依从性并有条件按照医嘱定期接受糖代谢评估的糖尿病前期个体。",
          "start_idx": 0,
          "end_idx": 436,
          "entities": [
            {
              "entity_id": "T107",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T108",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T109",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 60,
              "end_idx": 62,
              "entity_en": "T2"
            },
            {
              "entity_id": "T110",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T111",
              "entity": "850mg",
              "entity_type": "Amount",
              "start_idx": 43,
              "end_idx": 48,
              "entity_en": "850mg"
            },
            {
              "entity_id": "T112",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "2 times/day"
            },
            {
              "entity_id": "T113",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 31,
              "end_idx": 37,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T114",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T115",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 117,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T116",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T117",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 162,
              "end_idx": 167,
              "entity_en": "Prediabetes"
            },
            {
              "entity_id": "T118",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T119",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 182,
              "end_idx": 186,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T120",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "IGT"
            },
            {
              "entity_id": "T121",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 146,
              "end_idx": 152,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T122",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 212,
              "end_idx": 216,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T123",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 222,
              "end_idx": 228,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T124",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 236,
              "end_idx": 239,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T125",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 274,
              "end_idx": 278,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T126",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 274,
              "end_idx": 276,
              "entity_en": "T2"
            },
            {
              "entity_id": "T127",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 285,
              "end_idx": 288,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T128",
              "entity": "IFG",
              "entity_type": "Disease",
              "start_idx": 301,
              "end_idx": 304,
              "entity_en": "IFG"
            },
            {
              "entity_id": "T129",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 312,
              "end_idx": 314,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T130",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 320,
              "end_idx": 324,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T131",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 292,
              "end_idx": 298,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T132",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 329,
              "end_idx": 334,
              "entity_en": "Prediabetes"
            },
            {
              "entity_id": "T133",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 339,
              "end_idx": 345,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T134",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 357,
              "end_idx": 359,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T135",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 365,
              "end_idx": 369,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T136",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 374,
              "end_idx": 377,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T137",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 380,
              "end_idx": 384,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T138",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 395,
              "end_idx": 398,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T139",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 428,
              "end_idx": 433,
              "entity_en": "Prediabetes"
            },
            {
              "entity_id": "T140",
              "entity": "糖代谢评估",
              "entity_type": "Test",
              "start_idx": 422,
              "end_idx": 427,
              "entity_en": "Glucose metabolism assessment"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R41",
              "head_entity_id": "T111",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R42",
              "head_entity_id": "T107",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R43",
              "head_entity_id": "T112",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R44",
              "head_entity_id": "T113",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R45",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R46",
              "head_entity_id": "T114",
              "tail_entity_id": "T120"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R47",
              "head_entity_id": "T116",
              "tail_entity_id": "T117"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R48",
              "head_entity_id": "T121",
              "tail_entity_id": "T117"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T122",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R50",
              "head_entity_id": "T123",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T126",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R52",
              "head_entity_id": "T131",
              "tail_entity_id": "T127"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T130",
              "tail_entity_id": "T128"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T130",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R55",
              "head_entity_id": "T133",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T134",
              "tail_entity_id": "T136"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R57",
              "head_entity_id": "T135",
              "tail_entity_id": "T136"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T137",
              "tail_entity_id": "T138"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R59",
              "head_entity_id": "T140",
              "tail_entity_id": "T139"
            }
          ],
          "sentence_en": "DPP is a randomized controlled study of the diabetes prevention program. The results of this study showed that intensive lifestyle intervention and metformin (850 mg, twice a day) treatment reduced the incidence of T2DM by 58% and 31% within 3 years, respectively (grade I). DPP follow-up studies showed that metformin could reduce the incidence of diabetes in IGT population by about 13% (grade I) compared with placebo. The results of DPP/DPPOS showed that compared with intensive lifestyle intervention, metformin could reduce the incidence of prediabetes to diabetes, reduce weight gain in patients, and cost less within 10 years (grade I). The Indian IDPP study showed that metformin alone or in combination with intensive lifestyle intervention could reduce the risk of diabetes by 26.4% and 28.2%, respectively (grade II). The 2012 IDF Global T2DM Guidelines recommend that the best way to prevent diabetes is to start with lifestyle intervention; for IFG and obese people aged <60 years, metformin intervention can be given. It is recommended that people with prediabetes should start lifestyle intervention. For patients whose lifestyle cannot effectively control blood sugar, metformin can effectively prevent diabetes. Patients who receive metformin intervention should be limited to prediabetic individuals who are willing to prevent diabetes, have good treatment compliance, and have the conditions to undergo regular glucose metabolism assessment according to doctor's orders."
        }
      ],
      "paragraph_en": "DPP is a randomized controlled study of the diabetes prevention program. The results of this study showed that intensive lifestyle intervention and metformin (850 mg, twice a day) treatment reduced the incidence of T2DM by 58% and 31% within 3 years, respectively (grade I). DPP follow-up studies showed that metformin could reduce the incidence of diabetes in IGT population by about 13% (grade I) compared with placebo. The results of DPP/DPPOS showed that compared with intensive lifestyle intervention, metformin could reduce the incidence of prediabetes to diabetes, reduce weight gain in patients, and cost less within 10 years (grade I). The Indian IDPP study showed that metformin alone or in combination with intensive lifestyle intervention could reduce the risk of diabetes by 26.4% and 28.2%, respectively (grade II). The 2012 IDF Global T2DM Guidelines recommend that the best way to prevent diabetes is to start with lifestyle intervention; for IFG and obese people aged <60 years, metformin intervention can be given. It is recommended that people with prediabetes should start lifestyle intervention. For patients whose lifestyle cannot effectively control blood sugar, metformin can effectively prevent diabetes. Patients who receive metformin intervention should be limited to prediabetic individuals who are willing to prevent diabetes, have good treatment compliance, and have the conditions to undergo regular glucose metabolism assessment according to doctor's orders."
    },
    {
      "paragraph_id": "8",
      "paragraph": "二、作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、作用机制",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "2. Mechanism of Action"
        }
      ],
      "paragraph_en": "2. Mechanism of Action"
    },
    {
      "paragraph_id": "9",
      "paragraph": "二甲双胍改善高血糖主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低FFA，提高IS，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高GLP-1水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍改善高血糖主要机制包括：(1)作用于肝脏，抑制糖异生，减少肝糖输出；(2)作用于外周组织(肌肉、脂肪)，改善肌肉糖原合成，降低FFA，提高IS，增加对葡萄糖的摄取和利用；(3)作用于肠道，抑制肠壁细胞摄取葡萄糖，提高GLP-1水平。",
          "start_idx": 0,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T141",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T142",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T143",
              "entity": "FFA",
              "entity_type": "Test_items",
              "start_idx": 67,
              "end_idx": 70,
              "entity_en": "FFA"
            },
            {
              "entity_id": "T144",
              "entity": "IS",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 75,
              "entity_en": "IS"
            },
            {
              "entity_id": "T145",
              "entity": "GLP-1水平",
              "entity_type": "Test_items",
              "start_idx": 112,
              "end_idx": 119,
              "entity_en": "GLP-1 levels"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T141",
              "tail_entity_id": "T142"
            }
          ],
          "sentence_en": "The main mechanisms by which metformin improves hyperglycemia include: (1) acting on the liver, inhibiting gluconeogenesis and reducing hepatic glucose output; (2) acting on peripheral tissues (muscle, fat), improving muscle glycogen synthesis, reducing FFA, increasing IS, and increasing glucose uptake and utilization; (3) acting on the intestine, inhibiting intestinal wall cells from taking in glucose and increasing GLP-1 levels."
        }
      ],
      "paragraph_en": "The main mechanisms by which metformin improves hyperglycemia include: (1) acting on the liver, inhibiting gluconeogenesis and reducing hepatic glucose output; (2) acting on peripheral tissues (muscle, fat), improving muscle glycogen synthesis, reducing FFA, increasing IS, and increasing glucose uptake and utilization; (3) acting on the intestine, inhibiting glucose uptake by intestinal wall cells and increasing GLP-1 levels."
    },
    {
      "paragraph_id": "10",
      "paragraph": "三、剂量与临床疗效",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、剂量与临床疗效",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "III. Dosage and Clinical Efficacy"
        }
      ],
      "paragraph_en": "III. Dosage and Clinical Efficacy"
    },
    {
      "paragraph_id": "11",
      "paragraph": "1.二甲双胍的最小、最大及最佳使用剂量：临床研究显示，在500~2000mg/d的剂量范围内，二甲双胍的降糖效果与剂量呈正相关。500mg/d二甲双胍可降低HbA1c 0.6%(减去安慰剂效应后，以下同)，2000 mg/d可降低HbA1c 2.0%，且与1000mg或1500mg比较，胃肠道反应差异无统计学意义。UKPDS研究中，二甲双胍强化治疗剂量中位数达到2550 mg/d，缓释剂型推荐最大用量为2000 mg/d，普通片推荐成人可用的最大剂量为2550 mg/d。综上所述，二甲双胍起效的最小推荐剂量为500mg/d，成人可用的最大剂量为2550mg/d，最佳有效剂量为2000mg/d。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍的最小、最大及最佳使用剂量：临床研究显示，在500~2000mg/d的剂量范围内，二甲双胍的降糖效果与剂量呈正相关。500mg/d二甲双胍可降低HbA1c 0.6%(减去安慰剂效应后，以下同)，2000 mg/d可降低HbA1c 2.0%，且与1000mg或1500mg比较，胃肠道反应差异无统计学意义。UKPDS研究中，二甲双胍强化治疗剂量中位数达到2550 mg/d，缓释剂型推荐最大用量为2000 mg/d，普通片推荐成人可用的最大剂量为2550 mg/d。综上所述，二甲双胍起效的最小推荐剂量为500mg/d，成人可用的最大剂量为2550mg/d，最佳有效剂量为2000mg/d。",
          "start_idx": 0,
          "end_idx": 300,
          "entities": [
            {
              "entity_id": "T146",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T147",
              "entity": "500~2000mg/d",
              "entity_type": "Amount",
              "start_idx": 28,
              "end_idx": 40,
              "entity_en": "500–2000 mg/day"
            },
            {
              "entity_id": "T148",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T149",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 64,
              "end_idx": 71,
              "entity_en": "500 mg/day"
            },
            {
              "entity_id": "T150",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T151",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T152",
              "entity": "0.6%",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "0.6%"
            },
            {
              "entity_id": "T153",
              "entity": "2000 mg/d",
              "entity_type": "Amount",
              "start_idx": 103,
              "end_idx": 112,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T154",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T155",
              "entity": "2.0%",
              "entity_type": "Test_Value",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "2.0%"
            },
            {
              "entity_id": "T156",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 128,
              "end_idx": 134,
              "entity_en": "1000mg"
            },
            {
              "entity_id": "T157",
              "entity": "1500mg",
              "entity_type": "Amount",
              "start_idx": 135,
              "end_idx": 141,
              "entity_en": "1500mg"
            },
            {
              "entity_id": "T158",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 144,
              "end_idx": 149,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T159",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T160",
              "entity": "2550 mg/d",
              "entity_type": "Amount",
              "start_idx": 182,
              "end_idx": 191,
              "entity_en": "2550 mg/day"
            },
            {
              "entity_id": "T161",
              "entity": "2000 mg/d",
              "entity_type": "Amount",
              "start_idx": 203,
              "end_idx": 212,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T162",
              "entity": "2550 mg/d",
              "entity_type": "Amount",
              "start_idx": 228,
              "end_idx": 237,
              "entity_en": "2550 mg/day"
            },
            {
              "entity_id": "T163",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 243,
              "end_idx": 247,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T164",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 257,
              "end_idx": 264,
              "entity_en": "500 mg/day"
            },
            {
              "entity_id": "T165",
              "entity": "2550mg/d",
              "entity_type": "Amount",
              "start_idx": 275,
              "end_idx": 283,
              "entity_en": "2550 mg/day"
            },
            {
              "entity_id": "T166",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 291,
              "end_idx": 299,
              "entity_en": "2000 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R61",
              "head_entity_id": "T147",
              "tail_entity_id": "T148"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R62",
              "head_entity_id": "T149",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R63",
              "head_entity_id": "T153",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R64",
              "head_entity_id": "T156",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R65",
              "head_entity_id": "T157",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R66",
              "head_entity_id": "T158",
              "tail_entity_id": "T150"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R67",
              "head_entity_id": "T161",
              "tail_entity_id": "T159"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R68",
              "head_entity_id": "T162",
              "tail_entity_id": "T159"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R69",
              "head_entity_id": "T160",
              "tail_entity_id": "T159"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R70",
              "head_entity_id": "T164",
              "tail_entity_id": "T163"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R71",
              "head_entity_id": "T165",
              "tail_entity_id": "T163"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R72",
              "head_entity_id": "T166",
              "tail_entity_id": "T163"
            }
          ],
          "sentence_en": "1. Minimum, maximum and optimal dosage of metformin: Clinical studies have shown that within the dosage range of 500-2000 mg/d, the hypoglycemic effect of metformin is positively correlated with the dosage. 500 mg/d of metformin can reduce HbA1c by 0.6% (after subtracting the placebo effect, the same below), 2000 mg/d can reduce HbA1c by 2.0%, and there is no statistically significant difference in gastrointestinal reactions compared with 1000 mg or 1500 mg. In the UKPDS study, the median dose of metformin for intensive treatment reached 2550 mg/d, the maximum recommended dose of sustained-release formulations was 2000 mg/d, and the maximum recommended dose for adults of ordinary tablets was 2550 mg/d. In summary, the minimum recommended dose of metformin for onset is 500 mg/d, the maximum dose available to adults is 2550 mg/d, and the optimal effective dose is 2000 mg/d."
        }
      ],
      "paragraph_en": "1. Minimum, maximum and optimal dosage of metformin: Clinical studies have shown that within the dosage range of 500-2000 mg/d, the hypoglycemic effect of metformin is positively correlated with the dosage. 500 mg/d of metformin can reduce HbA1c by 0.6% (after subtracting the placebo effect, the same below), 2000 mg/d can reduce HbA1c by 2.0%, and there is no statistically significant difference in gastrointestinal reactions compared with 1000 mg or 1500 mg. In the UKPDS study, the median dose of metformin for intensive treatment reached 2550 mg/d, the maximum recommended dose of sustained-release formulations was 2000 mg/d, and the maximum recommended dose for adults of ordinary tablets was 2550 mg/d. In summary, the minimum recommended dose of metformin for onset is 500 mg/d, the maximum dose available to adults is 2550 mg/d, and the optimal effective dose is 2000 mg/d."
    },
    {
      "paragraph_id": "12",
      "paragraph": "2.二甲双胍使用时的剂量调整：剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000 mg/d，1~2周后加量至最大有效剂量2000 mg/d或最大耐受剂量。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案，建议起始500mg，2次/d，如无明显胃肠道不良反应，随后可逐步增加至1000mg，2次/d。二甲双胍的血浆半衰期为5.1h，但其同时分布于红细胞储藏室，使得全血消除半衰期达17.6h。二甲双胍1000mg，2次/d，可维持24h有效血药浓度。可根据患者状况个体化治疗，通常剂量1500~2000mg/d，分2~3次服用。注意老年人群及肝肾功能不全的患者需调整剂量，具体方法详见“二甲双胍在特殊人群的使用”。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍使用时的剂量调整：剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000 mg/d，1~2周后加量至最大有效剂量2000 mg/d或最大耐受剂量。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案，建议起始500mg，2次/d，如无明显胃肠道不良反应，随后可逐步增加至1000mg，2次/d。二甲双胍的血浆半衰期为5.1h，但其同时分布于红细胞储藏室，使得全血消除半衰期达17.6h。二甲双胍1000mg，2次/d，可维持24h有效血药浓度。可根据患者状况个体化治疗，通常剂量1500~2000mg/d，分2~3次服用。注意老年人群及肝肾功能不全的患者需调整剂量，具体方法详见“二甲双胍在特殊人群的使用”。",
          "start_idx": 0,
          "end_idx": 358,
          "entities": [
            {
              "entity_id": "T167",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T168",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 40,
              "end_idx": 47,
              "entity_en": "500 mg/day"
            },
            {
              "entity_id": "T169",
              "entity": "<1000 mg/d",
              "entity_type": "Amount",
              "start_idx": 48,
              "end_idx": 58,
              "entity_en": "< 1000 mg/day"
            },
            {
              "entity_id": "T170",
              "entity": "2000 mg/d",
              "entity_type": "Amount",
              "start_idx": 73,
              "end_idx": 82,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T171",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T172",
              "entity": "1次/d",
              "entity_type": "Frequency",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "1 time/day"
            },
            {
              "entity_id": "T173",
              "entity": "500mg",
              "entity_type": "Amount",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "500mg"
            },
            {
              "entity_id": "T174",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 164,
              "end_idx": 168,
              "entity_en": "2 times/day"
            },
            {
              "entity_id": "T175",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 173,
              "end_idx": 180,
              "entity_en": "Gastrointestinal adverse reactions"
            },
            {
              "entity_id": "T176",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 189,
              "end_idx": 195,
              "entity_en": "1000mg"
            },
            {
              "entity_id": "T177",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 196,
              "end_idx": 200,
              "entity_en": "2 times/day"
            },
            {
              "entity_id": "T178",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 201,
              "end_idx": 205,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T179",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 247,
              "end_idx": 251,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T180",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 251,
              "end_idx": 257,
              "entity_en": "1000mg"
            },
            {
              "entity_id": "T181",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 258,
              "end_idx": 262,
              "entity_en": "2 times/day"
            },
            {
              "entity_id": "T182",
              "entity": "1500~2000mg/d",
              "entity_type": "Amount",
              "start_idx": 293,
              "end_idx": 306,
              "entity_en": "1500~2000mg/day"
            },
            {
              "entity_id": "T183",
              "entity": "分2~3次",
              "entity_type": "Frequency",
              "start_idx": 307,
              "end_idx": 312,
              "entity_en": "2~3 times"
            },
            {
              "entity_id": "T184",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 344,
              "end_idx": 348,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T185",
              "entity": "进餐时或餐后立即服用",
              "entity_type": "Method",
              "start_idx": 96,
              "end_idx": 106,
              "entity_en": "Take with or immediately after a meal"
            },
            {
              "entity_id": "T186",
              "entity": "晚餐时或餐后立即服用",
              "entity_type": "Method",
              "start_idx": 116,
              "end_idx": 126,
              "entity_en": "Take with or immediately after dinner"
            },
            {
              "entity_id": "T187",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 271,
              "end_idx": 275,
              "entity_en": "Blood concentration"
            },
            {
              "entity_id": "T188",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 322,
              "end_idx": 328,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T189",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 322,
              "end_idx": 323,
              "entity_en": "liver"
            },
            {
              "entity_id": "T190",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 323,
              "end_idx": 324,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R73",
              "head_entity_id": "T172",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R74",
              "head_entity_id": "T185",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R75",
              "head_entity_id": "T186",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R76",
              "head_entity_id": "T180",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R77",
              "head_entity_id": "T181",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T184",
              "tail_entity_id": "T188"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R79",
              "head_entity_id": "T189",
              "tail_entity_id": "T188"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T190",
              "tail_entity_id": "T188"
            }
          ],
          "sentence_en": "2. Dose adjustment when using metformin: The principle of dose adjustment is \"start with a small dose and gradually increase the dose\". Take 500 mg/d or <1000 mg/d at the beginning, and increase the dose to the maximum effective dose of 2000 mg/d or the maximum tolerated dose after 1 to 2 weeks. Metformin can be taken during or immediately after meals, and the sustained-release dosage form is taken once a day at dinner or immediately after meals. Considering the clinical efficacy of the drug and patient compliance, a simplified dosage regimen can be adopted. It is recommended to start with 500 mg, twice a day. If there are no obvious gastrointestinal adverse reactions, it can be gradually increased to 1000 mg, twice a day. The plasma half-life of metformin is 5.1h, but it is also distributed in the red blood cell storage compartment, making the whole blood elimination half-life reach 17.6h. Metformin 1000mg, twice a day, can maintain an effective blood drug concentration for 24h. Individualized treatment can be provided according to the patient's condition. The usual dose is 1500~2000mg/d, taken in 2~3 times. Note that the dose needs to be adjusted for the elderly and patients with impaired liver and kidney function. For details, see \"Use of Metformin in Special Populations\"."
        }
      ],
      "paragraph_en": "2. Dose adjustment when using metformin: The principle of dose adjustment is \"start with a small dose and gradually increase the dose\". Take 500 mg/d or <1000 mg/d at the beginning, and increase the dose to the maximum effective dose of 2000 mg/d or the maximum tolerated dose after 1 to 2 weeks. Metformin can be taken during or immediately after meals, and the sustained-release dosage form is taken once a day at dinner or immediately after meals. Considering the clinical efficacy of the drug and patient compliance, a simplified dosage regimen can be adopted. It is recommended to start with 500 mg, twice a day. If there are no obvious gastrointestinal adverse reactions, it can be gradually increased to 1000 mg, twice a day. The plasma half-life of metformin is 5.1h, but it is also distributed in the red blood cell storage compartment, making the whole blood elimination half-life reach 17.6h. Metformin 1000mg, twice a day, can maintain an effective blood drug concentration for 24h. Individualized treatment can be provided according to the patient's condition. The usual dose is 1500~2000mg/d, taken in 2~3 times. Note that the dose needs to be adjusted for the elderly and patients with impaired liver and kidney function. For details, see \"Use of Metformin in Special Populations\"."
    },
    {
      "paragraph_id": "13",
      "paragraph": "3.二甲双胍的剂型：目前，国内外主要有单一成分的二甲双胍普通片(250 mg/片、500 mg/片或850 mg/片)、二甲双胍缓释片或胶囊(500mg/片或500 mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250 mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药，如磺脲类药物或DPP-4抑制剂组成的复方制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.二甲双胍的剂型：目前，国内外主要有单一成分的二甲双胍普通片(250 mg/片、500 mg/片或850 mg/片)、二甲双胍缓释片或胶囊(500mg/片或500 mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250 mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药，如磺脲类药物或DPP-4抑制剂组成的复方制剂。",
          "start_idx": 0,
          "end_idx": 161,
          "entities": [
            {
              "entity_id": "T191",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T192",
              "entity": "二甲双胍粉剂",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 126,
              "entity_en": "Metformin powder"
            },
            {
              "entity_id": "T193",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 132,
              "end_idx": 134,
              "entity_en": "oral"
            },
            {
              "entity_id": "T194",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T195",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 153,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T196",
              "entity": "二甲双胍肠溶片或胶囊",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 100,
              "entity_en": "Metformin enteric-coated tablets or capsules"
            },
            {
              "entity_id": "T197",
              "entity": "二甲双胍缓释片或胶囊",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 70,
              "entity_en": "Metformin extended-release tablets or capsules"
            },
            {
              "entity_id": "T198",
              "entity": "二甲双胍普通片",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 31,
              "entity_en": "Metformin regular tablets"
            }
          ],
          "relations": [],
          "sentence_en": "3. Dosage forms of metformin: At present, the main domestic and foreign products include single-ingredient metformin ordinary tablets (250 mg/tablet, 500 mg/tablet or 850 mg/tablet), metformin sustained-release tablets or capsules (500 mg/tablet or 500 mg/capsule), metformin enteric-coated tablets or capsules (250 mg/tablet or 250 mg/capsule), metformin powder, and compound preparations with other oral hypoglycemic drugs such as sulfonylureas or DPP-4 inhibitors."
        }
      ],
      "paragraph_en": "3. Dosage forms of metformin: At present, the main domestic and foreign products include single-ingredient metformin ordinary tablets (250 mg/tablet, 500 mg/tablet or 850 mg/tablet), metformin sustained-release tablets or capsules (500 mg/tablet or 500 mg/capsule), metformin enteric-coated tablets or capsules (250 mg/tablet or 250 mg/capsule), metformin powder, and compound preparations with other oral hypoglycemic drugs such as sulfonylureas or DPP-4 inhibitors."
    },
    {
      "paragraph_id": "14",
      "paragraph": "4.不同剂型二甲双胍疗效的区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放；肠溶片从胃排空到肠道后崩解释放；缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放。(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。因而每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，多剂量给药后的达稳时间也不一致。(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性。(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性。(5)不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.不同剂型二甲双胍疗效的区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同，普通片剂在胃内崩解释放；肠溶片从胃排空到肠道后崩解释放；缓释片和缓释胶囊在胃肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T199",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "4. Differences in the efficacy of metformin in different dosage forms: (1) The main difference between the various dosage forms is the different dissolution and release behaviors of the drugs in the preparations after administration. Ordinary tablets disintegrate and release in the stomach; enteric-coated tablets disintegrate and release after the stomach is emptied into the intestine; sustained-release tablets and sustained-release capsules dissolve and release slowly in the gastrointestinal tract; and enteric-coated capsules dissolve and release in the intestine."
        },
        {
          "sentence_id": "1",
          "sentence": "(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。",
          "start_idx": 112,
          "end_idx": 148,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Ordinary tablets dissolve faster in the stomach, followed by enteric-coated tablets and enteric-coated capsules, and then sustained-release tablets."
        },
        {
          "sentence_id": "2",
          "sentence": "因而每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，多剂量给药后的达稳时间也不一致。",
          "start_idx": 148,
          "end_idx": 201,
          "entities": [
            {
              "entity_id": "T200",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Blood concentration"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, there are certain differences in parameters such as peak blood drug concentration, peak time, apparent half-life, etc. after administration of each preparation, and the time to reach stability after multiple doses is also inconsistent."
        },
        {
          "sentence_id": "3",
          "sentence": "(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性。",
          "start_idx": 201,
          "end_idx": 251,
          "entities": [
            {
              "entity_id": "T201",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Gastrointestinal reactions"
            }
          ],
          "relations": [],
          "sentence_en": "(3) Compared with ordinary tablets, sustained-release tablets/capsules and enteric-coated tablets/capsules can reduce gastrointestinal reactions after administration and improve patients' medication compliance."
        },
        {
          "sentence_id": "4",
          "sentence": "(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性。",
          "start_idx": 251,
          "end_idx": 286,
          "entities": [],
          "relations": [],
          "sentence_en": "(4) Qualified drug preparations should be bioequivalent among various dosage forms at the same dosage."
        },
        {
          "sentence_id": "5",
          "sentence": "(5)不同剂型的临床疗效是否一致，尚需更多的临床研究证实。",
          "start_idx": 286,
          "end_idx": 315,
          "entities": [],
          "relations": [],
          "sentence_en": "(5) Whether the clinical efficacy of different dosage forms is consistent still needs more clinical research to confirm."
        }
      ],
      "paragraph_en": "4. Differences in the efficacy of metformin in different dosage forms: (1) The main difference between various dosage forms is the different dissolution and release behaviors of the drug in the preparation after administration. Ordinary tablets disintegrate and release in the stomach; enteric-coated tablets disintegrate and release after the stomach is emptied into the intestine; sustained-release tablets and sustained-release capsules dissolve and release slowly in the gastrointestinal tract; and enteric-coated capsules dissolve and release in the intestine. (2) Ordinary tablets dissolve faster in the stomach, followed by enteric-coated tablets and enteric-coated capsules, and then sustained-release tablets. Therefore, there are certain differences in parameters such as peak blood drug concentration, peak time, and apparent half-life after administration of each preparation, and the time to reach stability after multiple doses is also inconsistent. (3) Compared with ordinary tablets, sustained-release tablets/capsules and enteric-coated tablets/capsules can reduce gastrointestinal reactions after administration and improve patients' medication compliance. (4) Qualified drug preparations should have bioequivalence among various dosage forms at the same dosage. (5) Whether the clinical efficacy of different dosage forms is consistent still needs more clinical research to confirm."
    },
    {
      "paragraph_id": "15",
      "paragraph": "5.二甲双胍单药治疗的降糖疗效：一项随机、双盲、平行对照研究结果显示，在减去安慰剂效应后二甲双胍单药治疗29周可降低FPG3.2mmol/L、PPG4.0mmol/L、HbA1c1.8%(I级)。在中国人群开展的安慰剂对照的临床研究中，1000mg/d或1700mg/d二甲双胍单药治疗可使HbA1c分别降低0.7%和1.0%(去除安慰剂效应后)(I级)。一项前瞻性、随机对照研究显示，在新诊断的曾经接受短期胰岛素治疗后的T2DM患者中，以二甲双胍(2000mg/d)为基础的口服降糖药物组疗效与甘精胰岛素组的降糖疗效相当(I级)。在中国人群中的研究显示，2000mg/d二甲双胍的疗效与1000mg/d二甲双胍联合DPP-4抑制剂的疗效相当(I级)。一项前瞻性、随机对照研究显示，在新诊断的T2DM患者中，二甲双胍(1500mg/d)的降糖疗效和阿卡波糖(300mg/d)相当。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.二甲双胍单药治疗的降糖疗效：一项随机、双盲、平行对照研究结果显示，在减去安慰剂效应后二甲双胍单药治疗29周可降低FPG3.2mmol/L、PPG4.0mmol/L、HbA1c1.8%(I级)。在中国人群开展的安慰剂对照的临床研究中，1000mg/d或1700mg/d二甲双胍单药治疗可使HbA1c分别降低0.7%和1.0%(去除安慰剂效应后)(I级)。一项前瞻性、随机对照研究显示，在新诊断的曾经接受短期胰岛素治疗后的T2DM患者中，以二甲双胍(2000mg/d)为基础的口服降糖药物组疗效与甘精胰岛素组的降糖疗效相当(I级)。在中国人群中的研究显示，2000mg/d二甲双胍的疗效与1000mg/d二甲双胍联合DPP-4抑制剂的疗效相当(I级)。一项前瞻性、随机对照研究显示，在新诊断的T2DM患者中，二甲双胍(1500mg/d)的降糖疗效和阿卡波糖(300mg/d)相当。",
          "start_idx": 0,
          "end_idx": 390,
          "entities": [
            {
              "entity_id": "T202",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T203",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T204",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T205",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 74,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T206",
              "entity": "4.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 74,
              "end_idx": 83,
              "entity_en": "4.0mmol/L"
            },
            {
              "entity_id": "T207",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 89,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T208",
              "entity": "1.8%",
              "entity_type": "Test_Value",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "1.8%"
            },
            {
              "entity_id": "T209",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T210",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 118,
              "end_idx": 126,
              "entity_en": "1000 mg/day"
            },
            {
              "entity_id": "T211",
              "entity": "1700mg/d",
              "entity_type": "Amount",
              "start_idx": 127,
              "end_idx": 135,
              "entity_en": "1700 mg/day"
            },
            {
              "entity_id": "T212",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 139,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T213",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 145,
              "end_idx": 150,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T214",
              "entity": "降低0.7%和1.0%",
              "entity_type": "Test_Value",
              "start_idx": 152,
              "end_idx": 163,
              "entity_en": "Reduce by 0.7% and 1.0%"
            },
            {
              "entity_id": "T215",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 204,
              "end_idx": 207,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T216",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 211,
              "end_idx": 215,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T217",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 211,
              "end_idx": 213,
              "entity_en": "T2"
            },
            {
              "entity_id": "T218",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 224,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T219",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 225,
              "end_idx": 233,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T220",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 238,
              "end_idx": 240,
              "entity_en": "oral"
            },
            {
              "entity_id": "T221",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 248,
              "end_idx": 253,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T222",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 278,
              "end_idx": 286,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T223",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 286,
              "end_idx": 290,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T224",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 294,
              "end_idx": 302,
              "entity_en": "1000 mg/day"
            },
            {
              "entity_id": "T225",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 302,
              "end_idx": 306,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T226",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 308,
              "end_idx": 316,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T227",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 346,
              "end_idx": 350,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T228",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 346,
              "end_idx": 348,
              "entity_en": "T2"
            },
            {
              "entity_id": "T229",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 354,
              "end_idx": 358,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T230",
              "entity": "1500mg/d",
              "entity_type": "Amount",
              "start_idx": 359,
              "end_idx": 367,
              "entity_en": "1500 mg/day"
            },
            {
              "entity_id": "T231",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 374,
              "end_idx": 378,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T232",
              "entity": "300mg/d",
              "entity_type": "Amount",
              "start_idx": 379,
              "end_idx": 386,
              "entity_en": "300 mg/day"
            },
            {
              "entity_id": "T233",
              "entity": "29周",
              "entity_type": "Duration",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "29 weeks"
            },
            {
              "entity_id": "T234",
              "entity": "3.2mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 70,
              "entity_en": "3.2mmol/L"
            }
          ],
          "relations": [
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R81",
              "head_entity_id": "T233",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R82",
              "head_entity_id": "T210",
              "tail_entity_id": "T212"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R83",
              "head_entity_id": "T211",
              "tail_entity_id": "T212"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R84",
              "head_entity_id": "T215",
              "tail_entity_id": "T216"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R85",
              "head_entity_id": "T217",
              "tail_entity_id": "T216"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T218",
              "tail_entity_id": "T216"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R87",
              "head_entity_id": "T221",
              "tail_entity_id": "T216"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R88",
              "head_entity_id": "T219",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R89",
              "head_entity_id": "T220",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R90",
              "head_entity_id": "T222",
              "tail_entity_id": "T223"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R91",
              "head_entity_id": "T224",
              "tail_entity_id": "T225"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R92",
              "head_entity_id": "T228",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R93",
              "head_entity_id": "T229",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R94",
              "head_entity_id": "T231",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R95",
              "head_entity_id": "T230",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R96",
              "head_entity_id": "T232",
              "tail_entity_id": "T231"
            }
          ],
          "sentence_en": "5. Glucose-lowering efficacy of metformin monotherapy: A randomized, double-blind, parallel-controlled study showed that after subtracting the placebo effect, 29 weeks of metformin monotherapy can reduce FPG3.2mmol/L, PPG4.0mmol/L, and HbA1c1.8% (level I). In a placebo-controlled clinical study conducted in the Chinese population, 1000mg/d or 1700mg/d of metformin monotherapy can reduce HbA1c by 0.7% and 1.0%, respectively (after removing the placebo effect) (level I). A prospective, randomized controlled study showed that in newly diagnosed T2DM patients who had received short-term insulin treatment, the efficacy of oral glucose-lowering drugs based on metformin (2000mg/d) was equivalent to that of glargine insulin group (level I). Studies in the Chinese population showed that the efficacy of 2000mg/d of metformin was equivalent to that of 1000mg/d of metformin combined with DPP-4 inhibitors (level I). A prospective, randomized controlled study showed that in newly diagnosed T2DM patients, the glucose-lowering efficacy of metformin (1500 mg/d) was equivalent to that of acarbose (300 mg/d)."
        }
      ],
      "paragraph_en": "5. Glucose-lowering efficacy of metformin monotherapy: A randomized, double-blind, parallel-controlled study showed that after subtracting the placebo effect, 29 weeks of metformin monotherapy can reduce FPG3.2mmol/L, PPG4.0mmol/L, and HbA1c1.8% (level I). In a placebo-controlled clinical study conducted in the Chinese population, 1000mg/d or 1700mg/d of metformin monotherapy can reduce HbA1c by 0.7% and 1.0%, respectively (after removing the placebo effect) (level I). A prospective, randomized controlled study showed that in newly diagnosed T2DM patients who had received short-term insulin treatment, the efficacy of oral glucose-lowering drugs based on metformin (2000mg/d) was equivalent to that of glargine insulin group (level I). Studies in the Chinese population showed that the efficacy of 2000mg/d of metformin was equivalent to that of 1000mg/d of metformin combined with DPP-4 inhibitors (level I). A prospective, randomized controlled study showed that in newly diagnosed T2DM patients, the glucose-lowering efficacy of metformin (1500 mg/d) was equivalent to that of acarbose (300 mg/d)."
    },
    {
      "paragraph_id": "16",
      "paragraph": "6.二甲双胍联合磺脲类药物的疗效：二甲双胍可改善IR，减少肝糖输出；磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c(I级)。磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时复合制剂治疗组FPG水平控制更好(I级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降低幅度(1.7%)高于二甲双胍联合阿卡波糖治疗组(0.9%)，且两组低血糖、体重增加比较，差异无统计学意义(I级)。另有随机、双盲、双模拟、平行对照研究显示，与相同剂量的格列本脲相比，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂降糖效果相当，但低血糖发生的风险减低(I级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.二甲双胍联合磺脲类药物的疗效：二甲双胍可改善IR，减少肝糖输出；磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c(I级)。磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时复合制剂治疗组FPG水平控制更好(I级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降低幅度(1.7%)高于二甲双胍联合阿卡波糖治疗组(0.9%)，且两组低血糖、体重增加比较，差异无统计学意义(I级)。另有随机、双盲、双模拟、平行对照研究显示，与相同剂量的格列本脲相比，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂降糖效果相当，但低血糖发生的风险减低(I级)。",
          "start_idx": 0,
          "end_idx": 465,
          "entities": [
            {
              "entity_id": "T235",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T236",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T237",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T238",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T239",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T240",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 69,
              "end_idx": 71,
              "entity_en": "T2"
            },
            {
              "entity_id": "T241",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "IR"
            },
            {
              "entity_id": "T242",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T243",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T244",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 120,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T245",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 123,
              "end_idx": 127,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T246",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 137,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T247",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 143,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T248",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 148,
              "end_idx": 153,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T249",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T250",
              "entity": "格列吡嗪/二甲双胍复合制剂",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 182,
              "entity_en": "Glipizide/Metformin combination"
            },
            {
              "entity_id": "T251",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 186,
              "end_idx": 188,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T252",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 192,
              "end_idx": 197,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T253",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 215,
              "end_idx": 219,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T254",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 231,
              "end_idx": 235,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T255",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 263,
              "end_idx": 266,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T256",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 280,
              "end_idx": 284,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T257",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 280,
              "end_idx": 282,
              "entity_en": "T2"
            },
            {
              "entity_id": "T258",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 304,
              "end_idx": 308,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T259",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 310,
              "end_idx": 314,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T260",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 318,
              "end_idx": 323,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T261",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 335,
              "end_idx": 339,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T262",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 341,
              "end_idx": 345,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T263",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 358,
              "end_idx": 361,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T264",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 362,
              "end_idx": 366,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T265",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 409,
              "end_idx": 413,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T266",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 417,
              "end_idx": 421,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T267",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 429,
              "end_idx": 433,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T268",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 450,
              "end_idx": 453,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T269",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T270",
              "entity": "18周",
              "entity_type": "Duration",
              "start_idx": 164,
              "end_idx": 167,
              "entity_en": "18 weeks"
            },
            {
              "entity_id": "T271",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 197,
              "end_idx": 202,
              "entity_en": "<7.0%"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R97",
              "head_entity_id": "T237",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R98",
              "head_entity_id": "T238",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R99",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R100",
              "head_entity_id": "T241",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R101",
              "head_entity_id": "T270",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R102",
              "head_entity_id": "T257",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R103",
              "head_entity_id": "T258",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R104",
              "head_entity_id": "T259",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R105",
              "head_entity_id": "T260",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R106",
              "head_entity_id": "T261",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R107",
              "head_entity_id": "T262",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R108",
              "head_entity_id": "T263",
              "tail_entity_id": "T258"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R109",
              "head_entity_id": "T264",
              "tail_entity_id": "T258"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R110",
              "head_entity_id": "T263",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R111",
              "head_entity_id": "T264",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R112",
              "head_entity_id": "T263",
              "tail_entity_id": "T261"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R113",
              "head_entity_id": "T264",
              "tail_entity_id": "T261"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R114",
              "head_entity_id": "T263",
              "tail_entity_id": "T262"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R115",
              "head_entity_id": "T264",
              "tail_entity_id": "T262"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R116",
              "head_entity_id": "T268",
              "tail_entity_id": "T265"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R117",
              "head_entity_id": "T268",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R118",
              "head_entity_id": "T268",
              "tail_entity_id": "T267"
            }
          ],
          "sentence_en": "6. Efficacy of metformin combined with sulfonylureas: Metformin can improve IR and reduce hepatic glucose output; sulfonylureas can promote insulin secretion. The combination of the two types of drugs has complementary mechanisms of action and is more comprehensive in targeting the pathophysiological defects of T2DM. A randomized, double-blind, parallel controlled study showed that the metformin combined with glibenclamide treatment group can better control FPG and HbA1c (grade I) than the metformin alone or glibenclamide alone group. After 18 weeks of treatment for patients with poor blood sugar control with sulfonylureas, the blood sugar control rate (HbA1c <7.0%) in the glipizide/metformin combination treatment group was 36.3%, which was 4.1 and 3.7 times that of the metformin alone treatment group (8.9%) and the glipizide alone treatment group (9.9%), respectively. At the same time, the FPG level in the combination treatment group was better controlled (grade I). A randomized, parallel-controlled study conducted in Chinese patients with T2DM showed that the reduction in HbA1c in the metformin combined with glibenclamide treatment group (1.7%) was higher than that in the metformin combined with acarbose treatment group (0.9%), and there was no statistically significant difference in hypoglycemia and weight gain between the two groups (level I). Another randomized, double-blind, double-simulation, parallel-controlled study showed that compared with the same dose of glibenclamide, the combined use of a fixed compound Chinese medicine containing glibenclamide on the basis of metformin had a comparable hypoglycemic effect, but the risk of hypoglycemia was reduced (level I)."
        }
      ],
      "paragraph_en": "6. Efficacy of metformin combined with sulfonylureas: Metformin can improve IR and reduce hepatic glucose output; sulfonylureas can promote insulin secretion. The combination of the two types of drugs has complementary mechanisms of action and is more comprehensive in targeting the pathophysiological defects of T2DM. A randomized, double-blind, parallel controlled study showed that the metformin combined with glibenclamide treatment group can better control FPG and HbA1c (grade I) than the metformin alone or glibenclamide alone group. After 18 weeks of treatment for patients with poor blood sugar control with sulfonylureas, the blood sugar control rate (HbA1c <7.0%) in the glipizide/metformin combination treatment group was 36.3%, which was 4.1 and 3.7 times that of the metformin alone treatment group (8.9%) and the glipizide alone treatment group (9.9%), respectively. At the same time, the FPG level in the combination treatment group was better controlled (grade I). A randomized, parallel-controlled study conducted in Chinese patients with T2DM showed that the reduction in HbA1c in the metformin combined with glibenclamide treatment group (1.7%) was higher than that in the metformin combined with acarbose treatment group (0.9%), and there was no statistically significant difference in hypoglycemia and weight gain between the two groups (level I). Another randomized, double-blind, double-simulation, parallel-controlled study showed that compared with the same dose of glibenclamide, the combined use of a fixed compound Chinese medicine containing glibenclamide on the basis of metformin had a comparable hypoglycemic effect, but the risk of hypoglycemia was reduced (level I)."
    },
    {
      "paragraph_id": "17",
      "paragraph": "7.二甲双胍联合TZDs的疗效：二甲双胍联合TZDs能更好地降低HbA1c，显著改善胰岛功能和IR，但联合治疗药物的不良反应(体重增加、升高LDL-C)高于单用二甲双胍；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著。故IR严重的患者可考虑二甲双胍联合TZDs药物的治疗方案(I级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.二甲双胍联合TZDs的疗效：二甲双胍联合TZDs能更好地降低HbA1c，显著改善胰岛功能和IR，但联合治疗药物的不良反应(体重增加、升高LDL-C)高于单用二甲双胍；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著。故IR严重的患者可考虑二甲双胍联合TZDs药物的治疗方案(I级)。",
          "start_idx": 0,
          "end_idx": 161,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T273",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "TZD"
            },
            {
              "entity_id": "T274",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T275",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "TZD"
            },
            {
              "entity_id": "T276",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T277",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "IR"
            },
            {
              "entity_id": "T278",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T279",
              "entity": "升高LDL-C",
              "entity_type": "ADE",
              "start_idx": 68,
              "end_idx": 75,
              "entity_en": "Raised LDL-C"
            },
            {
              "entity_id": "T280",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 80,
              "end_idx": 84,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T281",
              "entity": "罗格列酮/二甲双胍的复合制剂",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 99,
              "entity_en": "Rosiglitazone/metformin combination"
            },
            {
              "entity_id": "T282",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T283",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T284",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T285",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "IR"
            },
            {
              "entity_id": "T286",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 143,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T287",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "TZD"
            },
            {
              "entity_id": "T288",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 131,
              "end_idx": 133,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R119",
              "head_entity_id": "T278",
              "tail_entity_id": "T274"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R120",
              "head_entity_id": "T279",
              "tail_entity_id": "T274"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R121",
              "head_entity_id": "T278",
              "tail_entity_id": "T275"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R122",
              "head_entity_id": "T279",
              "tail_entity_id": "T275"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R123",
              "head_entity_id": "T278",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R124",
              "head_entity_id": "T279",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R125",
              "head_entity_id": "T286",
              "tail_entity_id": "T285"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R126",
              "head_entity_id": "T287",
              "tail_entity_id": "T285"
            }
          ],
          "sentence_en": "7. Efficacy of metformin combined with TZDs: Metformin combined with TZDs can better reduce HbA1c, significantly improve islet function and IR, but the adverse reactions of combined treatment drugs (weight gain, increased LDL-C) are higher than those of metformin alone; compared with metformin alone, the combination of rosiglitazone/metformin can reduce HbA1c and FPG more significantly. Therefore, patients with severe IR can consider the treatment of metformin combined with TZDs (level I)."
        }
      ],
      "paragraph_en": "7. Efficacy of metformin combined with TZDs: Metformin combined with TZDs can better reduce HbA1c, significantly improve islet function and IR, but the adverse reactions of combined treatment drugs (weight gain, increased LDL-C) are higher than those of metformin alone; compared with metformin alone, the combination of rosiglitazone/metformin can reduce HbA1c and FPG more significantly. Therefore, patients with severe IR can consider the treatment of metformin combined with TZDs (level I)."
    },
    {
      "paragraph_id": "18",
      "paragraph": "8.二甲双胍联合格列奈类药物的疗效：格列奈类药物属于餐时促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中，瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生风险却未增加。那格列奈联用二甲双胍与格列齐特联用二甲双胍的降糖强度相似，但低血糖发生的风险更小(I级)。故在二甲双胍联合磺脲类药物且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率比较，差异无统计学意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "8.二甲双胍联合格列奈类药物的疗效：格列奈类药物属于餐时促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中，瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生风险却未增加。那格列奈联用二甲双胍与格列齐特联用二甲双胍的降糖强度相似，但低血糖发生的风险更小(I级)。故在二甲双胍联合磺脲类药物且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。",
          "start_idx": 0,
          "end_idx": 217,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T290",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 14,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T291",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 24,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T292",
              "entity": "促胰岛素分泌剂",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 35,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T293",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T294",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 57,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T295",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T296",
              "entity": "11.0%",
              "entity_type": "Test_Value",
              "start_idx": 71,
              "end_idx": 76,
              "entity_en": "11.0%"
            },
            {
              "entity_id": "T297",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T298",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "T2"
            },
            {
              "entity_id": "T299",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T300",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T301",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T302",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 115,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T303",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T304",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 133,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T305",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 139,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T306",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 144,
              "entity_en": "Gliclazide"
            },
            {
              "entity_id": "T307",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T308",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T309",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 180,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T310",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 187,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T311",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 188,
              "end_idx": 191,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T312",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 204,
              "end_idx": 208,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T313",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 216,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T319",
              "entity": "较高",
              "entity_type": "Test_Value",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "Higher"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R127",
              "head_entity_id": "T294",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R128",
              "head_entity_id": "T295",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R129",
              "head_entity_id": "T298",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R130",
              "head_entity_id": "T299",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R131",
              "head_entity_id": "T300",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R132",
              "head_entity_id": "T301",
              "tail_entity_id": "T297"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R133",
              "head_entity_id": "T303",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R134",
              "head_entity_id": "T303",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R135",
              "head_entity_id": "T303",
              "tail_entity_id": "T301"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R136",
              "head_entity_id": "T308",
              "tail_entity_id": "T304"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R137",
              "head_entity_id": "T308",
              "tail_entity_id": "T305"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R138",
              "head_entity_id": "T308",
              "tail_entity_id": "T306"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R139",
              "head_entity_id": "T308",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R140",
              "head_entity_id": "T311",
              "tail_entity_id": "T309"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R141",
              "head_entity_id": "T311",
              "tail_entity_id": "T310"
            }
          ],
          "sentence_en": "8. Efficacy of Metformin Combined with Meglitinides: Meglitinides are prandial insulin secretagogues and have a synergistic effect when used in combination with metformin. In newly diagnosed T2DM patients with high blood sugar levels (HbA1c levels close to 11.0%), the combination of repaglinide and metformin can more effectively reduce HbA1c than repaglinide alone, without increasing the risk of hypoglycemia. The glucose-lowering intensity of nateglinide combined with metformin is similar to that of gliclazide combined with metformin, but the risk of hypoglycemia is lower (grade I). Therefore, when metformin is combined with sulfonylureas and the risk of hypoglycemia is high, the combination of metformin and meglitinides can be considered."
        },
        {
          "sentence_id": "1",
          "sentence": "在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率比较，差异无统计学意义。",
          "start_idx": 217,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T314",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T315",
              "entity": "米格列奈",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Mitiglinide"
            },
            {
              "entity_id": "T316",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T317",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T318",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "PPG"
            }
          ],
          "relations": [],
          "sentence_en": "Adding mitiglinide to metformin can further reduce HbA1c, FPG and PPG and improve the target achievement rate, while there is no statistically significant difference in the incidence of adverse events."
        }
      ],
      "paragraph_en": "8. Efficacy of Metformin Combined with Meglitinides: Meglitinides are prandial insulin secretagogues and have a synergistic effect when used in combination with metformin. In newly diagnosed T2DM patients with high blood sugar levels (HbA1c levels close to 11.0%), the combination of repaglinide and metformin can more effectively reduce HbA1c than repaglinide alone, without increasing the risk of hypoglycemia. The glucose-lowering intensity of nateglinide combined with metformin is similar to that of gliclazide combined with metformin, but the risk of hypoglycemia is lower (grade I). Therefore, when metformin is combined with sulfonylureas and the risk of hypoglycemia is high, metformin combined with meglitinides can be considered. The addition of mitiglinide to metformin can further reduce HbA1c, FPG and PPG, and improve the compliance rate, while the incidence of adverse events is not statistically significant."
    },
    {
      "paragraph_id": "19",
      "paragraph": "9.二甲双胍联合α-糖苷酶抑制剂的疗效：二甲双胍与α-糖苷酶抑制剂联合，可兼顾FPG和PPG。超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好控制HbA1c、FPG和体重。二甲双胍和磺脲类联用的降糖疗效优于二甲双胍和阿卡波糖联用(Ⅰ级)。这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "9.二甲双胍联合α-糖苷酶抑制剂的疗效：二甲双胍与α-糖苷酶抑制剂联合，可兼顾FPG和PPG。超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好控制HbA1c、FPG和体重。",
          "start_idx": 0,
          "end_idx": 91,
          "entities": [
            {
              "entity_id": "T320",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T321",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T322",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T323",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 33,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T324",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 42,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T325",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T326",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T327",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T328",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 50,
              "end_idx": 52,
              "entity_en": "T2"
            },
            {
              "entity_id": "T329",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T330",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T331",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T332",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 87,
              "entity_en": "FPG"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R142",
              "head_entity_id": "T329",
              "tail_entity_id": "T326"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R143",
              "head_entity_id": "T330",
              "tail_entity_id": "T326"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R144",
              "head_entity_id": "T331",
              "tail_entity_id": "T326"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R145",
              "head_entity_id": "T332",
              "tail_entity_id": "T326"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R146",
              "head_entity_id": "T328",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R147",
              "head_entity_id": "T329",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R148",
              "head_entity_id": "T330",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R149",
              "head_entity_id": "T331",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R150",
              "head_entity_id": "T332",
              "tail_entity_id": "T327"
            }
          ],
          "sentence_en": "9. Efficacy of metformin combined with α-glucosidase inhibitors: The combination of metformin and α-glucosidase inhibitors can take into account both FPG and PPG. When metformin is ineffective in overweight T2DM patients, adding acarbose can better control HbA1c, FPG and body weight."
        },
        {
          "sentence_id": "1",
          "sentence": "二甲双胍和磺脲类联用的降糖疗效优于二甲双胍和阿卡波糖联用(Ⅰ级)。",
          "start_idx": 91,
          "end_idx": 124,
          "entities": [
            {
              "entity_id": "T333",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T334",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T335",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T336",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Acarbose"
            }
          ],
          "relations": [],
          "sentence_en": "The hypoglycemic efficacy of the combination of metformin and sulfonylureas is better than that of the combination of metformin and acarbose (Grade I)."
        },
        {
          "sentence_id": "2",
          "sentence": "这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。",
          "start_idx": 124,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T337",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 17,
              "entity_en": "Gastrointestinal adverse reactions"
            },
            {
              "entity_id": "T338",
              "entity": "胃肠不适",
              "entity_type": "ADE",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Gastrointestinal discomfort"
            }
          ],
          "relations": [],
          "sentence_en": "Both drugs have certain gastrointestinal adverse reactions, and their combined use may increase gastrointestinal discomfort."
        }
      ],
      "paragraph_en": "9. Efficacy of metformin combined with α-glucosidase inhibitors: Metformin combined with α-glucosidase inhibitors can take into account both FPG and PPG. When overweight T2DM patients do not respond well to metformin, adding acarbose can better control HbA1c, FPG and body weight. The combined use of metformin and sulfonylureas has better hypoglycemic efficacy than the combined use of metformin and acarbose (grade I). Both drugs have certain gastrointestinal adverse reactions, and combined use may increase gastrointestinal discomfort."
    },
    {
      "paragraph_id": "20",
      "paragraph": "10.二甲双胍联合DPP-4抑制剂的疗效：二甲双胍与DPP-4抑制剂的联合治疗，可针对T2DM不同的病理生理缺陷，发挥机制互补、协同增效的降糖作用。一项随机、双盲、对照研究显示，二甲双胍单药控制不佳的T2DM患者加用DPP-4抑制剂可有效改善血糖水平，且耐受性良好(I级)。中国多中心、前瞻性、随机、对照研究显示，1000mg二甲双胍联合维格列汀与二甲双胍2000mg单药疗效和安全性相当；在新诊断T2DM患者中，1700mg/d二甲双胍单药治疗的降糖疗效非劣于1700mg二甲双胍联合西格列汀治疗(Ⅰ级)。建议遵循《中国2型糖尿病防治指南》的治疗原则，新诊断T2DM患者首选二甲双胍，可耐受的情况下加至最佳有效剂量(2000mg/d)；不达标的患者，可以联合DPP-4抑制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "10.二甲双胍联合DPP-4抑制剂的疗效：二甲双胍与DPP-4抑制剂的联合治疗，可针对T2DM不同的病理生理缺陷，发挥机制互补、协同增效的降糖作用。一项随机、双盲、对照研究显示，二甲双胍单药控制不佳的T2DM患者加用DPP-4抑制剂可有效改善血糖水平，且耐受性良好(I级)。中国多中心、前瞻性、随机、对照研究显示，1000mg二甲双胍联合维格列汀与二甲双胍2000mg单药疗效和安全性相当；在新诊断T2DM患者中，1700mg/d二甲双胍单药治疗的降糖疗效非劣于1700mg二甲双胍联合西格列汀治疗(Ⅰ级)。建议遵循《中国2型糖尿病防治指南》的治疗原则，新诊断T2DM患者首选二甲双胍，可耐受的情况下加至最佳有效剂量(2000mg/d)；不达标的患者，可以联合DPP-4抑制剂。",
          "start_idx": 0,
          "end_idx": 339,
          "entities": [
            {
              "entity_id": "T339",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T340",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 17,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T341",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T342",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 34,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T343",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T344",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "T2"
            },
            {
              "entity_id": "T345",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T346",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T347",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 100,
              "end_idx": 102,
              "entity_en": "T2"
            },
            {
              "entity_id": "T348",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 116,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T349",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 121,
              "end_idx": 123,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T350",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 157,
              "end_idx": 163,
              "entity_en": "1000mg"
            },
            {
              "entity_id": "T351",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T352",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T353",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 178,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T354",
              "entity": "2000mg",
              "entity_type": "Amount",
              "start_idx": 178,
              "end_idx": 184,
              "entity_en": "2000mg"
            },
            {
              "entity_id": "T355",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 199,
              "end_idx": 203,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T356",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 199,
              "end_idx": 201,
              "entity_en": "T2"
            },
            {
              "entity_id": "T357",
              "entity": "1700mg/d",
              "entity_type": "Amount",
              "start_idx": 207,
              "end_idx": 215,
              "entity_en": "1700 mg/day"
            },
            {
              "entity_id": "T358",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 215,
              "end_idx": 219,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T359",
              "entity": "1700mg",
              "entity_type": "Amount",
              "start_idx": 231,
              "end_idx": 237,
              "entity_en": "1700mg"
            },
            {
              "entity_id": "T360",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 237,
              "end_idx": 241,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T361",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 243,
              "end_idx": 247,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T362",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 261,
              "end_idx": 266,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T363",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 261,
              "end_idx": 263,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T364",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 280,
              "end_idx": 284,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T365",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 280,
              "end_idx": 282,
              "entity_en": "T2"
            },
            {
              "entity_id": "T366",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 288,
              "end_idx": 292,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T367",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 309,
              "end_idx": 317,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T368",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 330,
              "end_idx": 338,
              "entity_en": "DPP-4 inhibitors"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R151",
              "head_entity_id": "T341",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R152",
              "head_entity_id": "T342",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R153",
              "head_entity_id": "T344",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R154",
              "head_entity_id": "T345",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T347",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R156",
              "head_entity_id": "T348",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R157",
              "head_entity_id": "T349",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R158",
              "head_entity_id": "T350",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R159",
              "head_entity_id": "T354",
              "tail_entity_id": "T353"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R160",
              "head_entity_id": "T356",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R161",
              "head_entity_id": "T358",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R162",
              "head_entity_id": "T360",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R163",
              "head_entity_id": "T361",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R164",
              "head_entity_id": "T357",
              "tail_entity_id": "T358"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R165",
              "head_entity_id": "T359",
              "tail_entity_id": "T360"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R166",
              "head_entity_id": "T363",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R167",
              "head_entity_id": "T365",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R168",
              "head_entity_id": "T366",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R169",
              "head_entity_id": "T368",
              "tail_entity_id": "T364"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R170",
              "head_entity_id": "T367",
              "tail_entity_id": "T366"
            }
          ],
          "sentence_en": "10. Efficacy of metformin combined with DPP-4 inhibitors: The combined treatment of metformin and DPP-4 inhibitors can target different pathophysiological defects of T2DM and exert a hypoglycemic effect with complementary mechanisms and synergistic synergy. A randomized, double-blind, controlled study showed that the addition of DPP-4 inhibitors to patients with T2DM who were poorly controlled by metformin alone could effectively improve blood sugar levels and was well tolerated (grade I). A multicenter, prospective, randomized, controlled study in China showed that the efficacy and safety of 1000 mg of metformin combined with vildagliptin were equivalent to those of 2000 mg of metformin alone; in newly diagnosed T2DM patients, the hypoglycemic efficacy of 1700 mg/d metformin monotherapy was non-inferior to that of 1700 mg of metformin combined with sitagliptin (grade I). It is recommended to follow the treatment principles of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\". Metformin is the first choice for newly diagnosed T2DM patients, and the dose can be increased to the optimal effective dose (2000 mg/d) if tolerated. For patients who do not meet the standards, DPP-4 inhibitors can be used in combination."
        }
      ],
      "paragraph_en": "10. Efficacy of metformin combined with DPP-4 inhibitors: The combined treatment of metformin and DPP-4 inhibitors can target different pathophysiological defects of T2DM and exert a hypoglycemic effect with complementary mechanisms and synergistic synergy. A randomized, double-blind, controlled study showed that the addition of DPP-4 inhibitors to patients with T2DM who were poorly controlled by metformin alone could effectively improve blood sugar levels and was well tolerated (grade I). A multicenter, prospective, randomized, controlled study in China showed that the efficacy and safety of 1000 mg of metformin combined with vildagliptin were equivalent to those of 2000 mg of metformin alone; in newly diagnosed T2DM patients, the hypoglycemic efficacy of 1700 mg/d metformin monotherapy was non-inferior to that of 1700 mg of metformin combined with sitagliptin (grade I). It is recommended to follow the treatment principles of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China\". Metformin is the first choice for newly diagnosed T2DM patients, and the dose can be increased to the optimal effective dose (2000 mg/d) if tolerated. For patients who do not meet the standards, DPP-4 inhibitors can be used in combination."
    },
    {
      "paragraph_id": "21",
      "paragraph": "11.二甲双胍联合GLP-1受体激动剂的疗效：目前，中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG和HbA1c，提高血糖达标率，改善胰岛β细胞功能，改善IR，降低体重和SBP，且不增加严重低血糖发生的风险(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍降糖疗效相当，前者使体重和血压降低，低血糖发生风险减少。患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "11.二甲双胍联合GLP-1受体激动剂的疗效：目前，中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG和HbA1c，提高血糖达标率，改善胰岛β细胞功能，改善IR，降低体重和SBP，且不增加严重低血糖发生的风险(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍降糖疗效相当，前者使体重和血压降低，低血糖发生风险减少。",
          "start_idx": 0,
          "end_idx": 222,
          "entities": [
            {
              "entity_id": "T369",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T370",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 19,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T371",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 43,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T372",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T373",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T374",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T375",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 79,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T376",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 86,
              "end_idx": 89,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T377",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 90,
              "end_idx": 95,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T378",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T379",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "IR"
            },
            {
              "entity_id": "T380",
              "entity": "SBP",
              "entity_type": "Test",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "SBP"
            },
            {
              "entity_id": "T381",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T382",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 150,
              "end_idx": 152,
              "entity_en": "T2"
            },
            {
              "entity_id": "T383",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 173,
              "end_idx": 177,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T384",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 179,
              "end_idx": 183,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T385",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 188,
              "entity_en": "Glimepiride"
            },
            {
              "entity_id": "T386",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T389",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 212,
              "end_idx": 215,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T390",
              "entity": "严重低血糖",
              "entity_type": "ADE",
              "start_idx": 132,
              "end_idx": 137,
              "entity_en": "Severe hypoglycemia"
            },
            {
              "entity_id": "T391",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 207,
              "end_idx": 209,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T392",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 209,
              "end_idx": 211,
              "entity_en": "reduce"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R171",
              "head_entity_id": "T390",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R172",
              "head_entity_id": "T390",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R173",
              "head_entity_id": "T382",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R174",
              "head_entity_id": "T383",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R175",
              "head_entity_id": "T384",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R176",
              "head_entity_id": "T385",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R177",
              "head_entity_id": "T386",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R178",
              "head_entity_id": "T391",
              "tail_entity_id": "T381"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R179",
              "head_entity_id": "T389",
              "tail_entity_id": "T383"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R180",
              "head_entity_id": "T389",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R181",
              "head_entity_id": "T389",
              "tail_entity_id": "T385"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R182",
              "head_entity_id": "T389",
              "tail_entity_id": "T386"
            }
          ],
          "sentence_en": "11. Efficacy of metformin combined with GLP-1 receptor agonists: At present, the GLP-1 receptor agonists used clinically in China mainly include liraglutide and exenatide. Adding GLP-1 receptor agonists to metformin treatment can further reduce FPG and HbA1c, improve blood sugar compliance rate, improve pancreatic β-cell function, improve IR, reduce body weight and SBP, and do not increase the risk of severe hypoglycemia (grade I). Randomized, controlled studies conducted in the T2DM population in my country showed that the glucose-lowering efficacy of liraglutide combined with metformin is equivalent to that of glimepiride combined with metformin. The former reduces body weight and blood pressure and reduces the risk of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。",
          "start_idx": 222,
          "end_idx": 252,
          "entities": [
            {
              "entity_id": "T387",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T388",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Patients had worse tolerance to the adverse reactions caused by liraglutide combined with metformin treatment."
        }
      ],
      "paragraph_en": "11. Efficacy of metformin combined with GLP-1 receptor agonists: At present, the GLP-1 receptor agonists used clinically in China mainly include liraglutide and exenatide. The addition of GLP-1 receptor agonists on the basis of metformin treatment can further reduce FPG and HbA1c, improve the blood sugar compliance rate, improve pancreatic β-cell function, improve IR, reduce body weight and SBP, and does not increase the risk of severe hypoglycemia (level I). Randomized, controlled studies conducted in the T2DM population in my country showed that the hypoglycemic efficacy of liraglutide combined with metformin was equivalent to that of glimepiride combined with metformin. The former reduced body weight and blood pressure and reduced the risk of hypoglycemia. Patients have worse tolerance to the adverse reactions caused by liraglutide combined with metformin treatment."
    },
    {
      "paragraph_id": "22",
      "paragraph": "12.二甲双胍联合胰岛素的疗效：二甲双胍可以增强肝脏和肌肉组织的IS，口服降糖药联合治疗血糖控制不佳的T2DM患者启动胰岛素治疗后应保留二甲双胍。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险，联合使用还可能与心血管疾病和肿瘤风险下降相关(I级)。HOME研究是一项前瞻性、随机、双盲、安慰剂对照研究，该研究对接受胰岛素治疗的T2DM患者随访4.3年。结果显示，较单纯胰岛素治疗，二甲双胍联合胰岛素治疗能提高降糖疗效，降低胰岛素用量(胰岛素日剂量平均减少19.63U)，且体重增加更少。对该研究的次级终点的分析显示，二甲双胍的治疗与大血管事件相对风险降低40%相关(I级)。一项随机、对照研究纳入96例磺脲类继发性失效的T2DM患者，治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组均有所增加；且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大、每日胰岛素用量最少、低血糖的发生率最低。一项回顾性队列研究采用倾向匹配法分组分析发现，与胰岛素单药治疗组相比，二甲双胍联合胰素治疗组的死亡率降低。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "12.二甲双胍联合胰岛素的疗效：二甲双胍可以增强肝脏和肌肉组织的IS，口服降糖药联合治疗血糖控制不佳的T2DM患者启动胰岛素治疗后应保留二甲双胍。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量、体重增加和低血糖风险，联合使用还可能与心血管疾病和肿瘤风险下降相关(I级)。HOME研究是一项前瞻性、随机、双盲、安慰剂对照研究，该研究对接受胰岛素治疗的T2DM患者随访4.3年。结果显示，较单纯胰岛素治疗，二甲双胍联合胰岛素治疗能提高降糖疗效，降低胰岛素用量(胰岛素日剂量平均减少19.63U)，且体重增加更少。对该研究的次级终点的分析显示，二甲双胍的治疗与大血管事件相对风险降低40%相关(I级)。一项随机、对照研究纳入96例磺脲类继发性失效的T2DM患者，治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组均有所增加；且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大、每日胰岛素用量最少、低血糖的发生率最低。",
          "start_idx": 0,
          "end_idx": 428,
          "entities": [
            {
              "entity_id": "T393",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T394",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T395",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T396",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T397",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T398",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "T2"
            },
            {
              "entity_id": "T399",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 62,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T400",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T401",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 35,
              "end_idx": 37,
              "entity_en": "oral"
            },
            {
              "entity_id": "T402",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T403",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T404",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 93,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T405",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T406",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 110,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T407",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 113,
              "end_idx": 117,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T408",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 118,
              "end_idx": 121,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T409",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 132,
              "end_idx": 137,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T410",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 132,
              "end_idx": 135,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T411",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 194,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T412",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 190,
              "end_idx": 192,
              "entity_en": "T2"
            },
            {
              "entity_id": "T413",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 187,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T414",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 214,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T415",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T416",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 226,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T417",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 238,
              "end_idx": 241,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T418",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 244,
              "end_idx": 247,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T419",
              "entity": "19.63U",
              "entity_type": "Amount",
              "start_idx": 254,
              "end_idx": 260,
              "entity_en": "19.63U"
            },
            {
              "entity_id": "T420",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 263,
              "end_idx": 267,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T421",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 285,
              "end_idx": 289,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T422",
              "entity": "大血管事件",
              "entity_type": "Disease",
              "start_idx": 293,
              "end_idx": 298,
              "entity_en": "Macrovascular events"
            },
            {
              "entity_id": "T423",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 293,
              "end_idx": 296,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T424",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 328,
              "end_idx": 331,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T425",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 337,
              "end_idx": 341,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T426",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 337,
              "end_idx": 339,
              "entity_en": "T2"
            },
            {
              "entity_id": "T427",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 352,
              "end_idx": 355,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T428",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 356,
              "end_idx": 360,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T429",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 389,
              "end_idx": 392,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T430",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 393,
              "end_idx": 397,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T431",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 398,
              "end_idx": 403,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T432",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 410,
              "end_idx": 413,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T433",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 418,
              "end_idx": 421,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T437",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T438",
              "entity": "4.3年",
              "entity_type": "Duration",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "4.3 years"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R183",
              "head_entity_id": "T396",
              "tail_entity_id": "T397"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R184",
              "head_entity_id": "T398",
              "tail_entity_id": "T397"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R185",
              "head_entity_id": "T399",
              "tail_entity_id": "T397"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R186",
              "head_entity_id": "T400",
              "tail_entity_id": "T397"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R187",
              "head_entity_id": "T407",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R188",
              "head_entity_id": "T408",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R189",
              "head_entity_id": "T407",
              "tail_entity_id": "T404"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R190",
              "head_entity_id": "T408",
              "tail_entity_id": "T404"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R191",
              "head_entity_id": "T407",
              "tail_entity_id": "T406"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R192",
              "head_entity_id": "T408",
              "tail_entity_id": "T406"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R193",
              "head_entity_id": "T410",
              "tail_entity_id": "T409"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R194",
              "head_entity_id": "T412",
              "tail_entity_id": "T411"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R195",
              "head_entity_id": "T413",
              "tail_entity_id": "T411"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R196",
              "head_entity_id": "T438",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R197",
              "head_entity_id": "T420",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R198",
              "head_entity_id": "T420",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R199",
              "head_entity_id": "T420",
              "tail_entity_id": "T416"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R200",
              "head_entity_id": "T419",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R201",
              "head_entity_id": "T423",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R202",
              "head_entity_id": "T426",
              "tail_entity_id": "T425"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R203",
              "head_entity_id": "T427",
              "tail_entity_id": "T425"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R204",
              "head_entity_id": "T428",
              "tail_entity_id": "T425"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R205",
              "head_entity_id": "T431",
              "tail_entity_id": "T425"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R206",
              "head_entity_id": "T433",
              "tail_entity_id": "T429"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R207",
              "head_entity_id": "T433",
              "tail_entity_id": "T430"
            }
          ],
          "sentence_en": "12. Efficacy of metformin combined with insulin: Metformin can enhance the IS of liver and muscle tissue. Patients with T2DM who have poor blood sugar control and are treated with oral hypoglycemic drugs should retain metformin after starting insulin treatment. Compared with insulin monotherapy, metformin combined with insulin can further reduce HbA1c, reduce insulin dosage, weight gain and the risk of hypoglycemia. Combined use may also be associated with a reduced risk of cardiovascular disease and tumors (level I). The HOME study is a prospective, randomized, double-blind, placebo-controlled study that followed up T2DM patients receiving insulin for 4.3 years. The results showed that compared with insulin therapy alone, metformin combined with insulin therapy can improve the glucose-lowering effect, reduce insulin dosage (average insulin daily dose reduced by 19.63U), and have less weight gain. Analysis of the secondary endpoints of the study showed that metformin treatment was associated with a 40% reduction in the relative risk of macrovascular events (level I). A randomized, controlled study included 96 patients with T2DM and secondary failure of sulfonylureas. After one year of treatment, there was no significant change in body weight in the bedtime insulin + metformin group, while that in the other groups increased. Compared with the other groups, the bedtime insulin + metformin group had the largest reduction in HbA1c, the least daily insulin dosage, and the lowest incidence of hypoglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "一项回顾性队列研究采用倾向匹配法分组分析发现，与胰岛素单药治疗组相比，二甲双胍联合胰素治疗组的死亡率降低。",
          "start_idx": 428,
          "end_idx": 481,
          "entities": [
            {
              "entity_id": "T434",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T435",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T436",
              "entity": "胰素",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "Insulin"
            }
          ],
          "relations": [],
          "sentence_en": "A retrospective cohort study using propensity matching group analysis found that the mortality rate was reduced in the metformin combined with insulin treatment group compared with the insulin monotherapy group."
        }
      ],
      "paragraph_en": "12. Efficacy of metformin combined with insulin: Metformin can enhance the IS of liver and muscle tissue. Patients with T2DM who have poor blood sugar control and are treated with oral hypoglycemic drugs should retain metformin after starting insulin treatment. Compared with insulin monotherapy, metformin combined with insulin can further reduce HbA1c, reduce insulin dosage, weight gain and the risk of hypoglycemia. Combined use may also be associated with a reduced risk of cardiovascular disease and tumors (level I). The HOME study is a prospective, randomized, double-blind, placebo-controlled study that followed up T2DM patients receiving insulin for 4.3 years. The results showed that compared with insulin therapy alone, metformin combined with insulin therapy can improve the glucose-lowering effect, reduce insulin dosage (average insulin daily dose reduced by 19.63U), and have less weight gain. Analysis of the secondary endpoints of the study showed that metformin treatment was associated with a 40% reduction in the relative risk of macrovascular events (level I). A randomized, controlled study included 96 T2DM patients with secondary failure of sulfonylureas. After one year of treatment, the body weight of the bedtime insulin + metformin group did not change significantly, while that of the other groups increased. Compared with the other groups, the bedtime insulin + metformin group had the largest decrease in HbA1c, the lowest daily insulin dosage, and the lowest incidence of hypoglycemia. A retrospective cohort study used a propensity matching method to group and found that the mortality rate of the metformin combined with insulin treatment group was lower than that of the insulin monotherapy group."
    },
    {
      "paragraph_id": "23",
      "paragraph": "13.新诊断T2DM患者胰岛素短期强化治疗的后续治疗：对于有明显高血糖临床症状的新诊断T2DM患者可实施短期胰岛素治疗。在高血糖得到控制和症状缓解后可根据病情调整治疗方案，如改用口服降糖药物或医学营养和运动治疗。一项中国的研究将经短期胰岛素强化治疗后的T2DM患者随机分为甘精胰岛素治疗组和以二甲双胍为基础的口服降糖药治疗组，治疗24周的结果显示，两组降糖疗效相当，且以二甲双胍为基础的口服降糖药治疗方案简单易行、依从性好，较好地控制体重，成本-效益比更佳。因此，建议接受胰岛素短期治疗的新诊断T2DM患者可在高血糖症状得到改善后可考虑改成以二甲双胍为起始的口服降糖药物治疗方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "13.新诊断T2DM患者胰岛素短期强化治疗的后续治疗：对于有明显高血糖临床症状的新诊断T2DM患者可实施短期胰岛素治疗。在高血糖得到控制和症状缓解后可根据病情调整治疗方案，如改用口服降糖药物或医学营养和运动治疗。一项中国的研究将经短期胰岛素强化治疗后的T2DM患者随机分为甘精胰岛素治疗组和以二甲双胍为基础的口服降糖药治疗组，治疗24周的结果显示，两组降糖疗效相当，且以二甲双胍为基础的口服降糖药治疗方案简单易行、依从性好，较好地控制体重，成本-效益比更佳。因此，建议接受胰岛素短期治疗的新诊断T2DM患者可在高血糖症状得到改善后可考虑改成以二甲双胍为起始的口服降糖药物治疗方案。",
          "start_idx": 0,
          "end_idx": 290,
          "entities": [
            {
              "entity_id": "T439",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T440",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "T2"
            },
            {
              "entity_id": "T441",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T442",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T443",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T444",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "T2"
            },
            {
              "entity_id": "T445",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T446",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T447",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "oral"
            },
            {
              "entity_id": "T448",
              "entity": "医学营养",
              "entity_type": "Treatment",
              "start_idx": 96,
              "end_idx": 100,
              "entity_en": "Medical Nutrition"
            },
            {
              "entity_id": "T449",
              "entity": "运动治疗",
              "entity_type": "Treatment",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Exercise therapy"
            },
            {
              "entity_id": "T450",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T451",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 126,
              "end_idx": 130,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T452",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 126,
              "end_idx": 128,
              "entity_en": "T2"
            },
            {
              "entity_id": "T453",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 136,
              "end_idx": 141,
              "entity_en": "Insulin glargine"
            },
            {
              "entity_id": "T454",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T455",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 154,
              "end_idx": 156,
              "entity_en": "oral"
            },
            {
              "entity_id": "T456",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 185,
              "end_idx": 189,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T457",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 193,
              "end_idx": 195,
              "entity_en": "oral"
            },
            {
              "entity_id": "T458",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 236,
              "end_idx": 239,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T459",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 247,
              "end_idx": 251,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T460",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 247,
              "end_idx": 249,
              "entity_en": "T2"
            },
            {
              "entity_id": "T461",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 255,
              "end_idx": 258,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T462",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 275,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T463",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 279,
              "end_idx": 281,
              "entity_en": "oral"
            },
            {
              "entity_id": "T464",
              "entity": "明显",
              "entity_type": "Level",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "obvious"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R208",
              "head_entity_id": "T440",
              "tail_entity_id": "T439"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R209",
              "head_entity_id": "T441",
              "tail_entity_id": "T439"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R210",
              "head_entity_id": "T444",
              "tail_entity_id": "T443"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R211",
              "head_entity_id": "T445",
              "tail_entity_id": "T443"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R212",
              "head_entity_id": "T450",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R213",
              "head_entity_id": "T452",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R214",
              "head_entity_id": "T453",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R215",
              "head_entity_id": "T454",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R216",
              "head_entity_id": "T455",
              "tail_entity_id": "T454"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R217",
              "head_entity_id": "T457",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R218",
              "head_entity_id": "T458",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R219",
              "head_entity_id": "T460",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R220",
              "head_entity_id": "T462",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R221",
              "head_entity_id": "T463",
              "tail_entity_id": "T462"
            }
          ],
          "sentence_en": "13. Subsequent treatment of newly diagnosed T2DM patients with short-term intensive insulin therapy: Short-term insulin therapy can be implemented for newly diagnosed T2DM patients with obvious clinical symptoms of hyperglycemia. After hyperglycemia is controlled and symptoms are relieved, the treatment plan can be adjusted according to the condition, such as switching to oral hypoglycemic drugs or medical nutrition and exercise therapy. A Chinese study randomly divided T2DM patients who had undergone short-term intensive insulin treatment into a glargine insulin treatment group and a metformin-based oral hypoglycemic drug treatment group. The results of 24 weeks of treatment showed that the two groups had equivalent hypoglycemic efficacy, and the metformin-based oral hypoglycemic drug treatment plan was simple and easy to implement, with good compliance, better weight control, and better cost-effectiveness. Therefore, it is recommended that newly diagnosed T2DM patients who receive short-term insulin treatment can consider switching to an oral hypoglycemic drug treatment plan starting with metformin after their hyperglycemia symptoms improve."
        }
      ],
      "paragraph_en": "13. Subsequent treatment of newly diagnosed T2DM patients with short-term intensive insulin therapy: Short-term insulin therapy can be implemented for newly diagnosed T2DM patients with obvious clinical symptoms of hyperglycemia. After hyperglycemia is controlled and symptoms are relieved, the treatment plan can be adjusted according to the condition, such as switching to oral hypoglycemic drugs or medical nutrition and exercise therapy. A Chinese study randomly divided T2DM patients who had undergone short-term intensive insulin treatment into a glargine insulin treatment group and a metformin-based oral hypoglycemic drug treatment group. The results of 24 weeks of treatment showed that the two groups had equivalent hypoglycemic efficacy, and the metformin-based oral hypoglycemic drug treatment plan was simple and easy to implement, with good compliance, better weight control, and better cost-effectiveness. Therefore, it is recommended that newly diagnosed T2DM patients who receive short-term insulin treatment can consider switching to an oral hypoglycemic drug treatment plan starting with metformin after their hyperglycemia symptoms improve."
    },
    {
      "paragraph_id": "24",
      "paragraph": "14.二甲双胍是否应尽早足量使用以维持更长的达标时间：500~2000mg/d剂量，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本-效益比。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下(Ⅰ级)。在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周(I级)。因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可使血糖控制尽早达标，且可使血糖得到更长时间的良好控制。如果出现可以耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换为其他降糖药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "14.二甲双胍是否应尽早足量使用以维持更长的达标时间：500~2000mg/d剂量，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本-效益比。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下(Ⅰ级)。",
          "start_idx": 0,
          "end_idx": 155,
          "entities": [
            {
              "entity_id": "T465",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T466",
              "entity": "500~2000mg/d",
              "entity_type": "Amount",
              "start_idx": 27,
              "end_idx": 39,
              "entity_en": "500–2000 mg/day"
            },
            {
              "entity_id": "T467",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T468",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T469",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 102,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T470",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 98,
              "end_idx": 100,
              "entity_en": "T2"
            },
            {
              "entity_id": "T471",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T472",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 111,
              "end_idx": 119,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T473",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 136,
              "end_idx": 141,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T480",
              "entity": "维持在7%以下",
              "entity_type": "Test_Value",
              "start_idx": 143,
              "end_idx": 150,
              "entity_en": "Maintain below 7%"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R222",
              "head_entity_id": "T466",
              "tail_entity_id": "T467"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R223",
              "head_entity_id": "T470",
              "tail_entity_id": "T469"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R224",
              "head_entity_id": "T471",
              "tail_entity_id": "T469"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R225",
              "head_entity_id": "T473",
              "tail_entity_id": "T469"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R226",
              "head_entity_id": "T472",
              "tail_entity_id": "T471"
            }
          ],
          "sentence_en": "14. Should metformin be used as early as possible and in sufficient doses to maintain the target for a longer time? The efficacy of metformin is dose-dependent at a dose of 500-2000 mg/d, and compared with other hypoglycemic drugs, metformin has a better cost-effectiveness ratio. The ADOPT study showed that in newly diagnosed T2DM patients, monotherapy with metformin (2000 mg/d) can maintain the average HbA1c level of the subjects below 7% (level I) within 4 years."
        },
        {
          "sentence_id": "1",
          "sentence": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周(I级)。",
          "start_idx": 155,
          "end_idx": 247,
          "entities": [
            {
              "entity_id": "T474",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T475",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 24,
              "end_idx": 31,
              "entity_en": "100 mg/day"
            },
            {
              "entity_id": "T476",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T477",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 44,
              "end_idx": 52,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T478",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T479",
              "entity": "维持在7%以下",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 77,
              "entity_en": "Maintain below 7%"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R227",
              "head_entity_id": "T475",
              "tail_entity_id": "T474"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R228",
              "head_entity_id": "T477",
              "tail_entity_id": "T476"
            }
          ],
          "sentence_en": "In a 104-week controlled clinical study, metformin (2000 mg/d) monotherapy increased the time that the subjects' average HbA1c levels were maintained below 7% by approximately 24 weeks (Grade I) compared with sitagliptin (100 mg/d) monotherapy."
        },
        {
          "sentence_id": "2",
          "sentence": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可使血糖控制尽早达标，且可使血糖得到更长时间的良好控制。",
          "start_idx": 247,
          "end_idx": 317,
          "entities": [
            {
              "entity_id": "T481",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 24,
              "end_idx": 32,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T482",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T483",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T484",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R229",
              "head_entity_id": "T481",
              "tail_entity_id": "T482"
            }
          ],
          "sentence_en": "Therefore, if the patient can tolerate it, the use of the optimal dose of metformin (2000 mg/d) as a single drug can not only achieve blood sugar control as soon as possible, but also keep blood sugar under good control for a longer period of time."
        },
        {
          "sentence_id": "3",
          "sentence": "如果出现可以耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换为其他降糖药。",
          "start_idx": 317,
          "end_idx": 358,
          "entities": [],
          "relations": [],
          "sentence_en": "If tolerable adverse reactions occur, the dosage can be reduced appropriately; if they are not tolerated, it is recommended to switch to other hypoglycemic drugs as soon as possible."
        }
      ],
      "paragraph_en": "14. Should metformin be used as early as possible and in sufficient doses to maintain the target for a longer time? At a dose of 500-2000 mg/d, the efficacy of metformin is dose-dependent, and compared with other hypoglycemic drugs, metformin has a better cost-effectiveness ratio. The ADOPT study showed that in newly diagnosed T2DM patients, metformin (2000 mg/d) monotherapy can maintain the average HbA1c level of the subjects below 7% within 4 years (level I). In a 104-week controlled clinical study, compared with sitagliptin (100 mg/d) monotherapy, metformin (2000 mg/d) monotherapy increased the time that the average HbA1c level of the subjects was maintained below 7% by about 24 weeks (level I). Therefore, if the patient can tolerate it, the use of the optimal dose of metformin (2000 mg/d) can not only achieve the target blood sugar control as early as possible, but also keep blood sugar under good control for a longer period of time. If tolerable adverse reactions occur, the dosage can be reduced appropriately; if they are not tolerated, it is recommended to switch to other hypoglycemic drugs as soon as possible."
    },
    {
      "paragraph_id": "25",
      "paragraph": "15.二甲双胍可否用于胰岛素治疗的T1DM患者：T1DM患者可在胰岛素治疗基础上加用二甲双胍，尤其适用于胰岛素剂量较大、体重增加明显的患者；但DKA、糖尿病高血糖高渗综合征(HHS)、糖尿病乳酸酸中毒患者禁用。临床研究发现，二甲双胍不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C水平。对于单用胰岛素治疗血糖控制不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。荟萃分析结果显示，二甲双胍能降低T1DM患者的日常胰岛素剂量、体重及血脂水平，且不增加低血糖及DKA的发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "15.二甲双胍可否用于胰岛素治疗的T1DM患者：T1DM患者可在胰岛素治疗基础上加用二甲双胍，尤其适用于胰岛素剂量较大、体重增加明显的患者；但DKA、糖尿病高血糖高渗综合征(HHS)、糖尿病乳酸酸中毒患者禁用。临床研究发现，二甲双胍不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C水平。对于单用胰岛素治疗血糖控制不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。荟萃分析结果显示，二甲双胍能降低T1DM患者的日常胰岛素剂量、体重及血脂水平，且不增加低血糖及DKA的发生风险。",
          "start_idx": 0,
          "end_idx": 273,
          "entities": [
            {
              "entity_id": "T485",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T486",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T487",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "T1DM"
            },
            {
              "entity_id": "T488",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "T1"
            },
            {
              "entity_id": "T489",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "T1DM"
            },
            {
              "entity_id": "T490",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "T1"
            },
            {
              "entity_id": "T491",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T492",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T493",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T494",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 74,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T495",
              "entity": "糖尿病乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 100,
              "entity_en": "Diabetic lactic acidosis"
            },
            {
              "entity_id": "T496",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T497",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T498",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T499",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 151,
              "end_idx": 156,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T500",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T501",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 168,
              "end_idx": 170,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T502",
              "entity": "血脂水平",
              "entity_type": "Test",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Lipid levels"
            },
            {
              "entity_id": "T503",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 186,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T504",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 193,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T505",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 206,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T506",
              "entity": "体重过度增加",
              "entity_type": "ADE",
              "start_idx": 210,
              "end_idx": 216,
              "entity_en": "Excessive weight gain"
            },
            {
              "entity_id": "T507",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T508",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 237,
              "entity_en": "T1DM"
            },
            {
              "entity_id": "T509",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 233,
              "end_idx": 235,
              "entity_en": "T1"
            },
            {
              "entity_id": "T510",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 245,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T511",
              "entity": "血脂水平",
              "entity_type": "Test",
              "start_idx": 251,
              "end_idx": 255,
              "entity_en": "Lipid levels"
            },
            {
              "entity_id": "T512",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 260,
              "end_idx": 263,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T513",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 264,
              "end_idx": 267,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T514",
              "entity": "体重增加明显",
              "entity_type": "ADE",
              "start_idx": 60,
              "end_idx": 66,
              "entity_en": "Significant weight gain"
            },
            {
              "entity_id": "T515",
              "entity": "糖尿病高血糖高渗综合征(HHS)",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 91,
              "entity_en": "Hyperosmolar Hyperglycemic Syndrome (HHS)"
            },
            {
              "entity_id": "T516",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 170,
              "end_idx": 174,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R230",
              "head_entity_id": "T486",
              "tail_entity_id": "T487"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R231",
              "head_entity_id": "T488",
              "tail_entity_id": "T487"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R232",
              "head_entity_id": "T490",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R233",
              "head_entity_id": "T491",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R234",
              "head_entity_id": "T492",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R235",
              "head_entity_id": "T514",
              "tail_entity_id": "T493"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R236",
              "head_entity_id": "T506",
              "tail_entity_id": "T505"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R237",
              "head_entity_id": "T507",
              "tail_entity_id": "T508"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R238",
              "head_entity_id": "T509",
              "tail_entity_id": "T508"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R239",
              "head_entity_id": "T510",
              "tail_entity_id": "T508"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R240",
              "head_entity_id": "T511",
              "tail_entity_id": "T508"
            }
          ],
          "sentence_en": "15. Can metformin be used in patients with T1DM treated with insulin? T1DM patients can use metformin in addition to insulin treatment, especially for patients with large insulin doses and significant weight gain; however, it is contraindicated for patients with DKA, diabetic hyperglycemic hyperosmolar syndrome (HHS), and diabetic lactic acidosis. Clinical studies have found that metformin can not only reduce insulin dosage, but also further reduce blood lipid levels (regardless of lowering blood sugar), especially LDL-C levels. For patients with poor blood sugar control with insulin alone, if combined with metformin, the insulin dosage can be reduced by 10%, reducing the excessive weight gain caused by the use of insulin. The results of the meta-analysis showed that metformin can reduce the daily insulin dose, body weight and blood lipid levels of patients with T1DM without increasing the risk of hypoglycemia and DKA."
        }
      ],
      "paragraph_en": "15. Can metformin be used in patients with T1DM treated with insulin? T1DM patients can use metformin in addition to insulin treatment, especially for patients with large insulin doses and significant weight gain; however, it is contraindicated for patients with DKA, diabetic hyperglycemic hyperosmolar syndrome (HHS), and diabetic lactic acidosis. Clinical studies have found that metformin can not only reduce insulin dosage, but also further reduce blood lipid levels (regardless of lowering blood sugar), especially LDL-C levels. For patients with poor blood sugar control with insulin alone, if combined with metformin, the insulin dosage can be reduced by 10%, reducing the excessive weight gain caused by the use of insulin. The results of the meta-analysis showed that metformin can reduce the daily insulin dose, weight and blood lipid levels of patients with T1DM without increasing the risk of hypoglycemia and DKA."
    },
    {
      "paragraph_id": "26",
      "paragraph": "16.二甲双胍的减重效果：二甲双胍具有减轻体重的作用，其减轻体重的机制可能包括抑制食欲，减少热量摄入；改善高胰岛素血症，降低基础胰岛和负荷后胰岛素水平；增加瘦素敏感性。一项前瞻性、开放标签研究表明，新诊断T2DM患者经二甲双胍单药治疗16周，正常(BMI 18.5~23.9kg/m2)、超重(BMI 24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81、2.92kg，患者不同基线BMI水平不会造成二甲双胍单药对血糖控制的差异(Ⅰ级)。在中国T2DM人群中开展的另外一项研究结果提示，接受二甲双胍(最大剂量1500mg/d)治疗48周后，体重降低1.88kg(可能包含部分安慰剂效应)。磺脲类、格列酮类和胰岛素治疗伴有体重增加，联用二甲双胍可减轻上述药物对体重增加的影响；HOME研究显示，与单用胰岛素组相比，二甲双胍联合胰岛素治疗组体重少增加2.28~3.85kg(I级)。由于不同研究的入组人群及试验方法存在一定的差异，其结果可能有所不同。荟萃分析显示，体重降幅最大的常用口服降糖药为二甲双胍，可使体重降低1.1kg。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "16.二甲双胍的减重效果：二甲双胍具有减轻体重的作用，其减轻体重的机制可能包括抑制食欲，减少热量摄入；改善高胰岛素血症，降低基础胰岛和负荷后胰岛素水平；增加瘦素敏感性。一项前瞻性、开放标签研究表明，新诊断T2DM患者经二甲双胍单药治疗16周，正常(BMI 18.5~23.9kg/m2)、超重(BMI 24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81、2.92kg，患者不同基线BMI水平不会造成二甲双胍单药对血糖控制的差异(Ⅰ级)。在中国T2DM人群中开展的另外一项研究结果提示，接受二甲双胍(最大剂量1500mg/d)治疗48周后，体重降低1.88kg(可能包含部分安慰剂效应)。磺脲类、格列酮类和胰岛素治疗伴有体重增加，联用二甲双胍可减轻上述药物对体重增加的影响；HOME研究显示，与单用胰岛素组相比，二甲双胍联合胰岛素治疗组体重少增加2.28~3.85kg(I级)。由于不同研究的入组人群及试验方法存在一定的差异，其结果可能有所不同。荟萃分析显示，体重降幅最大的常用口服降糖药为二甲双胍，可使体重降低1.1kg。",
          "start_idx": 0,
          "end_idx": 500,
          "entities": [
            {
              "entity_id": "T517",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T518",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T519",
              "entity": "高胰岛素血症",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 59,
              "entity_en": "Hyperinsulinemia"
            },
            {
              "entity_id": "T520",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T521",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 102,
              "end_idx": 104,
              "entity_en": "T2"
            },
            {
              "entity_id": "T522",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T523",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 144,
              "end_idx": 146,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T524",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 167,
              "end_idx": 169,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T525",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 238,
              "end_idx": 242,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T526",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 245,
              "end_idx": 247,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T527",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 260,
              "end_idx": 264,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T528",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "T2"
            },
            {
              "entity_id": "T529",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 283,
              "end_idx": 287,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T530",
              "entity": "1500mg/d",
              "entity_type": "Amount",
              "start_idx": 292,
              "end_idx": 300,
              "entity_en": "1500 mg/day"
            },
            {
              "entity_id": "T531",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 332,
              "end_idx": 335,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T532",
              "entity": "格列酮类",
              "entity_type": "Drug",
              "start_idx": 336,
              "end_idx": 340,
              "entity_en": "Glitazones"
            },
            {
              "entity_id": "T533",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 341,
              "end_idx": 344,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T534",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 355,
              "end_idx": 359,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T535",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 367,
              "end_idx": 371,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T536",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 387,
              "end_idx": 390,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T537",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 394,
              "end_idx": 398,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T538",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 400,
              "end_idx": 403,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T539",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 477,
              "end_idx": 479,
              "entity_en": "oral"
            },
            {
              "entity_id": "T540",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 483,
              "end_idx": 487,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T541",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 348,
              "end_idx": 352,
              "entity_en": "Weight gain"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R241",
              "head_entity_id": "T518",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R242",
              "head_entity_id": "T521",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R243",
              "head_entity_id": "T522",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R244",
              "head_entity_id": "T528",
              "tail_entity_id": "T527"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R245",
              "head_entity_id": "T529",
              "tail_entity_id": "T527"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R246",
              "head_entity_id": "T530",
              "tail_entity_id": "T529"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R247",
              "head_entity_id": "T541",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R248",
              "head_entity_id": "T541",
              "tail_entity_id": "T532"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R249",
              "head_entity_id": "T541",
              "tail_entity_id": "T533"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R250",
              "head_entity_id": "T539",
              "tail_entity_id": "T540"
            }
          ],
          "sentence_en": "16. Weight loss effect of metformin: Metformin has the effect of reducing weight. Its weight loss mechanism may include suppressing appetite, reducing calorie intake; improving hyperinsulinemia, reducing basal insulin levels and post-load insulin levels; and increasing leptin sensitivity. A prospective, open-label study showed that after 16 weeks of metformin monotherapy in newly diagnosed T2DM patients, the weight of normal (BMI 18.5~23.9kg/m2), overweight (BMI 24.0~27.9kg/m2), and obese (BMI≥28.0kg/m2) patients decreased by 1.47, 2.81, and 2.92kg, respectively (possibly including some placebo effects). Different baseline BMI levels of patients did not cause differences in glycemic control by metformin monotherapy (level I). Another study conducted in the Chinese T2DM population showed that after 48 weeks of treatment with metformin (maximum dose 1500mg/d), the weight was reduced by 1.88kg (possibly including some placebo effects). Sulfonylureas, glitazones, and insulin therapy are associated with weight gain, and the combined use of metformin can reduce the effect of the above drugs on weight gain; the HOME study showed that compared with the insulin alone group, the metformin combined with insulin treatment group gained 2.28~3.85kg less weight (level I). Due to certain differences in the populations and experimental methods of different studies, the results may be different. Meta-analysis shows that the commonly used oral hypoglycemic drug with the largest weight loss is metformin, which can reduce body weight by 1.1kg."
        }
      ],
      "paragraph_en": "16. Weight loss effect of metformin: Metformin has the effect of reducing weight. Its weight loss mechanism may include suppressing appetite, reducing calorie intake; improving hyperinsulinemia, reducing basal insulin levels and post-load insulin levels; and increasing leptin sensitivity. A prospective, open-label study showed that after 16 weeks of metformin monotherapy in newly diagnosed T2DM patients, the weight of normal (BMI 18.5~23.9kg/m2), overweight (BMI 24.0~27.9kg/m2), and obese (BMI≥28.0kg/m2) patients decreased by 1.47, 2.81, and 2.92kg, respectively (possibly including some placebo effects). Different baseline BMI levels of patients did not cause differences in glycemic control by metformin monotherapy (level I). Another study conducted in the Chinese T2DM population showed that after 48 weeks of treatment with metformin (maximum dose 1500mg/d), the weight was reduced by 1.88kg (possibly including some placebo effects). Sulfonylureas, glitazones, and insulin therapy are associated with weight gain, and the combined use of metformin can reduce the effect of the above drugs on weight gain; the HOME study showed that compared with the insulin alone group, the metformin combined with insulin treatment group gained 2.28~3.85kg less weight (level I). Due to certain differences in the populations and experimental methods of different studies, the results may be different. Meta-analysis shows that the commonly used oral hypoglycemic drug with the largest weight loss is metformin, which can reduce body weight by 1.1kg."
    },
    {
      "paragraph_id": "27",
      "paragraph": "四、特殊人群用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、特殊人群用药",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": [],
          "sentence_en": "IV. Use in Special Populations"
        }
      ],
      "paragraph_en": "IV. Use in Special Populations"
    },
    {
      "paragraph_id": "28",
      "paragraph": "1.心力衰竭是否是二甲双胍的绝对禁忌证：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证。但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。而且多项研究显示，二甲双胍的治疗可能与糖尿病患者心力衰竭和死亡发生风险的减少有关，可能与伴心力衰竭的糖尿病患者的存活率提高相关。2016年，ADA糖尿病指南指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者。欧洲版二甲双胍说明书中已删除慢性心力衰竭的禁忌证。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.心力衰竭是否是二甲双胍的绝对禁忌证：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证。但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。而且多项研究显示，二甲双胍的治疗可能与糖尿病患者心力衰竭和死亡发生风险的减少有关，可能与伴心力衰竭的糖尿病患者的存活率提高相关。",
          "start_idx": 0,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T542",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T543",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T544",
              "entity": "二甲双胍",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T545",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T546",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 31,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T547",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T548",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 74,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T549",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 70,
              "end_idx": 71,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T550",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 83,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T551",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 80,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T552",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T553",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 114,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T554",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 116,
              "end_idx": 120,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T555",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 116,
              "end_idx": 117,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T556",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 141,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T557",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 137,
              "end_idx": 138,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T558",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 145,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T565",
              "entity": "充血性心力衰竭(CHF)",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 39,
              "entity_en": "Congestive heart failure (CHF)"
            },
            {
              "entity_id": "T566",
              "entity": "充血性",
              "entity_type": "Class",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Congestive"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R251",
              "head_entity_id": "T545",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R252",
              "head_entity_id": "T546",
              "tail_entity_id": "T565"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R253",
              "head_entity_id": "T549",
              "tail_entity_id": "T548"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R254",
              "head_entity_id": "T551",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R255",
              "head_entity_id": "T552",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R256",
              "head_entity_id": "T555",
              "tail_entity_id": "T554"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R257",
              "head_entity_id": "T557",
              "tail_entity_id": "T556"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R261",
              "head_entity_id": "T566",
              "tail_entity_id": "T565"
            }
          ],
          "sentence_en": "1. Is heart failure an absolute contraindication to metformin: Congestive heart failure (CHF) that requires drug treatment is a contraindication to the use of metformin. However, retrospective studies have shown that metformin itself does not cause heart failure, nor does it have adverse effects on patients with heart failure. In addition, multiple studies have shown that metformin treatment may be associated with a reduced risk of heart failure and death in diabetic patients, and may be associated with an increased survival rate in diabetic patients with heart failure."
        },
        {
          "sentence_id": "1",
          "sentence": "2016年，ADA糖尿病指南指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者。",
          "start_idx": 156,
          "end_idx": 199,
          "entities": [
            {
              "entity_id": "T559",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T560",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T561",
              "entity": "CHF",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "CHF"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R258",
              "head_entity_id": "T560",
              "tail_entity_id": "T561"
            }
          ],
          "sentence_en": "In 2016, the ADA diabetes guidelines stated that metformin can be used in stable CHF patients if renal function is normal."
        },
        {
          "sentence_id": "2",
          "sentence": "欧洲版二甲双胍说明书中已删除慢性心力衰竭的禁忌证。",
          "start_idx": 199,
          "end_idx": 224,
          "entities": [
            {
              "entity_id": "T562",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T563",
              "entity": "慢性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 20,
              "entity_en": "Chronic heart failure"
            },
            {
              "entity_id": "T564",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 16,
              "end_idx": 17,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R259",
              "head_entity_id": "T562",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R260",
              "head_entity_id": "T564",
              "tail_entity_id": "T563"
            }
          ],
          "sentence_en": "The contraindication for chronic heart failure has been deleted from the European version of the metformin instructions."
        }
      ],
      "paragraph_en": "1. Is heart failure an absolute contraindication to metformin: Congestive heart failure (CHF) that requires drug treatment is a contraindication to the use of metformin. However, retrospective studies have shown that metformin itself does not cause heart failure, nor does it have adverse effects on patients with heart failure. In addition, multiple studies have shown that metformin treatment may be associated with a reduced risk of heart failure and death in diabetic patients, and may be associated with an increased survival rate in diabetic patients with heart failure. In 2016, the ADA diabetes guidelines stated that if renal function is normal, metformin can be used in stable CHF patients. The contraindication for chronic heart failure has been deleted from the European version of the metformin instructions."
    },
    {
      "paragraph_id": "29",
      "paragraph": "2.针对65岁以上老年患者如何使用二甲双胍：((2013年IDF老年糖尿病指南》和《中国老糖尿病诊疗措施专家共识》都推荐二甲双胍为一线首选用药，并没有限制二甲双胍的具体使用年龄。老年糖尿病患者合理应用二甲双胍可以达到良好的降糖效果，且较少的低血糖风险对老年患者也有一定益处，但需要定期监测肾功能(3~6个月检查1次)。80岁以上患者[eGFR<45ml/(min·1.73m2)除外]如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍然可取得良好效果。因此，年龄并非二甲双胍治疗的禁忌，但需要定期监测肾功能。老年患者的eGFR 45~59ml/(min·1.73m2)者，应该减少剂量；如eGFR<45ml/(min·1.73m2)，则不能使用。适合我国CKD患者的eGFR评估公式为：eGFR=175XScr-1.234(mg/dl)×年龄-0.179(女性X0.79)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.针对65岁以上老年患者如何使用二甲双胍：((2013年IDF老年糖尿病指南》和《中国老糖尿病诊疗措施专家共识》都推荐二甲双胍为一线首选用药，并没有限制二甲双胍的具体使用年龄。老年糖尿病患者合理应用二甲双胍可以达到良好的降糖效果，且较少的低血糖风险对老年患者也有一定益处，但需要定期监测肾功能(3~6个月检查1次)。80岁以上患者[eGFR<45ml/(min·1.73m2)除外]如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍然可取得良好效果。因此，年龄并非二甲双胍治疗的禁忌，但需要定期监测肾功能。老年患者的eGFR 45~59ml/(min·1.73m2)者，应该减少剂量；如eGFR<45ml/(min·1.73m2)，则不能使用。适合我国CKD患者的eGFR评估公式为：eGFR=175XScr-1.234(mg/dl)×年龄-0.179(女性X0.79)。",
          "start_idx": 0,
          "end_idx": 393,
          "entities": [
            {
              "entity_id": "T567",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T568",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T569",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 48,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T570",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T571",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 81,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T572",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T573",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T574",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T575",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 167,
              "end_idx": 171,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T576",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 171,
              "end_idx": 188,
              "entity_en": "<45ml/(min·1.73m2"
            },
            {
              "entity_id": "T577",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 218,
              "end_idx": 222,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T578",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 243,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T579",
              "entity": "肾",
              "entity_type": "Test_items",
              "start_idx": 256,
              "end_idx": 257,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T580",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 256,
              "end_idx": 259,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T581",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 144,
              "end_idx": 147,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T582",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T583",
              "entity": "45~59ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 270,
              "end_idx": 289,
              "entity_en": "45~59ml/(min·1.73m2"
            },
            {
              "entity_id": "T584",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T585",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 304,
              "end_idx": 321,
              "entity_en": "<45ml/(min·1.73m2"
            },
            {
              "entity_id": "T586",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 333,
              "end_idx": 336,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T587",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 339,
              "end_idx": 343,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T588",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 349,
              "end_idx": 353,
              "entity_en": "eGFR"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R262",
              "head_entity_id": "T570",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R263",
              "head_entity_id": "T570",
              "tail_entity_id": "T569"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R264",
              "head_entity_id": "T573",
              "tail_entity_id": "T572"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R265",
              "head_entity_id": "T581",
              "tail_entity_id": "T572"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R266",
              "head_entity_id": "T574",
              "tail_entity_id": "T573"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R267",
              "head_entity_id": "T587",
              "tail_entity_id": "T586"
            }
          ],
          "sentence_en": "2. How to use metformin for elderly patients over 65 years old: (The 2013 IDF Guidelines for Elderly Diabetes and the Expert Consensus on Diagnosis and Treatment Measures for Elderly Diabetes in China both recommend metformin as the first-line drug of choice, and do not limit the specific age of metformin use. The rational use of metformin in elderly patients with diabetes can achieve good blood sugar-lowering effects, and the lower risk of hypoglycemia is also beneficial to elderly patients, but regular monitoring of renal function is required (check once every 3 to 6 months). Patients over 80 years old [except eGFR<45ml/(min·1.73m2)] can still achieve good results with metformin if they have a good grasp of the indications, start with a small dose, and under reasonable monitoring conditions. Therefore, age is not a contraindication to metformin treatment, but regular monitoring of renal function is required. The eGFR of elderly patients For patients with eGFR of 45-59 ml/(min·1.73 m2), the dose should be reduced; if eGFR<45 ml/(min·1.73 m2), it cannot be used. The eGFR evaluation formula suitable for CKD patients in my country is: eGFR=175XScr-1.234(mg/dl)×age-0.179(femaleX0.79)."
        }
      ],
      "paragraph_en": "2. How to use metformin for elderly patients over 65 years old: (The 2013 IDF Guidelines for Elderly Diabetes and the Expert Consensus on Diagnosis and Treatment Measures for Elderly Diabetes in China both recommend metformin as the first-line drug of choice, and do not limit the specific age of metformin use. The rational use of metformin in elderly patients with diabetes can achieve good blood sugar-lowering effects, and the lower risk of hypoglycemia is also beneficial to elderly patients, but regular monitoring of renal function is required (check once every 3 to 6 months). Patients over 80 years old [except eGFR<45ml/(min·1.73m2)] can still achieve good results with metformin if they have a good grasp of the indications, start with a small dose, and under reasonable monitoring conditions. Therefore, age is not a contraindication to metformin treatment, but regular monitoring of renal function is required. The eGFR of elderly patients For patients with eGFR of 45-59 ml/(min·1.73 m2), the dose should be reduced; if eGFR<45 ml/(min·1.73 m2), it cannot be used. The eGFR evaluation formula suitable for CKD patients in my country is: eGFR=175XScr-1.234(mg/dl)×age-0.179(femaleX0.79)."
    },
    {
      "paragraph_id": "30",
      "paragraph": "3.二甲双胍可否用于儿童和青少年糖尿病患者：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，糖尿病得到诊断后可给予生活方式干预，不达标者以二甲双胍为起始治疗药物。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的患儿。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.二甲双胍可否用于儿童和青少年糖尿病患者：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，糖尿病得到诊断后可给予生活方式干预，不达标者以二甲双胍为起始治疗药物。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的患儿。",
          "start_idx": 0,
          "end_idx": 140,
          "entities": [
            {
              "entity_id": "T589",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T590",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T591",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T592",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "T2"
            },
            {
              "entity_id": "T593",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T594",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 59,
              "end_idx": 65,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T595",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T596",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T597",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T598",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 97,
              "end_idx": 99,
              "entity_en": "T2"
            },
            {
              "entity_id": "T599",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 117,
              "end_idx": 125,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T600",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "diabetes"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R268",
              "head_entity_id": "T590",
              "tail_entity_id": "T591"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R269",
              "head_entity_id": "T592",
              "tail_entity_id": "T591"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R270",
              "head_entity_id": "T594",
              "tail_entity_id": "T593"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R271",
              "head_entity_id": "T595",
              "tail_entity_id": "T593"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R272",
              "head_entity_id": "T596",
              "tail_entity_id": "T597"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R273",
              "head_entity_id": "T599",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R274",
              "head_entity_id": "T598",
              "tail_entity_id": "T597"
            }
          ],
          "sentence_en": "3. Can metformin be used for children and adolescents with diabetes: Children aged 10 years and above with T2DM who do not need insulin as initial treatment can be given lifestyle intervention after diabetes is diagnosed, and those who do not meet the target can use metformin as the initial treatment drug. Metformin can be used for children or adolescents with T2DM aged 10 years and above, and the maximum dose does not exceed 2000 mg/d. It is not recommended for children under 10 years old."
        }
      ],
      "paragraph_en": "3. Can metformin be used for children and adolescents with diabetes: Children aged 10 years and above with T2DM who do not need insulin as initial treatment can be given lifestyle intervention after diabetes is diagnosed, and those who do not meet the target can use metformin as the initial treatment drug. Metformin can be used for children or adolescents with T2DM aged 10 years and above, and the maximum dose does not exceed 2000 mg/d. It is not recommended for children under 10 years old."
    },
    {
      "paragraph_id": "31",
      "paragraph": "4.GDM患者能否使用二甲双胍：虽然国际多个学术组织推荐二甲双胍可用于GDM患者，但基于目前国内证据缺乏，暂不推荐(V级)。二甲双胍在FDA妊娠期用药分级中为B类药物。2013年，《糖尿病和妊娠：美国内分泌学会临床实践指南》建议，在妊娠前3个月内医学营养治疗血糖控制不佳，以及拒绝和不适合使用胰岛素和格列本脲的GDM患者可使用二甲双胍治疗。2015年，NICE《妊娠糖尿病及其并发症的管理指南》建议，饮食和运动1~2周血糖未达标的GDM患者，可使用二甲双胍治疗。但我国药监部门尚未批准二甲双胍用于妊娠妇女。对于有糖尿病病史的产妇，二甲双胍干预可以有效减缓10年随访期中糖尿病的发展。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率，在控制孕妇体重和治疗IR方面有优势。在有效控制血糖的前提下，二甲双胍较胰岛素更有益于产妇健康。一项前瞻性随机对照临床试验结果显示，二甲双胍或二甲双胍联用胰岛素治疗GDM在体重、先兆子痫、新生儿死亡率等方面优于胰岛素单药治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.GDM患者能否使用二甲双胍：虽然国际多个学术组织推荐二甲双胍可用于GDM患者，但基于目前国内证据缺乏，暂不推荐(V级)。二甲双胍在FDA妊娠期用药分级中为B类药物。2013年，《糖尿病和妊娠：美国内分泌学会临床实践指南》建议，在妊娠前3个月内医学营养治疗血糖控制不佳，以及拒绝和不适合使用胰岛素和格列本脲的GDM患者可使用二甲双胍治疗。2015年，NICE《妊娠糖尿病及其并发症的管理指南》建议，饮食和运动1~2周血糖未达标的GDM患者，可使用二甲双胍治疗。但我国药监部门尚未批准二甲双胍用于妊娠妇女。对于有糖尿病病史的产妇，二甲双胍干预可以有效减缓10年随访期中糖尿病的发展。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率，在控制孕妇体重和治疗IR方面有优势。在有效控制血糖的前提下，二甲双胍较胰岛素更有益于产妇健康。一项前瞻性随机对照临床试验结果显示，二甲双胍或二甲双胍联用胰岛素治疗GDM在体重、先兆子痫、新生儿死亡率等方面优于胰岛素单药治疗。",
          "start_idx": 0,
          "end_idx": 433,
          "entities": [
            {
              "entity_id": "T601",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T602",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T603",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T604",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T605",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T606",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T607",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T608",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 149,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T609",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Glyburide"
            },
            {
              "entity_id": "T610",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 158,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T611",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T612",
              "entity": "妊娠糖尿病",
              "entity_type": "Disease",
              "start_idx": 181,
              "end_idx": 186,
              "entity_en": "Gestational diabetes"
            },
            {
              "entity_id": "T613",
              "entity": "饮食",
              "entity_type": "Treatment",
              "start_idx": 200,
              "end_idx": 202,
              "entity_en": "diet"
            },
            {
              "entity_id": "T614",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 203,
              "end_idx": 205,
              "entity_en": "sports"
            },
            {
              "entity_id": "T615",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 209,
              "end_idx": 211,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T616",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 218,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T617",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 224,
              "end_idx": 228,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T618",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 246,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T619",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 256,
              "end_idx": 259,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T620",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T621",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 284,
              "end_idx": 287,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T622",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 291,
              "end_idx": 295,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T623",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 298,
              "end_idx": 302,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T624",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 313,
              "end_idx": 316,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T625",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 331,
              "end_idx": 333,
              "entity_en": "IR"
            },
            {
              "entity_id": "T626",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 344,
              "end_idx": 346,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T627",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 351,
              "end_idx": 355,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T628",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 356,
              "end_idx": 359,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T629",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 386,
              "end_idx": 390,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T630",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 391,
              "end_idx": 395,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T631",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 397,
              "end_idx": 400,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T632",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 402,
              "end_idx": 405,
              "entity_en": "GDM"
            },
            {
              "entity_id": "T633",
              "entity": "先兆子痫",
              "entity_type": "Disease",
              "start_idx": 409,
              "end_idx": 413,
              "entity_en": "Preeclampsia"
            },
            {
              "entity_id": "T634",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 425,
              "end_idx": 428,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T635",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 131,
              "end_idx": 135,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T636",
              "entity": "未达标",
              "entity_type": "Test_Value",
              "start_idx": 211,
              "end_idx": 214,
              "entity_en": "Not up to standard"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R275",
              "head_entity_id": "T603",
              "tail_entity_id": "T604"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R276",
              "head_entity_id": "T611",
              "tail_entity_id": "T610"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R277",
              "head_entity_id": "T613",
              "tail_entity_id": "T616"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R278",
              "head_entity_id": "T614",
              "tail_entity_id": "T616"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R279",
              "head_entity_id": "T615",
              "tail_entity_id": "T616"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R280",
              "head_entity_id": "T617",
              "tail_entity_id": "T616"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R281",
              "head_entity_id": "T620",
              "tail_entity_id": "T621"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R282",
              "head_entity_id": "T622",
              "tail_entity_id": "T623"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R283",
              "head_entity_id": "T622",
              "tail_entity_id": "T624"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R284",
              "head_entity_id": "T625",
              "tail_entity_id": "T623"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R285",
              "head_entity_id": "T625",
              "tail_entity_id": "T624"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R286",
              "head_entity_id": "T629",
              "tail_entity_id": "T632"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R287",
              "head_entity_id": "T630",
              "tail_entity_id": "T632"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R288",
              "head_entity_id": "T631",
              "tail_entity_id": "T632"
            }
          ],
          "sentence_en": "4. Can GDM patients use metformin: Although many international academic organizations recommend that metformin can be used for GDM patients, it is not recommended for the time being (Grade V) due to the lack of evidence in China. Metformin is a Class B drug in the FDA's classification of medication for pregnancy. In 2013, the \"Diabetes and Pregnancy: Clinical Practice Guidelines of the American Endocrine Society\" recommended that GDM patients who have poor blood sugar control with medical nutrition therapy in the first 3 months of pregnancy, and who refuse or are not suitable for the use of insulin and glibenclamide, can use metformin for treatment. In 2015, the NICE \"Guidelines for the Management of Gestational Diabetes and Its Complications\" recommended that GDM patients whose blood sugar levels do not meet the target after 1 to 2 weeks of diet and exercise can use metformin for treatment. However, my country's drug regulatory authorities have not yet approved metformin for use in pregnant women. For pregnant women with a history of diabetes, metformin intervention can effectively slow the development of diabetes during the 10-year follow-up period. Metformin can reduce the miscarriage rate and the incidence of GDM in early pregnancy in PCOS patients, and has advantages in controlling maternal weight and treating IR. Under the premise of effective blood sugar control, metformin is more beneficial to maternal health than insulin. The results of a prospective randomized controlled clinical trial showed that metformin or metformin combined with insulin for the treatment of GDM is superior to insulin monotherapy in terms of weight, preeclampsia, neonatal mortality, etc."
        }
      ],
      "paragraph_en": "4. Can GDM patients use metformin: Although many international academic organizations recommend that metformin can be used for GDM patients, it is not recommended for the time being (Grade V) due to the lack of evidence in China. Metformin is a Class B drug in the FDA's classification of medication for pregnancy. In 2013, the \"Diabetes and Pregnancy: Clinical Practice Guidelines of the American Endocrine Society\" recommended that GDM patients who have poor blood sugar control with medical nutrition therapy in the first 3 months of pregnancy, and who refuse or are not suitable for the use of insulin and glibenclamide, can use metformin for treatment. In 2015, the NICE \"Guidelines for the Management of Gestational Diabetes and Its Complications\" recommended that GDM patients whose blood sugar levels do not meet the target after 1 to 2 weeks of diet and exercise can use metformin for treatment. However, my country's drug regulatory authorities have not yet approved metformin for use in pregnant women. For pregnant women with a history of diabetes, metformin intervention can effectively slow the development of diabetes during the 10-year follow-up period. Metformin can reduce the miscarriage rate and the incidence of GDM in early pregnancy in PCOS patients, and has advantages in controlling maternal weight and treating IR. Under the premise of effective blood sugar control, metformin is more beneficial to maternal health than insulin. The results of a prospective randomized controlled clinical trial showed that metformin or metformin combined with insulin for the treatment of GDM is superior to insulin monotherapy in terms of weight, preeclampsia, neonatal mortality, etc."
    },
    {
      "paragraph_id": "32",
      "paragraph": "5.肝功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍不经过肝脏代谢，无肝脏毒性。目前，肝功能不全患者使用二甲双胍的临床资料较少。肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者应避免使用二甲双胍。血清转氨酶轻度升高的患者使用时应密切监测肝功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.肝功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍不经过肝脏代谢，无肝脏毒性。目前，肝功能不全患者使用二甲双胍的临床资料较少。肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限或有严重肝功能不全的患者应避免使用二甲双胍。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T637",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T638",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "liver"
            },
            {
              "entity_id": "T639",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T640",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "T2"
            },
            {
              "entity_id": "T641",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T642",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T643",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 53,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T644",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49,
              "entity_en": "liver"
            },
            {
              "entity_id": "T645",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T646",
              "entity": "肝功能严重受损",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 76,
              "entity_en": "Severe liver damage"
            },
            {
              "entity_id": "T647",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70,
              "entity_en": "liver"
            },
            {
              "entity_id": "T648",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "serious"
            },
            {
              "entity_id": "T649",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 96,
              "entity_en": "Serum transaminases"
            },
            {
              "entity_id": "T650",
              "entity": "严重肝功能不全",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 113,
              "entity_en": "Severe liver dysfunction"
            },
            {
              "entity_id": "T651",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 106,
              "end_idx": 108,
              "entity_en": "serious"
            },
            {
              "entity_id": "T652",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 108,
              "end_idx": 109,
              "entity_en": "liver"
            },
            {
              "entity_id": "T653",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T657",
              "entity": "超过3倍正常上限",
              "entity_type": "Test_Value",
              "start_idx": 96,
              "end_idx": 104,
              "entity_en": "More than 3 times the normal upper limit"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R289",
              "head_entity_id": "T638",
              "tail_entity_id": "T637"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R290",
              "head_entity_id": "T641",
              "tail_entity_id": "T637"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R291",
              "head_entity_id": "T640",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R292",
              "head_entity_id": "T641",
              "tail_entity_id": "T639"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R293",
              "head_entity_id": "T647",
              "tail_entity_id": "T646"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R294",
              "head_entity_id": "T649",
              "tail_entity_id": "T646"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R295",
              "head_entity_id": "T652",
              "tail_entity_id": "T650"
            }
          ],
          "sentence_en": "5. Issues that should be noted when using metformin in patients with hepatic insufficiency: Metformin is not metabolized by the liver and has no hepatotoxicity. Currently, there is little clinical data on the use of metformin in patients with hepatic insufficiency. Severe liver damage will significantly limit the ability to clear lactate. It is recommended that patients with serum transaminase exceeding 3 times the upper limit of normal or severe hepatic insufficiency should avoid using metformin."
        },
        {
          "sentence_id": "1",
          "sentence": "血清转氨酶轻度升高的患者使用时应密切监测肝功能。",
          "start_idx": 126,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T654",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Serum transaminases"
            },
            {
              "entity_id": "T655",
              "entity": "轻度升高",
              "entity_type": "Test_Value",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Mildly elevated"
            },
            {
              "entity_id": "T656",
              "entity": "肝功能",
              "entity_type": "Test",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Liver function"
            }
          ],
          "relations": [],
          "sentence_en": "Liver function should be closely monitored in patients with mild elevations in serum transaminases."
        }
      ],
      "paragraph_en": "5. Issues that should be noted when using metformin in patients with hepatic insufficiency: Metformin is not metabolized by the liver and has no hepatotoxicity. Currently, there is little clinical data on the use of metformin in patients with hepatic insufficiency. Severe liver damage will significantly limit the ability to clear lactate. It is recommended that patients with serum transaminase exceeding 3 times the upper limit of normal or severe liver insufficiency should avoid using metformin. Patients with mildly elevated serum transaminase should closely monitor liver function when using metformin."
    },
    {
      "paragraph_id": "33",
      "paragraph": "6.肾功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。建议根据患者eGFR水平调整二甲双胍剂量。eGFR≥60ml/(min·1.73m2)无需调整剂量，eGFR 45~59ml/(min·1.73m2)减量，eGFR<45ml/(min·1.73m2)禁用(V级)。2015年，ADA/EASD立场声明，建议放宽二甲双胍用于中度肾功能不全T2DM患者的限制，仅在eGFR<30ml/(min·1.73m2)患者中禁用。2016年，ADA糖尿病指南指出，已有累积观察性数据显示，二甲双胍用于eGFR在30~45ml/(min·1.73m2)的患者依然安全。同时建议，如果二甲双胍用于这个eGFR范围内的患者，应减少药物剂量并停止使用治疗恶心、呕吐及脱水的药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.肾功能不全的T2DM患者使用二甲双胍应注意的问题：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。建议根据患者eGFR水平调整二甲双胍剂量。eGFR≥60ml/(min·1.73m2)无需调整剂量，eGFR 45~59ml/(min·1.73m2)减量，eGFR<45ml/(min·1.73m2)禁用(V级)。2015年，ADA/EASD立场声明，建议放宽二甲双胍用于中度肾功能不全T2DM患者的限制，仅在eGFR<30ml/(min·1.73m2)患者中禁用。2016年，ADA糖尿病指南指出，已有累积观察性数据显示，二甲双胍用于eGFR在30~45ml/(min·1.73m2)的患者依然安全。",
          "start_idx": 0,
          "end_idx": 318,
          "entities": [
            {
              "entity_id": "T658",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T659",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T660",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "T2"
            },
            {
              "entity_id": "T661",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T662",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T663",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Proteinuria"
            },
            {
              "entity_id": "T664",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T665",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T666",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T667",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 85,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T668",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T669",
              "entity": "≥60ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 92,
              "end_idx": 109,
              "entity_en": "≥60ml/(min·1.73m2"
            },
            {
              "entity_id": "T670",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T671",
              "entity": "45~59ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 122,
              "end_idx": 141,
              "entity_en": "45~59ml/(min·1.73m2"
            },
            {
              "entity_id": "T672",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T673",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 149,
              "end_idx": 166,
              "entity_en": "<45ml/(min·1.73m2"
            },
            {
              "entity_id": "T674",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 197,
              "end_idx": 201,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T675",
              "entity": "中度肾功能不全",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 210,
              "entity_en": "Moderate renal insufficiency"
            },
            {
              "entity_id": "T676",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 203,
              "end_idx": 205,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T677",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 205,
              "end_idx": 206,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T678",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 210,
              "end_idx": 214,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T679",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 210,
              "end_idx": 212,
              "entity_en": "T2"
            },
            {
              "entity_id": "T680",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 222,
              "end_idx": 226,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T681",
              "entity": "<30ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 226,
              "end_idx": 243,
              "entity_en": "<30ml/(min·1.73m2"
            },
            {
              "entity_id": "T682",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 259,
              "end_idx": 262,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T683",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 283,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T684",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 285,
              "end_idx": 289,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T685",
              "entity": "30~45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 290,
              "end_idx": 309,
              "entity_en": "30~45ml/(min·1.73m2"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R296",
              "head_entity_id": "T665",
              "tail_entity_id": "T658"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R297",
              "head_entity_id": "T661",
              "tail_entity_id": "T658"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R298",
              "head_entity_id": "T660",
              "tail_entity_id": "T659"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R299",
              "head_entity_id": "T661",
              "tail_entity_id": "T659"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R300",
              "head_entity_id": "T674",
              "tail_entity_id": "T675"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R301",
              "head_entity_id": "T674",
              "tail_entity_id": "T678"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R302",
              "head_entity_id": "T677",
              "tail_entity_id": "T675"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R303",
              "head_entity_id": "T680",
              "tail_entity_id": "T675"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R304",
              "head_entity_id": "T679",
              "tail_entity_id": "T678"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R305",
              "head_entity_id": "T680",
              "tail_entity_id": "T678"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R306",
              "head_entity_id": "T683",
              "tail_entity_id": "T682"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R307",
              "head_entity_id": "T684",
              "tail_entity_id": "T682"
            }
          ],
          "sentence_en": "6. Issues that should be noted when using metformin in patients with renal insufficiency: Metformin itself does not affect renal function, but there is a clinical misunderstanding that metformin should be discontinued based on proteinuria alone. It is recommended to adjust the dose of metformin according to the patient's eGFR level. No dose adjustment is required for eGFR ≥ 60 ml/(min·1.73 m2), dose reduction for eGFR 45~59 ml/(min·1.73 m2), and contraindication for eGFR < 45 ml/(min·1.73 m2) (Grade V). In 2015, the ADA/EASD position statement recommended relaxing the restrictions on the use of metformin in patients with moderate renal insufficiency in T2DM, and only contraindicating it in patients with eGFR < 30 ml/(min·1.73 m2). In 2016, the ADA diabetes guidelines pointed out that cumulative observational data have shown that metformin is still safe for patients with eGFR of 30~45 ml/(min·1.73 m2)."
        },
        {
          "sentence_id": "1",
          "sentence": "同时建议，如果二甲双胍用于这个eGFR范围内的患者，应减少药物剂量并停止使用治疗恶心、呕吐及脱水的药物。",
          "start_idx": 318,
          "end_idx": 370,
          "entities": [
            {
              "entity_id": "T686",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T687",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T688",
              "entity": "恶心",
              "entity_type": "Symptom",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T689",
              "entity": "呕吐",
              "entity_type": "Symptom",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T690",
              "entity": "脱水",
              "entity_type": "Symptom",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "Dehydration"
            }
          ],
          "relations": [],
          "sentence_en": "It is also recommended that if metformin is used in patients within this eGFR range, the drug dose should be reduced and medications for nausea, vomiting, and dehydration should be discontinued."
        }
      ],
      "paragraph_en": "6. Issues that should be noted when using metformin in patients with renal insufficiency: Metformin itself does not affect renal function, but there is a clinical misunderstanding that metformin should be discontinued based on proteinuria alone. It is recommended to adjust the dose of metformin according to the patient's eGFR level. No dose adjustment is required for eGFR ≥ 60 ml/(min·1.73 m2), dose reduction for eGFR 45~59 ml/(min·1.73 m2), and contraindication for eGFR < 45 ml/(min·1.73 m2) (Grade V). In 2015, the ADA/EASD position statement recommended relaxing the restrictions on the use of metformin in patients with moderate renal insufficiency in T2DM, and only contraindicating it in patients with eGFR < 30 ml/(min·1.73 m2). In 2016, the ADA diabetes guidelines pointed out that cumulative observational data have shown that metformin is still safe for patients with eGFR of 30~45 ml/(min·1.73 m2). It is also recommended that if metformin is used in patients within this eGFR range, the drug dose should be reduced and medications for nausea, vomiting, and dehydration should be discontinued."
    },
    {
      "paragraph_id": "34",
      "paragraph": "7.患者造影或全身麻醉术前停用二甲双胍的时间，以及再行启用的时间：肾功能正常的糖尿病患者，造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用造影剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.患者造影或全身麻醉术前停用二甲双胍的时间，以及再行启用的时间：肾功能正常的糖尿病患者，造影前不必停用二甲双胍，但使用造影剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用造影剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。",
          "start_idx": 0,
          "end_idx": 166,
          "entities": [
            {
              "entity_id": "T691",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Imaging"
            },
            {
              "entity_id": "T692",
              "entity": "全身麻醉术",
              "entity_type": "Operation",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "General anesthesia"
            },
            {
              "entity_id": "T693",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T694",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T695",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 42,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T696",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "Imaging"
            },
            {
              "entity_id": "T697",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T698",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T699",
              "entity": "肾功能异常",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 103,
              "entity_en": "Abnormal renal function"
            },
            {
              "entity_id": "T700",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 98,
              "end_idx": 99,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T701",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T702",
              "entity": "造影剂",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 112,
              "entity_en": "Contrast agents"
            },
            {
              "entity_id": "T703",
              "entity": "全身麻醉术",
              "entity_type": "Operation",
              "start_idx": 113,
              "end_idx": 118,
              "entity_en": "General anesthesia"
            },
            {
              "entity_id": "T704",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 132,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T705",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 148,
              "end_idx": 151,
              "entity_en": "Renal function"
            },
            {
              "entity_id": "T706",
              "entity": "正常",
              "entity_type": "Test_Value",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "normal"
            },
            {
              "entity_id": "T707",
              "entity": "正常",
              "entity_type": "Test_Value",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "normal"
            },
            {
              "entity_id": "T708",
              "entity": "正常",
              "entity_type": "Test_Value",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "normal"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R308",
              "head_entity_id": "T694",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R309",
              "head_entity_id": "T696",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R310",
              "head_entity_id": "T697",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R311",
              "head_entity_id": "T701",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R312",
              "head_entity_id": "T698",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R313",
              "head_entity_id": "T700",
              "tail_entity_id": "T699"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R314",
              "head_entity_id": "T705",
              "tail_entity_id": "T699"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R315",
              "head_entity_id": "T702",
              "tail_entity_id": "T699"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R316",
              "head_entity_id": "T703",
              "tail_entity_id": "T699"
            }
          ],
          "sentence_en": "7. The time when the patient stops taking metformin before angiography or general anesthesia, and the time to restart it: For diabetic patients with normal renal function, there is no need to stop taking metformin before angiography, but it should be stopped for 48 to 72 hours under the guidance of a doctor after the use of contrast agent. The medication can be continued after the renal function is normal. For patients with abnormal renal function, metformin should be temporarily stopped 48 hours before the use of contrast agent and general anesthesia, and then it needs to be stopped for 48 to 72 hours. The medication can be continued after the renal function results are normal (Grade V)."
        }
      ],
      "paragraph_en": "7. The time when the patient stops taking metformin before angiography or general anesthesia, and the time to restart it: For diabetic patients with normal renal function, there is no need to stop taking metformin before angiography, but it should be stopped for 48 to 72 hours under the guidance of a doctor after the use of contrast agent. The medication can be continued after the renal function is normal. For patients with abnormal renal function, metformin should be temporarily stopped 48 hours before the use of contrast agent and general anesthesia, and then it needs to be stopped for 48 to 72 hours. The medication can be continued after the renal function results are normal (Grade V)."
    },
    {
      "paragraph_id": "35",
      "paragraph": "五、安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "五、安全性",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "5. Security"
        }
      ],
      "paragraph_en": "5. Security"
    },
    {
      "paragraph_id": "36",
      "paragraph": "1.二甲双胍的禁忌证：(1)中度(3b级)和严重肾衰竭或肾功能不全[Cr<45ml/min或eGFR<45ml/(min·1.73m2)]；(2)可造成组织缺氧的疾病(尤其是急性疾病或慢性疾病的恶化)，如失代偿性心力衰竭、呼吸衰竭、近期发作的心肌梗死、休克；(3)严重感染和外伤、外科大手术、临床有低血压等；(4)已知对盐酸二甲双胍过敏者；(5)急性或慢性代谢性酸中毒，包括有或无昏迷的DKA(DKA需要用胰岛素治疗)；(6)酗酒者；(7)接受血管内注射碘化造影剂者，可以暂时停用本品；(8)维生素B12、叶酸缺乏未纠正者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍的禁忌证：(1)中度(3b级)和严重肾衰竭或肾功能不全[Cr<45ml/min或eGFR<45ml/(min·1.73m2)]；(2)可造成组织缺氧的疾病(尤其是急性疾病或慢性疾病的恶化)，如失代偿性心力衰竭、呼吸衰竭、近期发作的心肌梗死、休克；(3)严重感染和外伤、外科大手术、临床有低血压等；(4)已知对盐酸二甲双胍过敏者；(5)急性或慢性代谢性酸中毒，包括有或无昏迷的DKA(DKA需要用胰岛素治疗)；(6)酗酒者；(7)接受血管内注射碘化造影剂者，可以暂时停用本品；(8)维生素B12、叶酸缺乏未纠正者。",
          "start_idx": 0,
          "end_idx": 262,
          "entities": [
            {
              "entity_id": "T709",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T710",
              "entity": "中度(3b级)和严重肾衰竭",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 27,
              "entity_en": "Moderate (grade 3b) and severe renal failure"
            },
            {
              "entity_id": "T711",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T712",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 33,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T713",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 29,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T714",
              "entity": "Cr",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Cr"
            },
            {
              "entity_id": "T715",
              "entity": "<45ml/min",
              "entity_type": "Test_Value",
              "start_idx": 36,
              "end_idx": 45,
              "entity_en": "<45ml/min"
            },
            {
              "entity_id": "T716",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T717",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 50,
              "end_idx": 67,
              "entity_en": "<45ml/(min·1.73m2"
            },
            {
              "entity_id": "T718",
              "entity": "失代偿性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 110,
              "entity_en": "Decompensated heart failure"
            },
            {
              "entity_id": "T719",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 107,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T720",
              "entity": "呼吸衰竭",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "respiratory failure"
            },
            {
              "entity_id": "T721",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T722",
              "entity": "休克",
              "entity_type": "Disease",
              "start_idx": 126,
              "end_idx": 128,
              "entity_en": "shock"
            },
            {
              "entity_id": "T723",
              "entity": "严重感染",
              "entity_type": "Disease",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "Severe infection"
            },
            {
              "entity_id": "T724",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 132,
              "end_idx": 134,
              "entity_en": "serious"
            },
            {
              "entity_id": "T725",
              "entity": "外伤",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 139,
              "entity_en": "trauma"
            },
            {
              "entity_id": "T726",
              "entity": "低血压",
              "entity_type": "Disease",
              "start_idx": 149,
              "end_idx": 152,
              "entity_en": "Low blood pressure"
            },
            {
              "entity_id": "T727",
              "entity": "盐酸二甲双胍",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 166,
              "entity_en": "Metformin Hydrochloride"
            },
            {
              "entity_id": "T728",
              "entity": "急性或慢性代谢性酸中毒",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 184,
              "entity_en": "Acute or chronic metabolic acidosis"
            },
            {
              "entity_id": "T729",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 197,
              "end_idx": 200,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T730",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 206,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T731",
              "entity": "碘化造影剂",
              "entity_type": "Drug",
              "start_idx": 227,
              "end_idx": 232,
              "entity_en": "Iodinated contrast agents"
            },
            {
              "entity_id": "T732",
              "entity": "中度(3b级)和严重",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 24,
              "entity_en": "Moderate (grade 3b) and severe"
            },
            {
              "entity_id": "T733",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 121,
              "end_idx": 123,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T734",
              "entity": "过敏",
              "entity_type": "ADE",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "allergy"
            },
            {
              "entity_id": "T735",
              "entity": "昏迷",
              "entity_type": "Symptom",
              "start_idx": 190,
              "end_idx": 192,
              "entity_en": "coma"
            },
            {
              "entity_id": "T736",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 193,
              "end_idx": 196,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T737",
              "entity": "血管内注射",
              "entity_type": "Method",
              "start_idx": 222,
              "end_idx": 227,
              "entity_en": "Intravascular injection"
            },
            {
              "entity_id": "T738",
              "entity": "维生素B12、叶酸缺乏",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 257,
              "entity_en": "Vitamin B12 and folic acid deficiency"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R317",
              "head_entity_id": "T711",
              "tail_entity_id": "T710"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R318",
              "head_entity_id": "T732",
              "tail_entity_id": "T710"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R319",
              "head_entity_id": "T713",
              "tail_entity_id": "T712"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R320",
              "head_entity_id": "T714",
              "tail_entity_id": "T712"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R321",
              "head_entity_id": "T716",
              "tail_entity_id": "T712"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R322",
              "head_entity_id": "T719",
              "tail_entity_id": "T718"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R323",
              "head_entity_id": "T733",
              "tail_entity_id": "T721"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R324",
              "head_entity_id": "T734",
              "tail_entity_id": "T727"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R325",
              "head_entity_id": "T730",
              "tail_entity_id": "T729"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R326",
              "head_entity_id": "T737",
              "tail_entity_id": "T731"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R327",
              "head_entity_id": "T735",
              "tail_entity_id": "T736"
            }
          ],
          "sentence_en": "1. Contraindications of metformin: (1) moderate (grade 3b) and severe renal failure or renal insufficiency [Cr <45 ml/min or eGFR <45 ml/(min·1.73 m2)]; (2) diseases that can cause tissue hypoxia (especially acute diseases or exacerbation of chronic diseases), such as decompensated heart failure, respiratory failure, recent myocardial infarction, shock; (3) severe infection and trauma, major surgical operations, clinical hypotension, etc.; (4) patients with known allergy to metformin hydrochloride; (5) acute or chronic metabolic acidosis, including DKA with or without coma (DKA requires insulin treatment); (6) alcoholics; (7) patients receiving intravascular injection of iodinated contrast agents, in which case this product can be temporarily discontinued; (8) patients with uncorrected vitamin B12 and folic acid deficiencies."
        }
      ],
      "paragraph_en": "1. Contraindications for metformin: (1) moderate (grade 3b) and severe renal failure or renal insufficiency [Cr <45 ml/min or eGFR <45 ml/(min·1.73 m2)]; (2) diseases that can cause tissue hypoxia (especially acute diseases or exacerbation of chronic diseases), such as decompensated heart failure, respiratory failure, recent myocardial infarction, shock; (3) severe infection and trauma, major surgical operations, clinical hypotension, etc.; (4) patients with known allergy to metformin hydrochloride; (5) acute or chronic metabolic acidosis, including DKA with or without coma (DKA requires insulin treatment); (6) alcoholics; (7) patients receiving intravascular injection of iodinated contrast agents, in which case this product can be temporarily discontinued; (8) patients with uncorrected vitamin B12 and folic acid deficiencies."
    },
    {
      "paragraph_id": "37",
      "paragraph": "2.二甲双胍的常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。这些不良反应的发生往往见于药物治疗的早期，大多数患者可耐受。随着治疗时间的延长，上述不良反应可基本消失。小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍的常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T739",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T740",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "diarrhea"
            },
            {
              "entity_id": "T741",
              "entity": "恶心",
              "entity_type": "ADE",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T742",
              "entity": "呕吐",
              "entity_type": "ADE",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T743",
              "entity": "胃胀",
              "entity_type": "ADE",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "Stomach bloating"
            },
            {
              "entity_id": "T744",
              "entity": "乏力",
              "entity_type": "ADE",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Fatigue"
            },
            {
              "entity_id": "T745",
              "entity": "消化不良",
              "entity_type": "ADE",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "indigestion"
            },
            {
              "entity_id": "T746",
              "entity": "头痛",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "Headache"
            },
            {
              "entity_id": "T747",
              "entity": "腹部不适",
              "entity_type": "ADE",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Abdominal discomfort"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R328",
              "head_entity_id": "T740",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R329",
              "head_entity_id": "T741",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R330",
              "head_entity_id": "T742",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R331",
              "head_entity_id": "T743",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R332",
              "head_entity_id": "T744",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R333",
              "head_entity_id": "T745",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R334",
              "head_entity_id": "T747",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R335",
              "head_entity_id": "T746",
              "tail_entity_id": "T739"
            }
          ],
          "sentence_en": "2. Common adverse reactions of metformin: Common adverse reactions include diarrhea, nausea, vomiting, bloating, fatigue, indigestion, abdominal discomfort and headache."
        },
        {
          "sentence_id": "1",
          "sentence": "这些不良反应的发生往往见于药物治疗的早期，大多数患者可耐受。",
          "start_idx": 50,
          "end_idx": 80,
          "entities": [],
          "relations": [],
          "sentence_en": "These adverse reactions often occur in the early stages of drug treatment and are tolerable in most patients."
        },
        {
          "sentence_id": "2",
          "sentence": "随着治疗时间的延长，上述不良反应可基本消失。",
          "start_idx": 80,
          "end_idx": 102,
          "entities": [],
          "relations": [],
          "sentence_en": "As the treatment time increases, the above-mentioned adverse reactions can basically disappear."
        },
        {
          "sentence_id": "3",
          "sentence": "小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。",
          "start_idx": 102,
          "end_idx": 133,
          "entities": [],
          "relations": [],
          "sentence_en": "Starting with a low dose and gradually increasing the dose is an effective way to reduce the occurrence of adverse reactions in the early stages of treatment."
        }
      ],
      "paragraph_en": "2. Common adverse reactions of metformin: Common adverse reactions include diarrhea, nausea, vomiting, bloating, fatigue, indigestion, abdominal discomfort and headache. These adverse reactions often occur in the early stages of drug treatment and are tolerated by most patients. As the treatment time increases, the above adverse reactions can basically disappear. Starting with a low dose and gradually increasing the dose is an effective way to reduce the occurrence of adverse reactions in the early stages of treatment."
    },
    {
      "paragraph_id": "38",
      "paragraph": "3.二甲双胍的胃肠道反应与剂量的相关性，以及处理措施：二甲双胍引起的胃肠道反应多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。一项多中心、双盲、安慰剂对照研究显示，二甲双胍(1000mg/d)起始治疗，其胃肠道反应发生率为24%，增至2500mg/d时胃肠道反应发生率与1000mg/d比较，差异无统计学意义(Ⅰ级)。国内报道二甲双胍的胃肠道反应发生率为15%，且二甲双胍的胃肠道反应与患者的体重、二甲双胍剂量没有明显的相关性。如果增加二甲双胍剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量。缓释制剂也可以减少患者的胃肠道症状。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.二甲双胍的胃肠道反应与剂量的相关性，以及处理措施：二甲双胍引起的胃肠道反应多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。一项多中心、双盲、安慰剂对照研究显示，二甲双胍(1000mg/d)起始治疗，其胃肠道反应发生率为24%，增至2500mg/d时胃肠道反应发生率与1000mg/d比较，差异无统计学意义(Ⅰ级)。",
          "start_idx": 0,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T748",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T749",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T750",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T751",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T752",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T753",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 111,
              "end_idx": 119,
              "entity_en": "1000 mg/day"
            },
            {
              "entity_id": "T754",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 126,
              "end_idx": 131,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T755",
              "entity": "2500mg/d",
              "entity_type": "Amount",
              "start_idx": 141,
              "end_idx": 149,
              "entity_en": "2500 mg/day"
            },
            {
              "entity_id": "T756",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 150,
              "end_idx": 155,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T757",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 159,
              "end_idx": 167,
              "entity_en": "1000 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R336",
              "head_entity_id": "T749",
              "tail_entity_id": "T748"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R337",
              "head_entity_id": "T751",
              "tail_entity_id": "T750"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R338",
              "head_entity_id": "T753",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R339",
              "head_entity_id": "T755",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R340",
              "head_entity_id": "T757",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R341",
              "head_entity_id": "T754",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R342",
              "head_entity_id": "T756",
              "tail_entity_id": "T752"
            }
          ],
          "sentence_en": "3. The correlation between the gastrointestinal reaction of metformin and the dose, as well as the treatment measures: The gastrointestinal reactions caused by metformin often occur in the early stage of treatment (most of which occur in the first 10 weeks). Most patients can gradually tolerate or the symptoms disappear as the treatment time increases. A multicenter, double-blind, placebo-controlled study showed that the incidence of gastrointestinal reactions was 24% when metformin (1000 mg/d) was started. When the dose was increased to 2500 mg/d, there was no statistically significant difference in the incidence of gastrointestinal reactions compared with 1000 mg/d (level I)."
        },
        {
          "sentence_id": "1",
          "sentence": "国内报道二甲双胍的胃肠道反应发生率为15%，且二甲双胍的胃肠道反应与患者的体重、二甲双胍剂量没有明显的相关性。",
          "start_idx": 183,
          "end_idx": 238,
          "entities": [
            {
              "entity_id": "T758",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T759",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T760",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T761",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 28,
              "end_idx": 33,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T762",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Metformin"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R343",
              "head_entity_id": "T759",
              "tail_entity_id": "T758"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R344",
              "head_entity_id": "T761",
              "tail_entity_id": "T760"
            }
          ],
          "sentence_en": "Domestic reports show that the incidence of gastrointestinal reactions to metformin is 15%, and there is no obvious correlation between the gastrointestinal reactions to metformin and the patient's weight or metformin dosage."
        },
        {
          "sentence_id": "2",
          "sentence": "如果增加二甲双胍剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量。",
          "start_idx": 238,
          "end_idx": 283,
          "entities": [
            {
              "entity_id": "T763",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T764",
              "entity": "严重胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 20,
              "entity_en": "Severe gastrointestinal reactions"
            },
            {
              "entity_id": "T765",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R345",
              "head_entity_id": "T764",
              "tail_entity_id": "T763"
            }
          ],
          "sentence_en": "If severe gastrointestinal reactions occur after increasing the metformin dose, the dose can be reduced to the previous lower dose, and then increased after tolerance."
        },
        {
          "sentence_id": "3",
          "sentence": "缓释制剂也可以减少患者的胃肠道症状。",
          "start_idx": 283,
          "end_idx": 301,
          "entities": [
            {
              "entity_id": "T766",
              "entity": "胃肠道症状",
              "entity_type": "ADE",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Gastrointestinal symptoms"
            }
          ],
          "relations": [],
          "sentence_en": "Sustained-release formulations can also reduce gastrointestinal symptoms in patients."
        }
      ],
      "paragraph_en": "3. The correlation between the gastrointestinal reaction of metformin and the dose, as well as the treatment measures: The gastrointestinal reactions caused by metformin often occur in the early stage of treatment (most of which occur in the first 10 weeks). Most patients can gradually tolerate or the symptoms disappear as the treatment time increases. A multicenter, double-blind, placebo-controlled study showed that the incidence of gastrointestinal reactions was 24% when metformin (1000 mg/d) was started. When the incidence of gastrointestinal reactions was increased to 2500 mg/d, there was no statistically significant difference compared with 1000 mg/d (level I). Domestic reports show that the incidence of gastrointestinal reactions of metformin is 15%, and there is no obvious correlation between the gastrointestinal reactions of metformin and the patient's weight or metformin dose. If severe gastrointestinal reactions occur after increasing the dose of metformin, it can be reduced to the previous lower dose, and the dose can be increased after tolerance. Sustained-release preparations can also reduce patients' gastrointestinal symptoms."
    },
    {
      "paragraph_id": "39",
      "paragraph": "4.二甲双胍对维生素B12的吸收是否有影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。其机制可能是(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可以抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。一项研究结果显示，虽然二甲双胍可导致血清维生素B12水平降低，但可改善细胞内维生素B12代谢。二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。建议长期使用二甲双胍治疗的患者应适当补充维生素B12。不建议服用二甲双胍的患者常规监测维生素B12的水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.二甲双胍对维生素B12的吸收是否有影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T767",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T768",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T769",
              "entity": "维生素B12",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 60,
              "entity_en": "Vitamin B12"
            },
            {
              "entity_id": "T783",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "decline"
            }
          ],
          "relations": [],
          "sentence_en": "4. Does metformin affect the absorption of vitamin B12? Several cross-sectional trials and randomized controlled studies have shown that long-term use of metformin can cause a decrease in vitamin B12 levels."
        },
        {
          "sentence_id": "1",
          "sentence": "其机制可能是(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可以抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。",
          "start_idx": 66,
          "end_idx": 191,
          "entities": [
            {
              "entity_id": "T770",
              "entity": "维生素B12",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 51,
              "entity_en": "Vitamin B12"
            },
            {
              "entity_id": "T771",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 80,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T772",
              "entity": "钙剂",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 121,
              "entity_en": "Calcium"
            }
          ],
          "relations": [],
          "sentence_en": "The possible mechanisms are (1) changes in small intestinal motility that stimulate intestinal bacterial overgrowth and competitively inhibit vitamin B12 absorption; (2) changes in the level of vitamin B12 intrinsic factor and the interaction of cobalamin endocytic receptors; and (3) metformin can inhibit the calcium-dependent absorption of the vitamin B12 intrinsic factor complex in the terminal ileum (this inhibitory effect can be reversed by calcium supplementation)."
        },
        {
          "sentence_id": "2",
          "sentence": "一项研究结果显示，虽然二甲双胍可导致血清维生素B12水平降低，但可改善细胞内维生素B12代谢。",
          "start_idx": 191,
          "end_idx": 238,
          "entities": [
            {
              "entity_id": "T773",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T774",
              "entity": "血清维生素B12",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 26,
              "entity_en": "Serum vitamin B12"
            },
            {
              "entity_id": "T775",
              "entity": "水平降低",
              "entity_type": "Test_Value",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "Reduced levels"
            }
          ],
          "relations": [],
          "sentence_en": "A study showed that although metformin can lead to a decrease in serum vitamin B12 levels, it can improve intracellular vitamin B12 metabolism."
        },
        {
          "sentence_id": "3",
          "sentence": "二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。",
          "start_idx": 238,
          "end_idx": 272,
          "entities": [
            {
              "entity_id": "T776",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T777",
              "entity": "巨幼红细胞性贫血",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "Megaloblastic anemia"
            },
            {
              "entity_id": "T778",
              "entity": "维生素B12缺乏",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 33,
              "entity_en": "Vitamin B12 deficiency"
            }
          ],
          "relations": [],
          "sentence_en": "Metformin treatment-induced megaloblastic anemia is rare; if it occurs, vitamin B12 deficiency should be excluded."
        },
        {
          "sentence_id": "4",
          "sentence": "建议长期使用二甲双胍治疗的患者应适当补充维生素B12。",
          "start_idx": 272,
          "end_idx": 299,
          "entities": [
            {
              "entity_id": "T779",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T780",
              "entity": "维生素B12",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26,
              "entity_en": "Vitamin B12"
            }
          ],
          "relations": [],
          "sentence_en": "It is recommended that patients who are treated with metformin for a long time should take appropriate vitamin B12 supplements."
        },
        {
          "sentence_id": "5",
          "sentence": "不建议服用二甲双胍的患者常规监测维生素B12的水平。",
          "start_idx": 299,
          "end_idx": 325,
          "entities": [
            {
              "entity_id": "T781",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T782",
              "entity": "维生素B12",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 22,
              "entity_en": "Vitamin B12"
            }
          ],
          "relations": [],
          "sentence_en": "Routine monitoring of vitamin B12 levels is not recommended in patients taking metformin."
        }
      ],
      "paragraph_en": "4. Does metformin affect the absorption of vitamin B12? Several cross-sectional trials and randomized controlled studies have shown that long-term use of metformin can cause a decrease in vitamin B12 levels. The mechanism may be (1) changes in small intestinal motility stimulate intestinal bacterial overgrowth, which competitively inhibits the absorption of vitamin B12; (2) changes in the level of vitamin B12 intrinsic factor and the interaction of cobalamin endocytosis receptors; (3) metformin can inhibit the calcium-dependent absorption of the vitamin B12 intrinsic factor complex in the terminal ileum (this inhibitory effect can be reversed by calcium supplementation). The results of a study showed that although metformin can lead to a decrease in serum vitamin B12 levels, it can improve intracellular vitamin B12 metabolism. It is rare for metformin treatment to cause megaloblastic anemia. If it occurs, vitamin B12 deficiency should be excluded. It is recommended that patients who are treated with metformin for a long time should take appropriate vitamin B12 supplements. Routine monitoring of vitamin B12 levels in patients taking metformin is not recommended."
    },
    {
      "paragraph_id": "40",
      "paragraph": "5.二甲双胍是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍本身对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争肝脏P450酶，在体内也不降解，而是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此，二甲双胍无肝毒性，肝功能正常者，接受推荐剂量范围内用药，不会造成肝损害。但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.二甲双胍是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍本身对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争肝脏P450酶，在体内也不降解，而是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此，二甲双胍无肝毒性，肝功能正常者，接受推荐剂量范围内用药，不会造成肝损害。",
          "start_idx": 0,
          "end_idx": 256,
          "entities": [
            {
              "entity_id": "T784",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T785",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T786",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T787",
              "entity": "肌酐清除率",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 66,
              "entity_en": "Creatinine clearance"
            },
            {
              "entity_id": "T788",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 80,
              "end_idx": 84,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T789",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T790",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T791",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T792",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 220,
              "end_idx": 224,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T793",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 252,
              "end_idx": 255,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T794",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 252,
              "end_idx": 253,
              "entity_en": "liver"
            },
            {
              "entity_id": "T800",
              "entity": "肾清除率",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Renal clearance"
            },
            {
              "entity_id": "T801",
              "entity": "3.5倍",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "3.5 times"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R346",
              "head_entity_id": "T794",
              "tail_entity_id": "T793"
            }
          ],
          "sentence_en": "5. Does metformin damage the liver and kidneys? Metformin is mainly excreted in urine in its original form by the kidneys, and is cleared quickly, with about 90% being cleared in 12 to 24 hours. The renal clearance rate of metformin is about 3.5 times that of creatinine, and excretion through the renal tubules is the main route of metformin clearance. Therefore, metformin itself does not damage the kidneys. Studies have suggested that metformin may have a protective effect on the kidneys. Metformin is absorbed through the gastrointestinal tract and circulates in the blood. It hardly binds to plasma albumin, does not undergo liver metabolism, does not compete with liver P450 enzymes, and does not degrade in the body. Instead, it acts directly on the liver and muscles, reducing hepatic gluconeogenesis and increasing muscle glucose glycolysis. Therefore, metformin is non-hepatotoxic, and patients with normal liver function will not cause liver damage if they take the drug within the recommended dose range."
        },
        {
          "sentence_id": "1",
          "sentence": "但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。",
          "start_idx": 256,
          "end_idx": 297,
          "entities": [
            {
              "entity_id": "T795",
              "entity": "肝功能受损",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 6,
              "entity_en": "Impaired liver function"
            },
            {
              "entity_id": "T796",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 1,
              "end_idx": 2,
              "entity_en": "liver"
            },
            {
              "entity_id": "T797",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T798",
              "entity": "肝功能受损",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Impaired liver function"
            },
            {
              "entity_id": "T799",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 21,
              "entity_en": "liver"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R347",
              "head_entity_id": "T796",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R348",
              "head_entity_id": "T799",
              "tail_entity_id": "T798"
            }
          ],
          "sentence_en": "However, patients with impaired liver function should use metformin with caution because impaired liver function can significantly limit their ability to clear lactate."
        }
      ],
      "paragraph_en": "5. Does metformin damage the liver and kidneys? Metformin is mainly excreted in urine in its original form by the kidneys, and is cleared quickly, with about 90% being cleared in 12 to 24 hours. The renal clearance rate of metformin is about 3.5 times that of creatinine, and excretion through the renal tubules is the main route of metformin clearance. Therefore, metformin itself does not damage the kidneys. Studies have suggested that metformin may have a renal protective effect. Metformin is absorbed through the gastrointestinal tract and circulates in the blood. It is almost not bound to plasma albumin, is not metabolized by the liver, does not compete with liver P450 enzymes, and is not degraded in the body. Instead, it acts directly on the liver and muscles, reducing hepatic gluconeogenesis and increasing muscle glucose glycolysis. Therefore, metformin is non-hepatotoxic, and patients with normal liver function will not cause liver damage if they take the drug within the recommended dose range. However, patients with impaired liver function should be cautious when using metformin, because impaired liver function will significantly limit their ability to clear lactate."
    },
    {
      "paragraph_id": "41",
      "paragraph": "6.二甲双胍与乳酸酸中毒：目前，尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝、肾功能正常者长期应用并不增加乳酸酸中毒风险。COSMIC研究是一项随机、开放标签、活性对照、平行分组研究，结果显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗比较，差异无统计学意义(I级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因为二甲双胍直接以原形经肾脏排泄，所以有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用二甲双胍。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.二甲双胍与乳酸酸中毒：目前，尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝、肾功能正常者长期应用并不增加乳酸酸中毒风险。COSMIC研究是一项随机、开放标签、活性对照、平行分组研究，结果显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗比较，差异无统计学意义(I级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因为二甲双胍直接以原形经肾脏排泄，所以有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用二甲双胍。",
          "start_idx": 0,
          "end_idx": 305,
          "entities": [
            {
              "entity_id": "T802",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T803",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T804",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T805",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T806",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T807",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 107,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T808",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 108,
              "end_idx": 113,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T809",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 162,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T810",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 165,
              "end_idx": 170,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T811",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 178,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T812",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 180,
              "end_idx": 185,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T813",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 193,
              "end_idx": 195,
              "entity_en": "oral"
            },
            {
              "entity_id": "T814",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T815",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 221,
              "end_idx": 226,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T816",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 221,
              "end_idx": 222,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T817",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 230,
              "end_idx": 234,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T818",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 254,
              "entity_en": "Lactic acidosis"
            },
            {
              "entity_id": "T819",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 259,
              "end_idx": 264,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T820",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 259,
              "end_idx": 260,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T821",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T822",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 269,
              "end_idx": 286,
              "entity_en": "<45ml/(min·1.73m2"
            },
            {
              "entity_id": "T823",
              "entity": "低氧血症",
              "entity_type": "Disease",
              "start_idx": 289,
              "end_idx": 293,
              "entity_en": "Hypoxemia"
            },
            {
              "entity_id": "T824",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 300,
              "end_idx": 304,
              "entity_en": "Metformin"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R349",
              "head_entity_id": "T816",
              "tail_entity_id": "T815"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R350",
              "head_entity_id": "T820",
              "tail_entity_id": "T819"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R351",
              "head_entity_id": "T821",
              "tail_entity_id": "T819"
            }
          ],
          "sentence_en": "6. Metformin and lactic acidosis: Currently, there is no definite evidence to support that the use of metformin is related to lactic acidosis. Long-term use in patients with normal liver and kidney function does not increase the risk of lactic acidosis. The COSMIC study is a randomized, open-label, active-controlled, parallel-group study. The results showed that the incidence of lactic acidosis with metformin was not statistically significant compared with other hypoglycemic treatments (level I). Meta-analysis showed that the use of metformin in patients with normal renal function did not increase the risk of lactic acidosis, and the probability of lactic acidosis with metformin was not higher than that of other oral hypoglycemic drugs. Because metformin is excreted directly in its original form through the kidneys, it is easy for metformin and lactic acid to accumulate in the body when renal function is impaired, which may increase the risk of lactic acidosis. It is recommended that patients with impaired renal function [eGFR<45ml/(min·1.73m2)] and hypoxemia should avoid the use of metformin."
        }
      ],
      "paragraph_en": "6. Metformin and lactic acidosis: Currently, there is no definite evidence to support that the use of metformin is related to lactic acidosis. Long-term use in patients with normal liver and kidney function does not increase the risk of lactic acidosis. The COSMIC study is a randomized, open-label, active-controlled, parallel-group study. The results showed that the incidence of lactic acidosis with metformin was not statistically significant compared with other hypoglycemic treatments (level I). Meta-analysis showed that the use of metformin in patients with normal renal function did not increase the risk of lactic acidosis, and the probability of lactic acidosis with metformin was not higher than that of other oral hypoglycemic drugs. Because metformin is excreted directly in its original form through the kidneys, it is easy for metformin and lactic acid to accumulate in the body when renal function is impaired, which may increase the risk of lactic acidosis. It is recommended that patients with impaired renal function [eGFR<45ml/(min·1.73m2)] and hypoxemia should avoid the use of metformin."
    },
    {
      "paragraph_id": "42",
      "paragraph": "7.二甲双胍与哪些非降糖药物的相互作用值得关注",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.二甲双胍与哪些非降糖药物的相互作用值得关注",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T825",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "7. What non-diabetic drug interactions with metformin deserve attention?"
        }
      ],
      "paragraph_en": "7. What non-diabetic drug interactions with metformin deserve attention?"
    },
    {
      "paragraph_id": "43",
      "paragraph": "(1)建议密切监测血糖并调整二甲双胍和/或相互作用的药物剂量：使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯喋啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，会影响肾功能或二甲双胍分布。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)建议密切监测血糖并调整二甲双胍和/或相互作用的药物剂量：使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯喋啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，会影响肾功能或二甲双胍分布。",
          "start_idx": 0,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T826",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T827",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T828",
              "entity": "氨氯吡咪",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Amiloride"
            },
            {
              "entity_id": "T829",
              "entity": "地高辛",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "Digoxin"
            },
            {
              "entity_id": "T830",
              "entity": "吗啡",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "morphine"
            },
            {
              "entity_id": "T831",
              "entity": "普鲁卡因胺",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Procainamide"
            },
            {
              "entity_id": "T832",
              "entity": "奎尼丁",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "Quinidine"
            },
            {
              "entity_id": "T833",
              "entity": "奎宁",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 57,
              "entity_en": "Quinine"
            },
            {
              "entity_id": "T834",
              "entity": "雷尼替丁",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Ranitidine"
            },
            {
              "entity_id": "T835",
              "entity": "氨苯喋啶",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Triamterene"
            },
            {
              "entity_id": "T836",
              "entity": "甲氧苄氨嘧啶",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 74,
              "entity_en": "Trimethoprim"
            },
            {
              "entity_id": "T837",
              "entity": "万古霉素",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Vancomycin"
            },
            {
              "entity_id": "T838",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "(1) It is recommended to closely monitor blood glucose and adjust the dose of metformin and/or interacting drugs: the use of cationic drugs secreted through the renal tubules, such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin, may affect renal function or metformin distribution."
        }
      ],
      "paragraph_en": "(1) It is recommended to closely monitor blood glucose and adjust the dose of metformin and/or interacting drugs: the use of cationic drugs secreted through the renal tubules, such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin, may affect renal function or metformin distribution."
    },
    {
      "paragraph_id": "44",
      "paragraph": "(2)需密切监测血糖：同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物。而在这些药物停用后，要密切注意低血糖的发生；合并服用氯磺丙脲的患者在换用二甲双胍的最初两周要密切监测血糖，氯磺丙脲在体内有较长滞留，易发生低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)需密切监测血糖：同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物。而在这些药物停用后，要密切注意低血糖的发生；合并服用氯磺丙脲的患者在换用二甲双胍的最初两周要密切监测血糖，氯磺丙脲在体内有较长滞留，易发生低血糖。",
          "start_idx": 0,
          "end_idx": 165,
          "entities": [
            {
              "entity_id": "T839",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T840",
              "entity": "噻嗪类药物",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Thiazides"
            },
            {
              "entity_id": "T841",
              "entity": "其他利尿剂",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Other diuretics"
            },
            {
              "entity_id": "T842",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T843",
              "entity": "吩噻嗪",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Phenothiazines"
            },
            {
              "entity_id": "T844",
              "entity": "甲状腺制剂",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Thyroid preparations"
            },
            {
              "entity_id": "T845",
              "entity": "雌激素",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "Estrogen"
            },
            {
              "entity_id": "T846",
              "entity": "避孕药",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "Contraceptive pills"
            },
            {
              "entity_id": "T847",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "oral"
            },
            {
              "entity_id": "T848",
              "entity": "苯妥英",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 56,
              "entity_en": "Phenytoin"
            },
            {
              "entity_id": "T849",
              "entity": "烟碱酸",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Nicotinic acid"
            },
            {
              "entity_id": "T850",
              "entity": "拟交感神经药",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 67,
              "entity_en": "Sympathomimetic drugs"
            },
            {
              "entity_id": "T851",
              "entity": "钙离子通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 76,
              "entity_en": "Calcium channel blockers"
            },
            {
              "entity_id": "T852",
              "entity": "异烟肼",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "Isoniazid"
            },
            {
              "entity_id": "T853",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T854",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 107,
              "end_idx": 110,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T855",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 118,
              "end_idx": 122,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T856",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 132,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T857",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T858",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "Chlorpropamide"
            },
            {
              "entity_id": "T859",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T860",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "Elevated"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R352",
              "head_entity_id": "T847",
              "tail_entity_id": "T846"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R353",
              "head_entity_id": "T859",
              "tail_entity_id": "T858"
            }
          ],
          "sentence_en": "(2) Blood sugar needs to be closely monitored: patients taking thiazide or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, isoniazid and other drugs that may cause blood sugar to rise. After these drugs are discontinued, patients should pay close attention to the occurrence of hypoglycemia. Patients taking chlorpropamide should closely monitor blood sugar in the first two weeks of switching to metformin, as chlorpropamide has a long retention period in the body and is prone to hypoglycemia."
        }
      ],
      "paragraph_en": "(2) Blood sugar needs to be closely monitored: patients taking thiazide or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, isoniazid and other drugs that may cause blood sugar to rise. After these drugs are discontinued, patients should pay close attention to the occurrence of hypoglycemia. Patients taking chlorpropamide should closely monitor blood sugar in the first two weeks of switching to metformin, as chlorpropamide has a long retention period in the body and is prone to hypoglycemia."
    },
    {
      "paragraph_id": "45",
      "paragraph": "(3)二甲双胍有增加华法林的抗凝血倾向。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)二甲双胍有增加华法林的抗凝血倾向。",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T861",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T862",
              "entity": "华法林",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Warfarin"
            }
          ],
          "relations": [],
          "sentence_en": "(3) Metformin has the tendency to increase the anticoagulant effect of warfarin."
        }
      ],
      "paragraph_en": "(3) Metformin has the tendency to increase the anticoagulant effect of warfarin."
    },
    {
      "paragraph_id": "46",
      "paragraph": "(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T863",
              "entity": "树脂类药物",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Resin drugs"
            },
            {
              "entity_id": "T864",
              "entity": "苏合香",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Styrax"
            },
            {
              "entity_id": "T865",
              "entity": "血竭",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Dragon's Blood"
            },
            {
              "entity_id": "T866",
              "entity": "乳香",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "mastic"
            },
            {
              "entity_id": "T867",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "(4) Resin drugs, such as storax, dragon's blood, and frankincense, will reduce their absorption when used together with metformin."
        }
      ],
      "paragraph_en": "(4) Resin drugs, such as storax, dragon's blood, and frankincense, will reduce their absorption when used together with metformin."
    },
    {
      "paragraph_id": "47",
      "paragraph": "六、对心血管系统的影响",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "六、对心血管系统的影响",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": [],
          "sentence_en": "6. Effects on the Cardiovascular System"
        }
      ],
      "paragraph_en": "6. Effects on the Cardiovascular System"
    },
    {
      "paragraph_id": "48",
      "paragraph": "1.二甲双胍是否具有心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用。前瞻性糖尿病研究UKPDS结果显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%、心肌梗死风险下降39%(I级)；UKPDS 10年随访显示，使用二甲双胍治疗带来的大血管并发症及死亡风险的获益具有延续效应，且其降低死亡和心肌梗死的作用优于磺脲类和胰岛素(Ⅰ级)。REACH研究是一项全球、多中心、随机、双盲研究，结果提示二甲双胍治疗2年，全因死亡相对风险下降24%。HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险。意大利多中心队列研究将纳入的T2DM患者(平均67岁)按年龄及eGFR分层，结果提示，与其他降糖药物治疗相比，二甲双胍组心血管事件发生风险降低。SPREAD是一项在中国进行的多中心、随机、双盲、安慰剂对照研究，结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍是否具有心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用。前瞻性糖尿病研究UKPDS结果显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%、心肌梗死风险下降39%(I级)；UKPDS 10年随访显示，使用二甲双胍治疗带来的大血管并发症及死亡风险的获益具有延续效应，且其降低死亡和心肌梗死的作用优于磺脲类和胰岛素(Ⅰ级)。REACH研究是一项全球、多中心、随机、双盲研究，结果提示二甲双胍治疗2年，全因死亡相对风险下降24%。HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险。意大利多中心队列研究将纳入的T2DM患者(平均67岁)按年龄及eGFR分层，结果提示，与其他降糖药物治疗相比，二甲双胍组心血管事件发生风险降低。SPREAD是一项在中国进行的多中心、随机、双盲、安慰剂对照研究，结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。",
          "start_idx": 0,
          "end_idx": 461,
          "entities": [
            {
              "entity_id": "T868",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T869",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T870",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T871",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T872",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "IR"
            },
            {
              "entity_id": "T873",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 96,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T874",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 99,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T875",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T876",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 99,
              "end_idx": 101,
              "entity_en": "T2"
            },
            {
              "entity_id": "T877",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 124,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T878",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 156,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T879",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T880",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 189,
              "end_idx": 193,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T881",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 201,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T882",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 202,
              "end_idx": 205,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T883",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 243,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T884",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 273,
              "end_idx": 277,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T885",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 282,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T886",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 285,
              "end_idx": 288,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T887",
              "entity": "大血管事件",
              "entity_type": "Disease",
              "start_idx": 292,
              "end_idx": 297,
              "entity_en": "Macrovascular events"
            },
            {
              "entity_id": "T888",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 292,
              "end_idx": 295,
              "entity_en": "Large blood vessels"
            },
            {
              "entity_id": "T889",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 314,
              "end_idx": 318,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T890",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 314,
              "end_idx": 316,
              "entity_en": "T2"
            },
            {
              "entity_id": "T891",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 331,
              "end_idx": 335,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T892",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 355,
              "end_idx": 359,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T893",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 360,
              "end_idx": 365,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T894",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 360,
              "end_idx": 363,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T895",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 413,
              "end_idx": 416,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T896",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 419,
              "end_idx": 423,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T897",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 419,
              "end_idx": 421,
              "entity_en": "T2"
            },
            {
              "entity_id": "T898",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 427,
              "end_idx": 431,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T899",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 435,
              "end_idx": 439,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T900",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 120,
              "end_idx": 122,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T901",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 189,
              "end_idx": 191,
              "entity_en": "Myocardium"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R354",
              "head_entity_id": "T869",
              "tail_entity_id": "T870"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R355",
              "head_entity_id": "T869",
              "tail_entity_id": "T871"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R356",
              "head_entity_id": "T872",
              "tail_entity_id": "T870"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R357",
              "head_entity_id": "T872",
              "tail_entity_id": "T871"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R358",
              "head_entity_id": "T873",
              "tail_entity_id": "T874"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R359",
              "head_entity_id": "T873",
              "tail_entity_id": "T875"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R360",
              "head_entity_id": "T876",
              "tail_entity_id": "T875"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R361",
              "head_entity_id": "T900",
              "tail_entity_id": "T877"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R362",
              "head_entity_id": "T901",
              "tail_entity_id": "T880"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R363",
              "head_entity_id": "T888",
              "tail_entity_id": "T887"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R364",
              "head_entity_id": "T890",
              "tail_entity_id": "T889"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R365",
              "head_entity_id": "T891",
              "tail_entity_id": "T889"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R366",
              "head_entity_id": "T892",
              "tail_entity_id": "T889"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R367",
              "head_entity_id": "T894",
              "tail_entity_id": "T893"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R368",
              "head_entity_id": "T898",
              "tail_entity_id": "T895"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R369",
              "head_entity_id": "T899",
              "tail_entity_id": "T895"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R370",
              "head_entity_id": "T897",
              "tail_entity_id": "T896"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R371",
              "head_entity_id": "T898",
              "tail_entity_id": "T896"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R372",
              "head_entity_id": "T899",
              "tail_entity_id": "T896"
            }
          ],
          "sentence_en": "1. Does metformin have a cardiovascular protective effect? Metformin plays a direct or indirect cardiovascular protective role by effectively improving IR in diabetic and non-diabetic patients and reducing basal and post-load insulin levels. The results of the prospective diabetes study UKPDS showed that the risk of all-cause mortality in obese T2DM patients using metformin was relatively reduced by 35%, and the risk of myocardial infarction was reduced by 39% (grade I); the 10-year follow-up of UKPDS showed that the benefits of macrovascular complications and mortality risk brought about by metformin treatment had a sustained effect, and its effect on reducing mortality and myocardial infarction was better than sulfonylureas and insulin (grade I). The REACH study is a global, multicenter, randomized, double-blind study. The results show that the relative risk of all-cause mortality decreased by 24% after 2 years of metformin treatment. The results of the HOME study suggest that metformin combined with insulin can reduce the risk of macrovascular events compared with insulin alone. The Italian multicenter cohort study stratified the included T2DM patients (average age 67 years) by age and eGFR. The results showed that the risk of cardiovascular events in the metformin group was reduced compared with other hypoglycemic drug treatments. SPREAD is a multicenter, randomized, double-blind, placebo-controlled study conducted in China. The results showed that for T2DM patients with a history of coronary heart disease, the risk of primary endpoint events in the metformin group was reduced by 46% (Grade I) compared with the glipizide group."
        }
      ],
      "paragraph_en": "1. Does metformin have a cardiovascular protective effect? Metformin plays a direct or indirect cardiovascular protective role by effectively improving IR in diabetic and non-diabetic patients and reducing basal and post-load insulin levels. The results of the prospective diabetes study UKPDS showed that the risk of all-cause mortality in obese T2DM patients using metformin was relatively reduced by 35%, and the risk of myocardial infarction was reduced by 39% (grade I); the 10-year follow-up of UKPDS showed that the benefits of macrovascular complications and mortality risk brought about by metformin treatment had a sustained effect, and its effect on reducing mortality and myocardial infarction was better than sulfonylureas and insulin (grade I). The REACH study is a global, multicenter, randomized, double-blind study. The results show that the relative risk of all-cause mortality decreased by 24% after 2 years of metformin treatment. The results of the HOME study suggest that metformin combined with insulin can reduce the risk of macrovascular events compared with insulin alone. The Italian multicenter cohort study stratified the included T2DM patients (average age 67 years) by age and eGFR. The results showed that the risk of cardiovascular events in the metformin group was reduced compared with other hypoglycemic drug treatments. SPREAD is a multicenter, randomized, double-blind, placebo-controlled study conducted in China. The results showed that for T2DM patients with a history of coronary heart disease, the risk of primary endpoint events in the metformin group was reduced by 46% (Grade I) compared with the glipizide group."
    },
    {
      "paragraph_id": "49",
      "paragraph": "2.二甲双胍的心血管保护作用机制：二甲双胍可能通过减少心血管疾病的风险因素而达到心血管保护作用。心血管疾病的风因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制风险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等。此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍的心血管保护作用机制：二甲双胍可能通过减少心血管疾病的风险因素而达到心血管保护作用。心血管疾病的风因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制风险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等。",
          "start_idx": 0,
          "end_idx": 186,
          "entities": [
            {
              "entity_id": "T902",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T903",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T904",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T905",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 53,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T906",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T907",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "IR"
            },
            {
              "entity_id": "T908",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T909",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T910",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "NAFLD"
            },
            {
              "entity_id": "T911",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T912",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T913",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 127,
              "end_idx": 129,
              "entity_en": "IR"
            },
            {
              "entity_id": "T914",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 147,
              "end_idx": 149,
              "entity_en": "Blood lipids"
            },
            {
              "entity_id": "T915",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 155,
              "end_idx": 157,
              "entity_en": "TG"
            },
            {
              "entity_id": "T916",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 158,
              "end_idx": 163,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T917",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 166,
              "entity_en": "TC"
            },
            {
              "entity_id": "T918",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 170,
              "end_idx": 175,
              "entity_en": "HDL-C"
            },
            {
              "entity_id": "T920",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 126,
              "entity_en": "NAFLD"
            },
            {
              "entity_id": "T921",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T922",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T923",
              "entity": "肝脏",
              "entity_type": "Anatomy",
              "start_idx": 133,
              "end_idx": 135,
              "entity_en": "liver"
            },
            {
              "entity_id": "T924",
              "entity": "肌肉",
              "entity_type": "Anatomy",
              "start_idx": 136,
              "end_idx": 138,
              "entity_en": "muscle"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R373",
              "head_entity_id": "T921",
              "tail_entity_id": "T904"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R374",
              "head_entity_id": "T922",
              "tail_entity_id": "T905"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R375",
              "head_entity_id": "T911",
              "tail_entity_id": "T920"
            }
          ],
          "sentence_en": "2. Mechanism of cardiovascular protection of metformin: Metformin may achieve cardiovascular protection by reducing risk factors for cardiovascular disease. Risk factors for cardiovascular disease include dyslipidemia, IR, obesity, hypertension, NAFLD, etc. Controlling risk factors is one of the important ways to protect cardiovascular disease. Metformin has been proven to lower blood sugar, improve NAFLD and IR (especially liver and muscle), reduce weight, improve blood lipids (mainly improve TG, LDL-C and TC levels, with no significant changes in HDL-C) and anticoagulation."
        },
        {
          "sentence_id": "1",
          "sentence": "此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。",
          "start_idx": 186,
          "end_idx": 214,
          "entities": [
            {
              "entity_id": "T919",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "In addition, metformin can directly improve endothelial cell function and increase blood flow."
        }
      ],
      "paragraph_en": "2. Mechanism of cardiovascular protection of metformin: Metformin may achieve cardiovascular protection by reducing the risk factors of cardiovascular disease. Risk factors of cardiovascular disease include dyslipidemia, IR, obesity, hypertension, NAFLD, etc. Controlling risk factors is one of the important ways of cardiovascular protection. Metformin has been proven to lower blood sugar, improve NAFLD and IR (especially liver and muscle), reduce weight, improve blood lipids (mainly improve TG, LDL-C and TC levels, and have no obvious effect on HDL-C) and anticoagulation. In addition, metformin can directly improve the function of vascular endothelial cells and increase blood flow."
    },
    {
      "paragraph_id": "50",
      "paragraph": "七、降糖外作用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "七、降糖外作用",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "7. Effects other than hypoglycemic"
        }
      ],
      "paragraph_en": "7. Effects other than hypoglycemic"
    },
    {
      "paragraph_id": "51",
      "paragraph": "1.二甲双胍在改善血脂方面的作用：二甲双胍能改善脂肪的合成与代谢。多项研究显示，二甲双胍可降低T2DM患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍在改善血脂方面的作用：二甲双胍能改善脂肪的合成与代谢。多项研究显示，二甲双胍可降低T2DM患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。",
          "start_idx": 0,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T925",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T926",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Blood lipids"
            },
            {
              "entity_id": "T927",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T928",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T929",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T930",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "T2"
            },
            {
              "entity_id": "T931",
              "entity": "血浆TG",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Plasma TG"
            },
            {
              "entity_id": "T932",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T933",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "TC"
            },
            {
              "entity_id": "T934",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 76,
              "entity_en": "HDL-C"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R376",
              "head_entity_id": "T928",
              "tail_entity_id": "T929"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R377",
              "head_entity_id": "T930",
              "tail_entity_id": "T929"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R378",
              "head_entity_id": "T931",
              "tail_entity_id": "T929"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R379",
              "head_entity_id": "T932",
              "tail_entity_id": "T929"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R380",
              "head_entity_id": "T933",
              "tail_entity_id": "T929"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R381",
              "head_entity_id": "T934",
              "tail_entity_id": "T929"
            }
          ],
          "sentence_en": "1. The role of metformin in improving blood lipids: Metformin can improve the synthesis and metabolism of fat. Many studies have shown that metformin can reduce the levels of plasma TG, LDL-C and TC in patients with T2DM, but has no significant effect on HDL-C."
        }
      ],
      "paragraph_en": "1. The role of metformin in improving blood lipids: Metformin can improve the synthesis and metabolism of fat. Many studies have shown that metformin can reduce the levels of plasma TG, LDL-C and TC in patients with T2DM, but has no significant effect on HDL-C."
    },
    {
      "paragraph_id": "52",
      "paragraph": "2.二甲双胍在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组颁布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出，除非存在明显的肝损害(如血清转氨酶大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，NAFLD患者可安全使用二甲双胍(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况。所有研究均显示，HOMAI-IR明显改善，13项研究显示血清酶学(ALT、AST)明显下降，5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有显著改善。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组颁布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出，除非存在明显的肝损害(如血清转氨酶大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，NAFLD患者可安全使用二甲双胍(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况。所有研究均显示，HOMAI-IR明显改善，13项研究显示血清酶学(ALT、AST)明显下降，5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有显著改善。",
          "start_idx": 0,
          "end_idx": 260,
          "entities": [
            {
              "entity_id": "T935",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T936",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "NAFLD"
            },
            {
              "entity_id": "T937",
              "entity": "脂肪肝",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 33,
              "entity_en": "Fatty liver"
            },
            {
              "entity_id": "T938",
              "entity": "酒精性肝病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Alcoholic liver disease"
            },
            {
              "entity_id": "T939",
              "entity": "非酒精性脂肪性肝病",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 55,
              "entity_en": "Nonalcoholic fatty liver disease"
            },
            {
              "entity_id": "T940",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T941",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 80,
              "end_idx": 81,
              "entity_en": "liver"
            },
            {
              "entity_id": "T942",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Serum transaminases"
            },
            {
              "entity_id": "T943",
              "entity": "大于3倍正常值上限",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 99,
              "entity_en": "More than 3 times the upper limit of normal"
            },
            {
              "entity_id": "T944",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 106,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T945",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 101,
              "end_idx": 102,
              "entity_en": "liver"
            },
            {
              "entity_id": "T946",
              "entity": "失代偿期肝硬化",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 114,
              "entity_en": "Decompensated cirrhosis"
            },
            {
              "entity_id": "T947",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 111,
              "end_idx": 112,
              "entity_en": "liver"
            },
            {
              "entity_id": "T948",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 118,
              "end_idx": 123,
              "entity_en": "NAFLD"
            },
            {
              "entity_id": "T949",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T950",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T951",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 160,
              "entity_en": "NAFLD"
            },
            {
              "entity_id": "T952",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 173,
              "end_idx": 175,
              "entity_en": "IR"
            },
            {
              "entity_id": "T953",
              "entity": "HOMAI-IR",
              "entity_type": "Test_items",
              "start_idx": 192,
              "end_idx": 200,
              "entity_en": "HOMAI-IR"
            },
            {
              "entity_id": "T954",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 217,
              "end_idx": 220,
              "entity_en": "ALT"
            },
            {
              "entity_id": "T955",
              "entity": "AST",
              "entity_type": "Test_items",
              "start_idx": 221,
              "end_idx": 224,
              "entity_en": "AST"
            },
            {
              "entity_id": "T956",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 236,
              "end_idx": 240,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T957",
              "entity": "肝脏炎症",
              "entity_type": "Disease",
              "start_idx": 241,
              "end_idx": 245,
              "entity_en": "Liver inflammation"
            },
            {
              "entity_id": "T958",
              "entity": "肝脏",
              "entity_type": "Anatomy",
              "start_idx": 241,
              "end_idx": 243,
              "entity_en": "liver"
            },
            {
              "entity_id": "T959",
              "entity": "脂肪变性和纤维化",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 254,
              "entity_en": "Steatosis and fibrosis"
            },
            {
              "entity_id": "T960",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 33,
              "entity_en": "liver"
            },
            {
              "entity_id": "T961",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 38,
              "entity_en": "liver"
            },
            {
              "entity_id": "T962",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 53,
              "end_idx": 54,
              "entity_en": "liver"
            },
            {
              "entity_id": "T963",
              "entity": "失代偿期",
              "entity_type": "Class",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "Decompensation"
            },
            {
              "entity_id": "T964",
              "entity": "血清酶学",
              "entity_type": "Test",
              "start_idx": 168,
              "end_idx": 172,
              "entity_en": "Serum enzymology"
            },
            {
              "entity_id": "T965",
              "entity": "血清酶学",
              "entity_type": "Test",
              "start_idx": 212,
              "end_idx": 216,
              "entity_en": "Serum enzymology"
            },
            {
              "entity_id": "T966",
              "entity": "明显",
              "entity_type": "Level",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "obvious"
            },
            {
              "entity_id": "T967",
              "entity": "明显改善",
              "entity_type": "Test_Value",
              "start_idx": 200,
              "end_idx": 204,
              "entity_en": "Significant improvement"
            },
            {
              "entity_id": "T968",
              "entity": "明显下降",
              "entity_type": "Test_Value",
              "start_idx": 225,
              "end_idx": 229,
              "entity_en": "Significant decline"
            },
            {
              "entity_id": "T969",
              "entity": "非酒精性脂肪性",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 53,
              "entity_en": "Non-alcoholic fatty"
            },
            {
              "entity_id": "T970",
              "entity": "酒精性",
              "entity_type": "Class",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "Alcohol"
            },
            {
              "entity_id": "T971",
              "entity": "肝病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "Liver disease"
            },
            {
              "entity_id": "T972",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "liver"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R382",
              "head_entity_id": "T935",
              "tail_entity_id": "T936"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R383",
              "head_entity_id": "T960",
              "tail_entity_id": "T937"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R384",
              "head_entity_id": "T961",
              "tail_entity_id": "T938"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R385",
              "head_entity_id": "T970",
              "tail_entity_id": "T938"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R386",
              "head_entity_id": "T962",
              "tail_entity_id": "T939"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R387",
              "head_entity_id": "T969",
              "tail_entity_id": "T939"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R388",
              "head_entity_id": "T941",
              "tail_entity_id": "T940"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R389",
              "head_entity_id": "T942",
              "tail_entity_id": "T940"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R390",
              "head_entity_id": "T945",
              "tail_entity_id": "T944"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R391",
              "head_entity_id": "T947",
              "tail_entity_id": "T946"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R392",
              "head_entity_id": "T963",
              "tail_entity_id": "T946"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R393",
              "head_entity_id": "T949",
              "tail_entity_id": "T948"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R394",
              "head_entity_id": "T950",
              "tail_entity_id": "T951"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R395",
              "head_entity_id": "T964",
              "tail_entity_id": "T951"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R396",
              "head_entity_id": "T952",
              "tail_entity_id": "T951"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R397",
              "head_entity_id": "T956",
              "tail_entity_id": "T957"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R398",
              "head_entity_id": "T956",
              "tail_entity_id": "T959"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R399",
              "head_entity_id": "T958",
              "tail_entity_id": "T957"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R400",
              "head_entity_id": "T972",
              "tail_entity_id": "T971"
            }
          ],
          "sentence_en": "2. The role of metformin in the treatment of NAFLD: The Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association issued the \"Guidelines for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease in China (Revised in 2010)\", which stated that unless there is obvious liver damage (such as serum transaminase greater than 3 times the upper limit of normal value), liver dysfunction or decompensated cirrhosis, NAFLD patients can safely use metformin (Grade V). There are 14 clinical studies evaluating the improvement of metformin on liver histology, serum enzymes and IR in patients with NAFLD. All studies showed that HOMAI-IR was significantly improved, 13 studies showed a significant decrease in serum enzymes (ALT, AST), and 5 studies showed that metformin significantly improved liver inflammation, fatty degeneration and fibrosis."
        }
      ],
      "paragraph_en": "2. The role of metformin in the treatment of NAFLD: The Fatty Liver and Alcoholic Liver Disease Group of the Hepatology Branch of the Chinese Medical Association issued the \"Guidelines for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease in China (Revised in 2010)\", which stated that unless there is obvious liver damage (such as serum transaminase greater than 3 times the upper limit of normal value), liver dysfunction or decompensated cirrhosis, NAFLD patients can safely use metformin (Grade V). There are 14 clinical studies evaluating the improvement of metformin on liver histology, serum enzymes and IR in patients with NAFLD. All studies showed that HOMAI-IR was significantly improved, 13 studies showed a significant decrease in serum enzymes (ALT, AST), and 5 studies showed that metformin significantly improved liver inflammation, fatty degeneration and fibrosis."
    },
    {
      "paragraph_id": "53",
      "paragraph": "3.二甲双胍在治疗PCOS方面的作用：国内外应用二甲双胍治疗PCOS已有10余年的历史。美国内分泌学会推荐，二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。AACE/ACE PCOS临床诊治指南中推荐二甲双胍可作为青少年女性PCOS单药或联合避孕药和抗雄激素药治疗的一线用药。在偏瘦的青少年女性中，最低日剂量控制在850mg可有效改善PCOS症状；在超重和肥胖的青少年女性中，二甲双胍日治疗剂量常需要增至1500~2500mg(V级)。同时，该指南中提到，二甲双胍可减轻绝经前PCOS妇女的MS相关症状。循证医学证据表明，二甲双胍可降低血浆胰岛素水平、增加IS、降低雄激素水平、提高雌二醇(E2)水平，改善PCOS患者的多毛症，使月经规律、诱导排卵。同时，二甲双胍用于PCOS患者除改善IR和高血糖症等代谢状况外，还被证明可改善PCOS患者的排卵、受孕及生产存活率。PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分2次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。国外也有用到2500mg/d，安全性依然良好。目前，我国药监部门未批准二甲双胍用于治疗PCOS。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.二甲双胍在治疗PCOS方面的作用：国内外应用二甲双胍治疗PCOS已有10余年的历史。美国内分泌学会推荐，二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。AACE/ACE PCOS临床诊治指南中推荐二甲双胍可作为青少年女性PCOS单药或联合避孕药和抗雄激素药治疗的一线用药。在偏瘦的青少年女性中，最低日剂量控制在850mg可有效改善PCOS症状；在超重和肥胖的青少年女性中，二甲双胍日治疗剂量常需要增至1500~2500mg(V级)。同时，该指南中提到，二甲双胍可减轻绝经前PCOS妇女的MS相关症状。循证医学证据表明，二甲双胍可降低血浆胰岛素水平、增加IS、降低雄激素水平、提高雌二醇(E2)水平，改善PCOS患者的多毛症，使月经规律、诱导排卵。同时，二甲双胍用于PCOS患者除改善IR和高血糖症等代谢状况外，还被证明可改善PCOS患者的排卵、受孕及生产存活率。",
          "start_idx": 0,
          "end_idx": 429,
          "entities": [
            {
              "entity_id": "T973",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T974",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T975",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T976",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T977",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T978",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T979",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T980",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "T2"
            },
            {
              "entity_id": "T981",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "IGT"
            },
            {
              "entity_id": "T982",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 78,
              "end_idx": 84,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T983",
              "entity": "避孕药",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 106,
              "entity_en": "Contraceptive pills"
            },
            {
              "entity_id": "T984",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T985",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 162,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T986",
              "entity": "避孕药",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 170,
              "entity_en": "Contraceptive pills"
            },
            {
              "entity_id": "T987",
              "entity": "抗雄激素药",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 176,
              "entity_en": "Antiandrogen drugs"
            },
            {
              "entity_id": "T988",
              "entity": "850mg",
              "entity_type": "Amount",
              "start_idx": 203,
              "end_idx": 208,
              "entity_en": "850mg"
            },
            {
              "entity_id": "T989",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 213,
              "end_idx": 217,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T990",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 221,
              "end_idx": 223,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T991",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 226,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T992",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 234,
              "end_idx": 238,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T993",
              "entity": "1500~2500mg",
              "entity_type": "Amount",
              "start_idx": 248,
              "end_idx": 259,
              "entity_en": "1500~2500mg"
            },
            {
              "entity_id": "T994",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 274,
              "end_idx": 278,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T995",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 284,
              "end_idx": 288,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T996",
              "entity": "MS",
              "entity_type": "Disease",
              "start_idx": 291,
              "end_idx": 293,
              "entity_en": "MS"
            },
            {
              "entity_id": "T997",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 349,
              "end_idx": 353,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T998",
              "entity": "多毛症",
              "entity_type": "Symptom",
              "start_idx": 356,
              "end_idx": 359,
              "entity_en": "Hirsutism"
            },
            {
              "entity_id": "T999",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 374,
              "end_idx": 378,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1000",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 380,
              "end_idx": 384,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T1001",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 389,
              "end_idx": 391,
              "entity_en": "IR"
            },
            {
              "entity_id": "T1002",
              "entity": "高血糖症",
              "entity_type": "Disease",
              "start_idx": 392,
              "end_idx": 396,
              "entity_en": "Hyperglycemia"
            },
            {
              "entity_id": "T1003",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 410,
              "end_idx": 414,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T1012",
              "entity": "血浆胰岛素",
              "entity_type": "Test_items",
              "start_idx": 314,
              "end_idx": 319,
              "entity_en": "Plasma insulin"
            },
            {
              "entity_id": "T1013",
              "entity": "雄激素",
              "entity_type": "Test_items",
              "start_idx": 329,
              "end_idx": 332,
              "entity_en": "Androgens"
            },
            {
              "entity_id": "T1014",
              "entity": "雌二醇(E2)",
              "entity_type": "Test_items",
              "start_idx": 337,
              "end_idx": 344,
              "entity_en": "Estradiol (E2)"
            },
            {
              "entity_id": "T1015",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 307,
              "end_idx": 311,
              "entity_en": "Metformin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R401",
              "head_entity_id": "T973",
              "tail_entity_id": "T974"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R402",
              "head_entity_id": "T975",
              "tail_entity_id": "T976"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R403",
              "head_entity_id": "T977",
              "tail_entity_id": "T978"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R404",
              "head_entity_id": "T977",
              "tail_entity_id": "T979"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R405",
              "head_entity_id": "T977",
              "tail_entity_id": "T981"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R406",
              "head_entity_id": "T982",
              "tail_entity_id": "T978"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R407",
              "head_entity_id": "T982",
              "tail_entity_id": "T979"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R408",
              "head_entity_id": "T982",
              "tail_entity_id": "T981"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R409",
              "head_entity_id": "T984",
              "tail_entity_id": "T985"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R410",
              "head_entity_id": "T986",
              "tail_entity_id": "T985"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R411",
              "head_entity_id": "T987",
              "tail_entity_id": "T985"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R412",
              "head_entity_id": "T992",
              "tail_entity_id": "T990"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R413",
              "head_entity_id": "T992",
              "tail_entity_id": "T991"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R414",
              "head_entity_id": "T993",
              "tail_entity_id": "T992"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R415",
              "head_entity_id": "T994",
              "tail_entity_id": "T995"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R416",
              "head_entity_id": "T994",
              "tail_entity_id": "T996"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R417",
              "head_entity_id": "T1015",
              "tail_entity_id": "T997"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R418",
              "head_entity_id": "T1012",
              "tail_entity_id": "T997"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R419",
              "head_entity_id": "T1013",
              "tail_entity_id": "T997"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R420",
              "head_entity_id": "T1014",
              "tail_entity_id": "T997"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R421",
              "head_entity_id": "T998",
              "tail_entity_id": "T997"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R422",
              "head_entity_id": "T999",
              "tail_entity_id": "T1000"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R423",
              "head_entity_id": "T999",
              "tail_entity_id": "T1001"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R424",
              "head_entity_id": "T999",
              "tail_entity_id": "T1002"
            }
          ],
          "sentence_en": "3. The role of metformin in the treatment of PCOS: Metformin has been used to treat PCOS for more than 10 years at home and abroad. The American Society of Endocrinology recommends that metformin can be used as a treatment for patients with PCOS combined with T2DM/IGT, when lifestyle intervention (first-line treatment) fails or when menstruation is irregular and contraceptives cannot be used (second-line treatment). The AACE/ACE PCOS clinical diagnosis and treatment guidelines recommend that metformin can be used as a first-line medication for the treatment of PCOS in adolescent women alone or in combination with contraceptives and anti-androgens. In thin adolescent women, a minimum daily dose of 850 mg can effectively improve PCOS symptoms; in overweight and obese adolescent women, the daily treatment dose of metformin often needs to be increased to 1500~2500 mg (Grade V). At the same time, the guidelines mention that metformin can alleviate MS-related symptoms in premenopausal women with PCOS. Evidence-based medicine shows that metformin can reduce plasma insulin levels, increase IS, reduce androgen levels, increase estradiol (E2) levels, improve PCOS patients' hirsutism, regularize menstruation, and induce ovulation. At the same time, in addition to improving metabolic conditions such as IR and hyperglycemia, metformin has also been shown to improve PCOS patients' ovulation, pregnancy, and birth survival rates."
        },
        {
          "sentence_id": "1",
          "sentence": "PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分2次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。",
          "start_idx": 429,
          "end_idx": 504,
          "entities": [
            {
              "entity_id": "T1004",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "PCOS"
            },
            {
              "entity_id": "T1005",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 8,
              "end_idx": 15,
              "entity_en": "500 mg/day"
            },
            {
              "entity_id": "T1006",
              "entity": "500mg",
              "entity_type": "Amount",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "500mg"
            },
            {
              "entity_id": "T1007",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 30,
              "end_idx": 38,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T1008",
              "entity": "分2次餐时或餐后服用",
              "entity_type": "Method",
              "start_idx": 39,
              "end_idx": 49,
              "entity_en": "Take in 2 doses during or after meals"
            }
          ],
          "relations": [],
          "sentence_en": "PCOS patients can start with 500 mg/d, increase the dose by 500 mg per week up to 2000 mg/d (taken in 2 doses during or after meals), maintain this for several months until ovulation and resumption of menstruation, and stop taking the drug when pregnancy is discovered."
        },
        {
          "sentence_id": "2",
          "sentence": "国外也有用到2500mg/d，安全性依然良好。",
          "start_idx": 504,
          "end_idx": 527,
          "entities": [
            {
              "entity_id": "T1009",
              "entity": "2500mg/d",
              "entity_type": "Amount",
              "start_idx": 6,
              "end_idx": 14,
              "entity_en": "2500 mg/day"
            }
          ],
          "relations": [],
          "sentence_en": "2500mg/d is also used abroad and the safety is still good."
        },
        {
          "sentence_id": "3",
          "sentence": "目前，我国药监部门未批准二甲双胍用于治疗PCOS。",
          "start_idx": 527,
          "end_idx": 552,
          "entities": [
            {
              "entity_id": "T1010",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1011",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 24,
              "entity_en": "PCOS"
            }
          ],
          "relations": [],
          "sentence_en": "At present, my country’s drug regulatory authorities have not approved metformin for the treatment of PCOS."
        }
      ],
      "paragraph_en": "3. The role of metformin in the treatment of PCOS: Metformin has been used to treat PCOS for more than 10 years at home and abroad. The American Society of Endocrinology recommends that metformin can be used as a treatment for patients with PCOS combined with T2DM/IGT, when lifestyle intervention (first-line treatment) fails or when menstruation is irregular and contraceptives cannot be used (second-line treatment). The AACE/ACE PCOS clinical diagnosis and treatment guidelines recommend that metformin can be used as a first-line medication for the treatment of PCOS in adolescent women alone or in combination with contraceptives and anti-androgens. In thin adolescent women, a minimum daily dose of 850 mg can effectively improve PCOS symptoms; in overweight and obese adolescent women, the daily treatment dose of metformin often needs to be increased to 1500~2500 mg (Grade V). At the same time, the guidelines mention that metformin can alleviate MS-related symptoms in premenopausal women with PCOS. Evidence-based medicine shows that metformin can reduce plasma insulin levels, increase IS, reduce androgen levels, increase estradiol (E2) levels, improve hirsutism in PCOS patients, regularize menstruation, and induce ovulation. At the same time, in addition to improving metabolic conditions such as IR and hyperglycemia in PCOS patients, metformin has also been shown to improve ovulation, pregnancy, and production survival rates in PCOS patients. PCOS patients can start with 500 mg/d, increase the dose by 500 mg per week, until 2000 mg/d (taken twice during or after meals), maintain for several months until ovulation, menstruation resumes, and stop taking the drug when pregnancy is discovered. 2500 mg/d is also used abroad, and the safety is still good. At present, my country's drug regulatory authorities have not approved metformin for the treatment of PCOS."
    },
    {
      "paragraph_id": "54",
      "paragraph": "4.二甲双胍是否具有抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的风险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激酶(AMPK)通路，而AMPK通路的激活除了影响代谢外，还可能抑制肿瘤的发生和发展。英国一项大型病例对照研究显示，二甲双胍治疗与癌症的发生风险下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势。多项荟萃分析结果显示，二甲双胍治疗与肺癌、前列腺癌、直肠癌等癌症风险降低相关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.二甲双胍是否具有抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的风险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激酶(AMPK)通路，而AMPK通路的激活除了影响代谢外，还可能抑制肿瘤的发生和发展。英国一项大型病例对照研究显示，二甲双胍治疗与癌症的发生风险下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势。多项荟萃分析结果显示，二甲双胍治疗与肺癌、前列腺癌、直肠癌等癌症风险降低相关。",
          "start_idx": 0,
          "end_idx": 235,
          "entities": [
            {
              "entity_id": "T1016",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1017",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T1018",
              "entity": "乳腺癌",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Breast cancer"
            },
            {
              "entity_id": "T1019",
              "entity": "乳腺",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "Breast"
            },
            {
              "entity_id": "T1020",
              "entity": "胰腺癌",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "Pancreatic cancer"
            },
            {
              "entity_id": "T1021",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "pancreas"
            },
            {
              "entity_id": "T1022",
              "entity": "结直肠癌",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Colorectal cancer"
            },
            {
              "entity_id": "T1023",
              "entity": "结直肠",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Colorectal"
            },
            {
              "entity_id": "T1024",
              "entity": "子宫内膜癌",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Endometrial cancer"
            },
            {
              "entity_id": "T1025",
              "entity": "子宫内膜",
              "entity_type": "Anatomy",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "Endometrium"
            },
            {
              "entity_id": "T1026",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1027",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 137,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1028",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 181,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1029",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T1030",
              "entity": "肺癌",
              "entity_type": "Disease",
              "start_idx": 214,
              "end_idx": 216,
              "entity_en": "Lung cancer"
            },
            {
              "entity_id": "T1031",
              "entity": "肺",
              "entity_type": "Anatomy",
              "start_idx": 214,
              "end_idx": 215,
              "entity_en": "lung"
            },
            {
              "entity_id": "T1032",
              "entity": "前列腺癌",
              "entity_type": "Disease",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Prostate cancer"
            },
            {
              "entity_id": "T1033",
              "entity": "前列腺",
              "entity_type": "Anatomy",
              "start_idx": 217,
              "end_idx": 220,
              "entity_en": "prostate"
            },
            {
              "entity_id": "T1034",
              "entity": "直肠癌",
              "entity_type": "Disease",
              "start_idx": 222,
              "end_idx": 225,
              "entity_en": "Rectal cancer"
            },
            {
              "entity_id": "T1035",
              "entity": "直肠",
              "entity_type": "Anatomy",
              "start_idx": 222,
              "end_idx": 224,
              "entity_en": "rectum"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R425",
              "head_entity_id": "T1016",
              "tail_entity_id": "T1017"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R426",
              "head_entity_id": "T1019",
              "tail_entity_id": "T1018"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R427",
              "head_entity_id": "T1021",
              "tail_entity_id": "T1020"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R428",
              "head_entity_id": "T1023",
              "tail_entity_id": "T1022"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R429",
              "head_entity_id": "T1025",
              "tail_entity_id": "T1024"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R430",
              "head_entity_id": "T1029",
              "tail_entity_id": "T1030"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R431",
              "head_entity_id": "T1029",
              "tail_entity_id": "T1032"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R432",
              "head_entity_id": "T1029",
              "tail_entity_id": "T1034"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R433",
              "head_entity_id": "T1031",
              "tail_entity_id": "T1030"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R434",
              "head_entity_id": "T1033",
              "tail_entity_id": "T1032"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R435",
              "head_entity_id": "T1035",
              "tail_entity_id": "T1034"
            }
          ],
          "sentence_en": "4. Does metformin have anti-tumor effects: Diabetes may be a risk factor for a variety of tumors, such as breast cancer, pancreatic cancer, colorectal cancer, and endometrial cancer. Several studies have shown that metformin can activate the AMP-activated protein kinase (AMPK) pathway, and the activation of the AMPK pathway, in addition to affecting metabolism, may also inhibit the occurrence and development of tumors. A large case-control study in the UK showed that metformin treatment was correlated with a decreased risk of cancer, and it was observed that the protective effect of metformin tended to gradually increase with the extension of the duration of use and the increase in the number of uses. The results of multiple meta-analyses showed that metformin treatment was associated with a reduced risk of lung cancer, prostate cancer, colorectal cancer, and other cancers."
        }
      ],
      "paragraph_en": "4. Does metformin have anti-tumor effects: Diabetes may be a risk factor for a variety of tumors, such as breast cancer, pancreatic cancer, colorectal cancer, and endometrial cancer. Several studies have shown that metformin can activate the AMP-activated protein kinase (AMPK) pathway, and the activation of the AMPK pathway, in addition to affecting metabolism, may also inhibit the occurrence and development of tumors. A large case-control study in the UK showed that metformin treatment was correlated with a decreased risk of cancer, and it was observed that the protective effect of metformin tended to gradually increase with the extension of the duration of use and the increase in the number of uses. The results of multiple meta-analyses showed that metformin treatment was associated with a reduced risk of lung cancer, prostate cancer, colorectal cancer, and other cancers."
    }
  ]
}